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risk  factor  for  drug‐related  problems.  Common  causes  for  polypharmacy  are  treatment 
guidelines, which are usually formulated disease‐specific. Due to multimorbidity of a patient, 
combined  use  of  treatment  guidelines  may  also  lead  to  unnecessary  or  unfavourable 
combinations of medicines. According to national and international data, between 4‐7% of all 




safety,  avoid  medication  errors,  and  minimise  suffering  from  drug‐related  problems.  The 








patients  who  do  not  take  them"  describes  a  key  issue,  especially  for  outpatient 
pharmacotherapy. The pharmacist as the last  link in the supply chain of a medicine is  in the 
best  position  to  interview  the  patient  about  motivation,  knowledge,  and  obstacles  for  his 








in  the  Swiss  hospital  setting  and  discussing  the  strengths  and  limitations  of  pharmacist‐led 
medication reviews in primary care by evaluating the Swiss Polymedication Check. In addition, 




care  setting. We performed  the  first  comprehensive  survey of  clinical pharmacy practice  in 
Switzerland.  Our  data  show  considerable  regional  differences  concerning  the  extent  of 
implementation  and  pattern  of  clinical  pharmacy  services, which  points  out  to  the  existing 
crucial gap in seamless care activities. In particular, the regional presence of drug dispensing 
physicians in the ambulatory care setting seemed to limit the development of clinical pharmacy 
practice  in  the  corresponding  hospitals.  Institutions  in  regions  without  drug  dispensing 
physicians rather employed pharmacists assigned with clinical activities (n=20, 22% of 135.3 
full‐time equivalent, FTE) than regions with partial (n=8, 7% of 35.8 FTE) or unrestricted drug 
dispensing  by  physicians  (n=16,  6%  of  68.1  FTE,  p=0.026).  Of  hospitals  with  implemented 
clinical  pharmacy  services,  73%  had  weekly  interprofessional  ward  rounds.  In  9%,  clinical 





focus of  the Pharmaceutical Care Network Europe  (PCNE)  and was extensively discussed at 
several meetings and workshops. The following definition for the term ‘medication review’ has 
been  established  and  approved  by  the  board  of  PCNE:  ‘Medication  review  is  a  structured 
evaluation of a patient‘s medicines with the aim of optimising medicines use and  improving 
health  outcomes.  This  entails  detecting  drug‐related  problems  and  recommending 
interventions.’ The PCNE terminology takes into account that the amount of available sources 
of information defines different types of medication reviews. Specific expertise and skills are 






their  theoretical  process  structure  with  a  recommendation  for  an  intervention.  Health 





‐ In  Switzerland,  regional  differences  in  the  extent  of  implementation  and  pattern  of 










Project  B  extensively  studied  the  Polymedication  Check  (PMC),  a  cognitive  and  directly 
remunerated pharmacist‐led medication review service in Switzerland. For the first time in the 
Swiss health care system, a new nationally  implemented cognitive service underwent an  in‐





and  piloted.  Finally,  a  randomised  controlled  trial  was  conducted  in  54  Swiss  community 
pharmacies. Eligible patients used ≥4 prescribed medicines over >3 months. The intervention 
group received a PMC at study start (T‐0) and after 28 weeks (T‐28) while the control group 
received  a  PMC  only  at  T‐28.  Primary  outcome measure was  change  in  patients’  objective 
adherence,  calculated  as  Medication  Possession  Ratio  (MPR)  and  Daily  Polypharmacy 
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Possession  Ratio  (DPPR),  using  refill  data  from  the  pharmacies  and  patient  information  of 
dosing.  Subjective  adherence  was  assessed  as  secondary  outcome  by  self‐report 
questionnaires (at T‐0 and T‐28) and telephone interviews (at T‐2 and T‐16), where participants 
estimated their overall adherence on a scale from 0‐100%.  
A  total  of  450 patients was  randomly  allocated  to  intervention  (n=218,  48.4%)  and  control 
group (n=232, 51.6%). Main addressed DRP during PMC at T‐0 was insufficient adherence to at 
least one medicine (n=69, 26.7%). At T‐28, 1020 chronic therapies fulfilled inclusion criteria for 
MPR  calculation,  representing  293  of  372  patients  (78.8%).  Mean MPR  and  adherence  to 
polypharmacy (DPPR) for both groups were equally high (MPRInt=88.3, SD=19.03; MPRCont=87.5, 




was  significantly  higher  in  the  intervention  group  (nImprovement=30;  nWorsening=14)  than  in  the 
control group (nImprovement=20; nWorsening=24; p=0.028). We further evaluated the impact of the 
intervention on humanistic outcomes, i.e. patients’ acceptance of this new service, improved 







judged  the  counseling  by  the  pharmacist  as  being  helpful  for  their  daily  medication 




differentiate  for  patients  at  highest  risk.  The  promising  results  of  improved  adherence  and 
enhanced knowledge in a population with already well‐established therapy regimen points at 
the potential of  the service whenever patients at  risk are approached. Further, pharmacists 






and a  focus group discussion performed shortly after  the  implementation of  the service.  In 
addition, the participating pharmacists from the evalPMC project were asked to fill in an online 
questionnaire after completing the study. The participants (n=6) of the focus group discussions 
all  stated  that  recruitment  of  the  very  first  patient  for  a  PMC  was  the  main  barrier  for 
implementing the service in daily practice (‘The first is the worst!’). Further, training based on 
realistic case series from a community pharmacy setting and explicit communication aids were 
expected  to  be  delivered  through  the  regional  or  national  pharmacists’  associations.  The 
evaluation  of  study  pharmacists’  perspective  was  conducted  four  weeks  after  study  end 
individually in each study region by voluntary online survey. Out of 59 pharmacists at T‐28, a 
total of 50 (84.7%) completed the survey. Mean estimated time needed to prepare (14min), 
conduct  (30min),  and  finalise  (11min)  a  PMC  was  much  longer  than  proposed  by  the 






























(31.2%) of  them were not on  target. Glucose  targets were not  reached by 8  (27.6%) of  29 
patients  with  antidiabetic  treatment.  In  conclusion,  screening  detects  a  considerable 
proportion  of  patients  (43.8%)  who  fail  to  achieve  treatment  targets  despite  prescribed 





of patients with  systemic  sclerosis  (SSc)  from the European Centre  for  the Rehabilitation of 
Scleroderma  Rheinfelden,  Switzerland,  and  report  new  insights  on  care  issues  of  this 
population. The final questionnaire consisted of 35 items divided into five sections: complaints, 




(34%);  they were  of  strong  to  unbearable  intensity  (25%),  and  lead  to modification  of  the 
dosage  form  (40%).  Knowledge  of  the  pattern  of  complaints  with  medication  intake,  i.e. 









‐ Unreached  biomarkers  despite  drug  therapy  as  well  as  swallowing  difficulties  with 
medication  intake  need  further  clarification  by  a  health  professional  to  rule  out 
inadequate coping strategies or non‐adherence. 
‐ Patient  self‐reports  may  guide  health  professionals  in  the  future  when  providing 
tailored  counseling,  choosing  therapy  options,  or  optimising  a  patient’s  medication 
profile. 
 
In  conclusion,  this  thesis  showed  an  increase  of  the  involvement  of  clinical  pharmacists  in 
patient  care  in  Switzerland.  Regardless  of  the  setting,  the  traditional  role  of  pharmacists  is 
currently  expanding  to  a  respected  contributor  and  key  partner  for  interprofessional 
collaboration in patient care. Pharmacists’ contributions to patient care are no longer limited 
to medicines  supply only. Multiple opportunities  for new services are opening up and  their 












than  one  medicine  a  day  in  the  general  population.  This  phenomenon,  also  called 
‚polypharmacy‘ has no clear defined cut‐off, while the use of more than four or five different 
drug entities form an established definition.1 Polypharmacy is also known as an independent 
risk  factor  for  drug‐related  problems.2  Common  causes  for  polypharmacy  are  treatment 
guidelines, which are usually formulated disease‐specific. Due to multimorbidity of a patient, 
combined  use  of  treatment  guidelines  may  also  lead  to  unnecessary  or  unfavorable 
combinations. Given the increase of chronically ill patients and the lack of medical staff from 
different disciplines, new models of health care are required to sustain highest patient safety 







According  to  national  and  international  data,  between  4‐7%  of  all  hospital  admissions  are 
related  to  drug‐related  problems;  30‐50%  of  them  could  be  prevented.5‐7  Applied  to 
Switzerland, this corresponds to more than 10'000 drug‐related hospital admissions per year.8 
Especially  regarding  elderly  patients  on  polypharmacy,  patients  suffering  from  cognitive 
impairment or patients taking her medication not as prescribed approximately half of the drug‐




problems  include  events  with  significant  changes  in  drug  therapy  or  changes  in  existing 
diseases,  insufficient  response  to  drug  therapy,  suspected  lack  of  adherence  to  therapy  or 








care  issues  can be addressed and  relevant  interventions are  feasible. Mehuys et al.15  listed 
possible  roles  for  community  pharmacists  when  dealing  with  older  patients  with  chronic 





Medication  (PIM) use  in  the elderly  is  very prevalent  in  Switzerland as well. A  recent  study 






an  observed  problem),  and  the  acceptance  of  this  intervention.17  This  classification  system 
originally  was  developed  for  a  research  setting,  but  unfortunately  was  not  feasible  to  be 







patients  who  do  not  take  them"19  describes  a  key  issue,  especially  for  outpatient 





initiation,  implementation,  and  discontinuation.20  Their  research  has  resulted  in  a  new 
conceptual foundation for a transparent taxonomy, while some research also use primary and 




not  as  prescribed  e.g.  incorrect  dosing  (too  high,  too  low,  drug  holiday).21  Further, 
distinguishing between intentional non‐adherence (e.g. missing or altering doses to suit one's 
needs)  and  unintentional  non‐adherence  (forgetting  to  take  medication)  may  help  in 
understanding and discussing non‐adherence.22 
Approximately  25%  of  patients  with  different  diseases  take  medication  not  as  prescribed, 
although  the extent of  adherence  varies between 0‐95%.23  In  long‐term  therapy  treatment 
adherence is on average at 50%.24 Thus, the lack of adherence as a very specific drug‐related 
problem  is  the  most  common  cause  of  the  efficacy‐effectiveness  gap,25  meaning  the  gap 
between therapy efficacy in daily life compared to the effectiveness shown in clinical trials. Up 
to  57%  (or  269  billion  US  dollars  a  year)  of  the  world’s  total  avoidable  cost  are  spent  on 
suboptimal  medicine  use.26  Risk  factors  for  non‐adherence  with medication  are  older  age, 
increasing number of medicines prescribed (especially five or more different medicines taken 


















behaviour.  Further,  the  widespread  stages‐of‐change  model30  is  useful  to  understand 
intentional  non‐adherence  and  differentiates  individuals  at  different  levels  of  readiness  for 
change.  Another  specific  framework  regarding  health  behaviours  was  introduced  through 
Meichenbaum & Turk in 1987,31 outlining knowledge and skills, beliefs, motivation, and action 
as  the  major  factors  operating  on  the  behaviour  change.  Conclusively,  all  of  the  models 
encompass  patients’  knowledge  (e.g.  didactic  provision  of  generic  information)  and 
psychological  components  (e.g.  motivation,  beliefs)  to  explain  treatment  engagement  and 
adherence.28 Regarding the latter, patients’ beliefs are clustered into so‐called necessity‐beliefs 
(i.e. perceptions of personal need for treatment) and concerns (i.e. concerns about a range of 
potential  adverse  consequences).32  The  discussed  models  have  their  advantages  and 





healthcare  professionals  in  supporting  patients’  adherence,  especially  when  therapies 
concerning  fatal  diseases  as  human  immunodeficiency  virus  (HIV)  are  required.28,34  Major 
efforts were carried out to support patient groups with highest needs for individual care and 









interprofessional  interventions  including motivational  interviewing,  electronic monitoring of 
drug intake, and continuous follow‐up meetings to ensure acceptance and implementation of 








insufficient pharmacist motivation.39 However,  the pharmacist  as  the  last  link  in  the  supply 
chain of a medicine is in the best position to interview the patient about motivation, knowledge, 
and  obstacles  for  his  treatment  and  to  offer  customised  support  and  follow  adherence  to 
therapy. Support of adherence to treatment can only succeed if the entire medication is taken 







and  avoidance  of  drug‐induced  (re)  hospitalisations.  To  describe  the  future  role,  the 
Internationale  Pharmaceutical  Federation  (FIP)  published  in  collaboration  with  the  World 
Health Organization (WHO) a declaration of "Good Pharmaceutical Practice" in 2011,41 which 












These  international position  statements define an active  involvement of pharmacists  in  the 
medication management. Key objective is to improve the patient's health by enabling the best 
possible  utilization of  drug  therapy.  This  contribution must  be based on  the needs  of  each 





In  the  early  1990s,  pharmaceutical  care  was  introduced  in  community  pharmacy  practice; 
emphasis was given to providing patient‐centred care and cognitive pharmaceutical services 42. 
In  2013,  the  Pharmaceutical  Care  Network  Europe  (PCNE)  redefined  the  term  as  follows: 
‘Pharmaceutical  Care  is  the  pharmacist's  contribution  to  the  care  of  individuals  in  order  to 




carefully. The  first  competence  is  for example commonly needed  in case of handing over a 












safety  and  cost‐effective  impact.  Pharmaceutical  care  is  the  pharmacist’s  contribution  to  it 
(Figure 1).43 





















































It  is  important  to  identify  the  patients  with  the  highest  need  for  pharmaceutical  care  to 































































































to  maximise  their  treatment  efficiency.  The  choice  of  helpful  tools  to  detect  drug‐related 






Explicit  checklists,  particularly  for  geriatric  patients,  have  been  developed.  They  list  active 














Implicit  checklists  include  key  questions,  which  are  answered  step  by  step  during  the 




The  final question  in  the evaluation of a medication profile  should be carried out  regarding 
indications without  treatment,  e.g. methotrexate  therapy without  folic  acid  substitution.  In 
their  study  of  2008,  Kuijpers  et  al.  reported  underprescribing  as  an  increasingly  important 
problem.  In  their  population,  the  estimated  probability  of  underprescription  increased 
significantly  with  the  number  of  drugs.  Hence,  42.9%  of  patients  with  polypharmacy  were 
undertreated, in contrast to 13.5% of patients using four medicines or less (OR 4.8, 95% CI 2.0, 








resulting  triage  situation  requires  an  immediate  estimate  of  risks  for  the  patient  and  the 









the  proportion  of  issues  noted  and  potentially  relevant  factors  such  as  pharmacists' 
characteristics and their experience of doing reviews. As a limitation of their results, the authors 
did not report clinical relevance of missed opportunities. This might be discussed as a bias when 




When  investigating  the  impact  of  medication  reviews,  one  has  to  consider  that  only  an 
implemented  advice might  have  an  outcome.  In  order  to  perform  a  cost‐effective  service, 
highest  implementation  rates  of  accurate  advices  need  to  be  achieved.  Pharmacist  should 
always be able and empowered to check for sustainability of their advice within a follow‐up 
meeting, assuring the patient and/or prescriber took note of their intervention and was able to 
follow  the  recommendation.  Previous  studies  showed  positive  impact  of  structured 
interventions  to  improve  adherence  provided  by  pharmacists.59,60  But  there  is  still  little 
evidence of effectiveness of  community pharmacy  interventions. Blendniskopp et  al.  stated 
that the value of medication reviews is now generally accepted despite a lack of robust research 
evidence consistently demonstrating cost or clinical effectiveness compared to traditional care. 

























Kingdom  (UK)  (Medicines  Use  Review,  MUR),  United  States  of  America  (USA)  (Medication 
Therapy  Management,  MTM),  Australia  (Home  Medication  Review,  HMR),  Canada 
(MedsCheck)  and  New  Zealand  (Medicines  Use  Review,  MUR).46,  63‐65  These  developments 
support the efforts of pharmacists to take a more active role in the care of patients. Recent 
meta‐analysis  stated  that  a  majority  (57.9%)  of  fee‐for‐service  pharmacist‐led  medication 
reviews showed an  improvement  in medication adherence and showed positive benefits on 
patient outcomes.46 
Bulajeva  et  al.  aimed  at  exploring  availability  and  comprehensiveness  of medication  review 
practices in primary care in European countries.66 Countries, which reported medication review 
procedures  in  community  settings  (13/25,  15%), most  indicated having  a  type  II  procedure 












































































as  in  2002,  initiatives  from  the  national  prescribing  service  from  UK  presented  a  guide  to 
medication review aiming at reaching the agenda for patients, practitioners and managers.48 











Meanwhile,  online  training  programs  exist  to  teach  the  practitioners  on  how  to  perform  a 

































They  are  free  to  choose  their  health  care  physician  and  have  unlimited  access  to  general  practitioners  and 
specialists. There is no formal gatekeeping system in place. Almost half of the population (46%) holds a special 
insurance policy where they receive premium reductions in exchange for agreeing to join one of the 90 existing 
managed  care  networks  such  as  Health  Maintenance  Organisations,  family‐doctor  gatekeeping  schemes, 
Independent Practice Associations, or Preferred Provider Organisations. 
The national  health  care  system  is  individually  regulated by  the  cantons  and 26 different  systems have  to be 
considered. Notably, in 16 cantons physicians may dispense drugs directly to their patients (dispensing physicians). 
Ambulatory  services  are  largely  provided  by  physicians  operating  as  independent/single‐person  practices.  In 
addition, ambulatory services are also provided by outpatient departments of public and private hospitals and by 












cognitive  service  to  be  delivered  independently  from  the  prescriber  for  patients  on  ≥  4 












 Check  for:  eventual  possibility  of  repeat  dispensing,  dosage, 
limitations, interactions, risk factors, contraindications,  misuse 
 According activities: Patient counseling, eventual contact with 
prescriber,  choice  of  optimised  package  size,  immediate 
provision  
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professionals  might  worsen  the  situation,  the  co‐operation  of  pharmacists  and  general 
practitioners holds the potential to provide constructive support in medication management 
and coordination of  care. While efforts are made  to  re‐orient pharmacy practice  towards a 
focus on quality of care, politics allowing doctors to dispense drugs in some Swiss regions work 
against,  and  thus  provoke  unnecessary  competition  in  primary  care  and  complicate 
coordination  among  networks  of  healthcare  providers.  Regardless  of  these  barriers  (or 
eventually  induced  by  them),  the  Swiss  association  of  pharmacists  (pharmaSuisse) 
strengthened  the efforts  in  the development of  clinical  pharmacy  services by  the  following 
actions:  


























medicine  is  commonly  evaluated  by  the  GP  after  one  month;  on  this  occasion,  a  repeat 









respect  to  seamless  care,  reconciliation  of  therapies  (Y)  around  a  hospital  stay  represents 
another very relevant service and for disabled patients even a home medication review after 




(V)  by  the pharmacist  is  not  systematically  foreseen.  Still, measurement  of  blood  pressure, 
biomarkers  for diabetes patients or even  lipid values are  frequently offered.  In general,  the 
patient himself pays these services. However, accredited pharmacies following regular quality 












Targeting  individuals  and  not  a  population  or  society  as  a  whole  is  a  key  concept  of 
pharmaceutical care that can be viewed as an individualised service of pharmacists delivered 
to a distinct patient. These services  include various contributions of pharmacists  in patient‐
oriented  care  such  as  the  provision  of  medication  reviews.  Since  2010,  Swiss  community 
pharmacies can offer a ‘Polymedication‐Check’ (PMC) to patients on ≥4 prescribed drugs taken 
over ≥3 months. The PMC is a new cognitive service involving a consultation with a patient in a 
separate  room  and  taking  responsibility  for  his  therapy  through  interventions  and 
recommendations  concerning medication management.  Referring  to  the  different  types  of 
medication reviews as previously defined, the PMC is identified as an ‘intermediate’ medication 
review  (Table 1).  Information  is available  from the medication history, which  is mandatorily 
kept  in  Swiss  community  pharmacies,  and  from  a  structured  patient  interview.  The  check 
focuses on adherence problems, patients’ knowledge and handling problems. Pharmacists are 
instructed to use open questions to detect pharmaceutical care issues and to decide on the 
need  for  intervention. However,  they must prioritise  the problems detected and document 















the Organization  for  Economic  Cooperation  and  Development  (OECD).  The  level  of  patient 
satisfaction and the life expectancy is one of the highest in the world.76 The Swiss population 






of  the  evaluation  of  the  Swiss  Polymedication  Check.  In  addition,  specific  opportunities  for 
















































To  approach  the  topic  of  drug‐related  problems  in  patient  care  from  a  solution‐oriented 




Project  B  extensively  studies  the  Polymedication  Check  (PMC),  a  cognitive  and  directly 
remunerated pharmacist‐led service in Switzerland. For the first time in the Swiss health care 




purpose,  some  theoretical  challenges  in  adherence  calculation  from  refill  data  had  to  be 
considered (B1 + B2) and various specific outcome measurements had to be developed and 
piloted  (B3). Designed as a  randomised controlled  trial,  the  study  investigated as a primary 
outcome the objective adherence calculating the Medication Possession Ratio (MPR) and Daily 
Polypharmacy  Possession Ratio  (DPPR)  for  eligible  therapies  (B4).  Further  on, we  discussed 
detected drug‐related problems, unplanned visits at the general physician or hospital, and the 
impact  of  the  intervention  on  humanistic  outcomes,  e.g.  patients’  acceptance  of  this  new 
service, improved knowledge about their medicines through intervention, and the availability 
of  a  written  medication  plan  (B5).  Finally,  we  were  also  interested  in  the  pharmacists’ 
perspective and their perceptions regarding the new service they could offer. We assessed their 
arguments  in  a  written  survey  and  a  focus  group  discussion  performed  shortly  after  the 
implementation  of  the  service  in  community  pharmacies,  and  asked  the  participating 






the  pharmacist’s  skills  purposefully  to  patients  with  individual  needs.  On  one  hand,  the 




underestimated  drug‐related  problems,  i.e.  swallowing  difficulties  with  medication  intake. 
When asked,  swallowing difficulties  are  reported by 9‐27% of  outpatients.  They may  affect 
quality  of  life,  lead  to  hazardous  coping  strategies  (splitting  or  crushing  pills),  and  reduce 
adherence  to  medication  regimen.  However,  health  professionals  rarely  assess  swallowing 
difficulties with medication  intake. We  therefore  developed  an  in‐depth  patient  self‐report 
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Background Clinical pharmacy activities developed
signiﬁcantly in the last decade. The extent and
organisation of these activities in Switzerland remained
unknown.
Objectives To map clinical pharmacy services (CPS)
provided in Swiss hospitals and to discuss their
development focusing on different cultural regions and
healthcare systems.
Methods We enrolled all chief hospital pharmacists
afﬁliated with the Swiss Society of Public Health
Administration and Hospital Pharmacists (n=47) for an
online survey. We asked them to describe the extent and
organisation of CPS concerning patient-related, therapy-
related or process-related activities, the structural
organisation and the available human resources.
Results The survey took place from March to April
2013. It was completed by 44 chief hospital pharmacists
(return rate 94%), representing the hospital landscape in
Switzerland comprehensively. Thirty-three (75%)
hospitals offered regular CPS and seven (16%) planned
to do so. Institutions in regions without drug-dispensing
physicians rather employed pharmacists assigned with
clinical activities (n=20, 22% of 135.3 full-time
equivalent (FTE)) than regions with partial (n=8, 7% of
35.8 FTE) or unrestricted drug dispensing by physicians
(n=16, 6% of 68.1 FTE, p=0.026). Of hospitals with
implemented CPS, 73% had weekly interprofessional
ward rounds, and in 9.1%, clinical pharmacists daily
reconciled medicines at patient discharge.
Conclusions Our data show regional differences in the
implementation and pattern of CPS. A signiﬁcant
correlation to drug dispensing by physicians in
ambulatory care and human resources provided for CPS
was found. While interprofessional ward rounds were
performed periodically, seamless care activities by clinical
pharmacists remained insufﬁciently established.
INTRODUCTION
Since the publication of the concept of ‘pharma-
ceutical care’ by Hepler and Strand1 in 1990, great
efforts have been made to establish patient-centred
pharmaceutical services in outpatient and inpatient
settings, especially in the Anglo-Saxon countries.2
The pharmacists’ contribution is not only limited
to drug manufacture and supply, but it expands in
taking increasing responsibility for the appropriate
drug choice and application. Especially the pharma-
cist’s role in patient care during the hospital stay is
highly valuable since the clinical setting and related
medication process is recognised as a particularly
risky situation.3–5 Moreover, the transition from
inpatient to outpatient care adds further challenges
to patients and health professionals.6–8 As a
possible approach to reduce preventable medication
errors and correlated harm to the patient, around
the world the concept of clinical pharmacy got suc-
cessfully implemented in the hospital setting with
various patient-related services.9 10
Development of structured clinical pharmacy
activities in Switzerland
In 2006, the Swiss Society of Public Health
Administration and Hospital Pharmacists (GSASA)
organised four pioneering workshops to establish the
requirements for obtaining the degree of a clinical
pharmacist.11 The Swiss Pharmacy Federation
approved a structured postgraduate education pro-
gramme in 2008, leading to the certiﬁcate ‘Clinical
Pharmacy FPH’. In 2011, the GSASA deﬁned clinical
pharmacy as “an area of pharmacy aimed at develop-
ing and promoting an appropriate, safe and cost-
effective use of therapeutic products”.12 According
to this deﬁnition, the clinical pharmacist is part of a
multidisciplinary team and is present on the ward on
a daily basis or as a regular consultant for the differ-
ent services. The activities of clinical pharmacy are
organised along three axes:
1. Patient-related axis: To collaborate in patient
education and continuity of care to improve
medication history, adherence to therapy; transi-
tion to the ambulatory setting and education on
discharge medication (=seamless care).
2. Treatment-related axis: To analyse drug therapy
to optimise and reduce overuse, underuse and
misuse of medicines, taking into account the
aspects mentioned under (1), to optimise the
choice of medication after a risk/beneﬁt analysis
and cost-effectiveness; to ensure indications and
completeness of treatment; to avoid contraindi-
cations according to the pathophysiological
state; and to guarantee adaptation and individu-
alisation of treatment.
3. Process-related axis: To consolidate the drug
supply chain to ensure that the patient receives
the right medication at the right time as pre-
scribed by supporting good prescribing prac-
tices, development of guidelines on the
preparation and administration of medication;
development of treatment guidelines in collab-
oration with medical and nursing teams in the
departments involved; development of compu-
terised decision support systems for the pre-
scription and administration of drugs; and
prevention and documentation of adverse drug
events on the ward.
These three axes should be completed with the
following related activities, which are an integral
part of the role of the clinical pharmacist: contribu-
tion in continuing education of physicians, nurses
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and pharmacists, as well as in research and development of new
services.
Cultural and structural challenges for the development
of clinical pharmacy services in Switzerland
Switzerland is characterised by its federalist political system with
26 cantons and its multilingualism (German, French, Italian and
Romansh). Since the national healthcare system is independently
regulated by the cantons, 26 different systems have to be consid-
ered. These heterogeneous conditions can promote innovation
as well as create barriers to the development of new healthcare
models. Notable for our research is the fact that in 16 cantons
of Switzerland, physicians in ambulatory care are allowed to dis-
pense drugs directly to their patients (dispensing physicians).
Since lack of collaboration between competitors might be an
issue in the development of clinical pharmacy practice, we were
interested in the potential interference of this structural factor.
Our objectives were to map the clinical pharmacy services pro-
vided in Swiss hospitals, to reﬂect on the aims of the deﬁnition
and observed realities, and, ﬁnally, to discuss the results consid-




A literature search provided an overview of previously conducted
surveys with comparable research questions focusing on clinical
pharmacy practice.13–18 Based on these ﬁndings, general issues
and topics were extracted and supplemented by country-speciﬁc
elements. An expert panel with representatives from the univer-
sity, postgraduate lecturers and practitioners assessed the compre-
hensiveness and appropriateness of the survey (content, structure
and scope). To ensure an uniform understanding of clinical phar-
macy activities, the GSASA deﬁnition of clinical pharmacy12
formed the main reference for this survey. The questionnaire con-
tained 43 items and was phrased in a structured way to describe
nature and extent of clinical pharmacy services (patient-related,
therapy-related or process-related activities), structural organisa-
tion (extent of ward contact) and available human resources
(represented as full-time equivalents (FTEs)). Thereby,
FTETotPharm summed up all human resources for pharmacists’
activities in the hospital pharmacy while FTEClinPharm repre-
sented resources reserved for clinical pharmacy activities.
Data analysis
The data were transferred in Microsoft Ofﬁce 2013 Excel and
processed for statistical analysis with IBM SPSS Statistics 22. We
also used Microsoft Ofﬁce Excel 2013 and the add-in
‘GeoFlow’ to visualise our results. Analysis of possible correla-
tions within group and scale variables was provided using the
Mann–Whitney U test (nGroups=2) or the Kruskal–Wallis test




In a cross-sectional study, we enrolled all chief hospital pharma-
cists (n=47) that were afﬁliated with the GSASA at the index
date 1 January 2013 by email. The survey took place from 21
March to 25 April 2013. In the absence of feedback, the con-
tacts were reminded to participate by email or by phone call
twice during a period of 3 weeks. The survey was completed by
44 chief hospital pharmacists (return rate 94%).
Institution characteristics
In summary, 6 institutions were afﬁliated with a university, 21
were independent cantonal and regional hospitals, and 7 were
specialised clinics. Furthermore, 10 hospitals were organised in
networks. Hospitals were categorised following their character-
istics and assigned to the established categories of the Swiss
federal statistical ofﬁce.19 Overall, all general hospitals with
central supply level 1 (university hospitals) employed a pharma-
cist who could provide insights into their organisation.
Likewise, a majority of 80% of general hospitals with central
supply level 2 and 52% of general hospitals with primary care
level 3 took part in the survey. The coverage decreased in
general hospitals with primary care levels 4 and 5, where in 2 of
69 listed institutions a pharmacist was present at least part time
and thus surveyed (3%). This trend continued in the psychiatric,
rehabilitative facilities and specialty hospitals (4%). In total, 19
trainee placements for the national accredited postgraduate
degree in hospital pharmacy were provided by 17 hospitals.
Nine institutions offered a total of 13 trainee placements for
obtaining the certiﬁcate of proﬁciency in clinical pharmacy.
Extent of clinical pharmacy activities and human resources
The 44 institutions reported a total of 239.2 FTETotPharm for hos-
pital pharmacists. Of the surveyed hospitals, 33 (75%) already
offered permanently implemented clinical pharmacy services
(FTEClinPharm=35.9). Another seven (16%) hospitals were plan-
ning to introduce appropriate structures. The remaining four (9%)
hospitals indicated offering no clinical pharmacy services in the
near future. In the French-speaking part of Switzerland (11 institu-
tions), 23.2% of the total hospital pharmacy’s human resources
were assigned to clinical pharmacy services (FTEClinPharm=19.1;
FTETotPharm=82.4). In the German-speaking part (31 institutions),
this corresponded to 9.9% (FTEClinPharm=14.5;
FTETotPharm=146.2) and in the Italian-speaking part (2 institu-
tions) to 27.4% (FTEClinPharm=2.9; FTETotPharm=10.6). In
summary, the clinical pharmacy resources differed signiﬁcantly
over the three language regions (p=0.032, ﬁgure 1). Median year
of establishment for clinical pharmacy services were reported in
the French part of Switzerland with 2002 (range: 1989–2010), in
the German part with 2007 (range: 1985–2013) and in the Italian
part with 2011.
Hospitals in regions without dispensing physicians (n=20)
revealed signiﬁcantly more resources available for clinical phar-
macy activities (22.0% of FTETotPharm=135.25) compared with
regions with limited (n=8, 6.7% of FTETotPharm=35.8) or full-
dispensing rights for physicians (n=16, 6.3% of
FTETotPharm=68.1, p=0.026), shown in ﬁgure 2.
Structural organisation of ward contact
The 33 institutions providing clinical pharmacy services had
resources of 222.2 FTE, of which 35.9 were allocated to
patient-centred care. In four (12%) of these institutions, phar-
macists worked >50% of their time on the ward. Twenty-six
(79%) hospitals mentioned part-time activities with patient
contact, while three (9%) institutions reported no presence on
the wards.
Treatment-related services were more frequent than patient-
related activities (ﬁgure 3). In 73% of all hospitals with clinical
pharmacy services, interdisciplinary ward rounds with pharma-
cists, nurses and physicians took place weekly. A proportion of
18% of the hospital pharmacists reported weekly involvement
of clinical pharmacists in the medication reconciliation process
at hospital admission. Meanwhile, pharmacists validated
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patients’ prescriptions in 9% of institutions at discharge to
ambulatory care. Weekly medication reviews according
Pharmaceutical Care Network Europe typology20 IIb (medica-
tion proﬁle+clinical data) were performed in 42% and type III
(medication proﬁle+clinical data+information from physician)
in 39% of institutions.
An overview of process-related services revealed ambiguous
trends. One-third of all institutions (n=11) maintained a hotline
to allow external professionals to ask questions (eg, community
pharmacies in case of concern after hospital discharge). A major-
ity of 81% of hospital pharmacies with according services
reported daily enquiries from health professionals. Maintaining
a hotline for internal professionals was an integral part of the
daily routine for 31 out of 33 institutions (94%).
DISCUSSION
To our knowledge, this is the ﬁrst comprehensive national
survey of the clinical pharmacy practice in Switzerland reﬂecting
the practical implementation of a recently introduced theoretical
deﬁnition. Our data indicated relevant regional differences in
the implementation of clinical pharmacy services, while the
presence of drug-dispensing physicians seemed to limit the
development of clinical pharmacy services.
Characteristics of institutions participating in the survey
All categories of hospitals were represented in the survey. It is
surprising that only 47 of 300 listed hospital institutions in
Switzerland employed a chief pharmacist. In institutions without
GSASA contact information (84%), it may be assumed that no
structured clinical pharmacy activities take place since there is
no other professional association for hospital or clinical pharma-
cists in Switzerland.
Interfering factors in the dissemination of clinical
pharmacy practice
As a result of the cantonal regulation of the health system in
Switzerland, heterogeneous conditions and structures exist and
inﬂuence the implementation of new disciplines and concepts at
the national level. In our study, a signiﬁcant association between
dispensing physicians in ambulatory care and the absence of
clinical pharmacy services in hospitals of corresponding regions
is shown. In primary care, collaboration between physicians and
pharmacists is hampered by this keen competition, which
caused multiple public votings with according local altercation
between the two professional associations. Apparently this strug-
gle in primary care inﬂuenced the collaboration in the institu-
tions. The observed structural differences in drug supply must
be clearly evaluated as a disadvantage: hospitals in regions with
prevailing dispensing physicians seem to barely tolerate clinical
pharmacy activities. This is not favourable in terms of patient
safety and cost-effectiveness. A recent study of health insurance
data revealed that prescriptions of dispensing physicians show a
higher potential for drug-related problems compared with
normal prescribing, non-dispensing physicians.21 In order to
promote the expansion of the interprofessional collaboration,
ﬁnancial disincentives must be discussed critically. Thus, eco-
nomic competition in primary care affects collaboration in
primary care as well as in hospital care and both effects are crit-
ical in regard of patient safety.
Clinical pharmacy practice: discussing a deﬁnition’s theory
and observed realities in Swiss hospitals
From a total of 239.2 FTE of pharmacists in Switzerland,
around 15% were assigned to the ﬁeld of clinical pharmacy.
Since the introduction of the certiﬁcate ‘FPH Clinical
Pharmacy’, 58 pharmacists had successfully graduated until
2013.22 This may represent a ﬁrst accomplished step in the right
direction, leading to an improved involvement by pharmacists in
patient care. However, present resources are insufﬁcient for the
adequate coverage of needs. The comprehensive and publicly
available supervision by clinical pharmacists at present cannot
be guaranteed in Swiss hospitals due to a lack of resources (35.9
FTEClinPharm in relation to 1.4 million hospitalisations in
2013).23
Regarding the deﬁned axes of activities, pharmacists’ efforts
seem to focus on treatment-related and process-related services.
In the institutions with clinical pharmacy services, interprofes-
sional ward rounds seemed well established since they took
place regularly. Weekly performed treatment recommendations
may be also considered as regular. Since they are only per-
formed on selected wards, a large number of drug-related issues
endangering patient safety remain unsolved.
The pharmacist’s competence in answering medication-related
questions to hospital staff seemed to be well established and
accepted. However, there were hardly any services enabling
external access to valid information about a patient’s medication
during his hospital stay for community pharmacies and general
practitioners. This indicates a huge potential for improvement.
Participation of pharmacists in direct patient-related care was
rare, probably due to a lack of resources. A crucial gap was
observed in the ﬁeld of ‘seamless care’. Structured discharge
management (eg, medication reconciliation) involving a clinical
pharmacist was implemented in <10% of the institutions. No
institution reported the involvement of a clinical pharmacist in
the validation process of a patient’s written medication plan (eg,
hand over24 25).
Current resources are not sufﬁcient to ensure comprehensive
patient care through clinical pharmacists. We propose to discuss
the pattern of resource allocation that might have the highest
level of efﬁciency. To demand a maximum of personal resources
for all axes of clinical pharmacy activities at once might not be
an effective strategy to maximise the clinical pharmacist’s
impact. For example, an optimised medication process may
prevent many interventions at the patient level. Therefore, a rea-
sonable balance between the mentioned axes of activities, that
is, direct patient contact, optimising the medication process and
development of treatment guidelines, seems more reasonable
and might become a topic of further investigation of clinical
pharmacists’ impact on patient outcome.
Comparing Swiss resources to the international community
Compared with the human resources in North America
(FTETotPharm=17.5 per 100 beds),
18 Swiss hospitals showed a
striking neglect of pharmaceutical expertise in hospitals.
Compared with data from Europe 2010,13 Switzerland offered a
similar spread of implemented clinical pharmacy services and
corresponding gaps in patient-centred care. Around 40% of
European institutions provided regular clinical pharmacy ser-
vices on the wards. The wide range of reported extent (3.6–
79.2%) indicates a heterogeneous distribution of resources,
analogous to the situation in Switzerland. The European leader
in the ﬁeld of clinical pharmacy practice was the UK. On
average, 90% of National Health Services’ institutions carried
out daily clinical pharmacy visits on the hospital wards.26 Out
of the 30 survey countries, Switzerland ranked on the 20th
place right behind the former Yugoslav Republic of Macedonia
and just ahead of the Czech Republic.13 In particular, the area
of transition of care showed to be neglected in Europe:
Messerli M, et al. Eur J Hosp Pharm 2016;0:1–6. doi:10.1136/ejhpharm-2015-000868 3
Original article
medication reconciliation supported by a clinical pharmacist
took place in only 17% of European institutions upon admis-
sion and in 22% at discharge, respectively.13 It remained unclear
how regularly and frequently these services were provided. In
the year 2000, Canada reported seamless care services in 33%
of the examined institutions reaching on average 11% of all
patients treated (range: 5–50%).14 In the future, such indicators
might become important target values for discussing the impact
and extent of the practice of clinical pharmacy, for example,
beds supplied with clinical pharmacy services instead of the
total number of an institution’s beds provided.
Strengths and limitations
Our study has some strengths. First, the high response rate to
the survey of 94% of registered and invited chief pharmacists
resulted in a comprehensive overview of the actual clinical phar-
macy practices in the institutions contacted. Second, a represen-
tative sample of participating institutions was achieved by the
Figure 1 Ratio of clinical pharmacy practice (red) versus other hospital pharmacy activities (yellow) in the different language areas: French (blue),
German (light blue) and Italian (dark blue). Hospital networks are represented as one location. Squares without ﬁlling represent areas without any
pharmacy information. FTE, full-time equivalent.
Figure 2 Extent of clinical pharmacy practice (full-time equivalent (FTE) heat map, blue=low extent, red=high extent) in parts with no (dark
green), partial (green) and unrestricted drug-dispensing physicians (light green).
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survey (all general hospitals with central supply level 1 and 80%
of general hospitals with central supply level 2). Third, since the
survey took a national approach, we report data from all cul-
tural areas of Switzerland and are able to discuss corresponding
patterns of resources and inﬂuencing factors on the develop-
ment of clinical pharmacy services.
The survey was designed as a self-declaration, involving several
limitations. First, although the established GSASA deﬁnition for
clinical pharmacy was implied as a standard reference, different
perceptions for practice may persist and could not be validated by
the authors. To minimise this effect, we tried to narrow the scope
of individual beliefs and personal opinions with explanations and
clariﬁcations within the survey. Second, individual institutions
reported on services that they have developed and established
according to local needs, but that could not be divided into the cat-
egories of the survey itself. These results could not be considered
in the analysis but should be pursued as an innovation in each
case. Third, our results allow no statements as to the quality, efﬁ-
ciency and beneﬁts of provided services on patient outcomes.
CONCLUSION
To our knowledge, this is the ﬁrst comprehensive national survey
of clinical pharmacy practice in Switzerland. Our data show
important regional differences in the extent of implementation
and pattern of clinical pharmacy services. A striking extent of low
dissemination was observed within regions of drug-dispensing
physicians in ambulatory care. While interprofessional ward
rounds were performed at least periodically in hospitals, which
offer clinical pharmacy services, seamless care activities by clinical
pharmacists remained insufﬁciently established.
Key messages
What is already known on this subject
▸ The pharmacist’s involvement in patient care during the
hospital stay appears to be highly valuable since the clinical
setting and related medication processes are recognised as
particularly risky situations.
▸ Around the world, the concept of clinical pharmacy was
successfully implemented in the hospital setting with various
speciﬁc services.
What this study adds
▸ This is the ﬁrst comprehensive survey of clinical pharmacy
practice in Switzerland reﬂecting the practical
implementation of a recently introduced theoretical
deﬁnition.
▸ Our data show important regional differences in the extent
of implementation and pattern of clinical pharmacy services,
highlighting a crucial gap in seamless care activities.
▸ In particular, the regional presence of drug-dispensing
physicians in the ambulatory care setting seemed to limit
the development of clinical pharmacy practice in
corresponding hospitals.
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Messerli M, et al. Eur J Hosp Pharm 2016;0:1–6. doi:10.1136/ejhpharm-2015-000868 5
Original article
Contributors MM and KAM initiated and conducted the survey. MLL and KEH
helped in developing the measurement tools. MM accessed and analysed the data.
He also prepared the ﬁrst draft of the manuscript. KAM, KEH and MLL contributed
to the discussion and reviewed the manuscript. They all approved the ﬁnal version to
be published.
Competing interests None declared.
Provenance and peer review Not commissioned; internally peer reviewed.
REFERENCES
1 Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care.
Am J Hosp Pharm 1990;47:533–43.
2 Penna RP. Pharmaceutical care: pharmacy’s mission for the 1990s. Am J Hosp
Pharm 1990;47:543–9.
3 Hohmann C, Neumann-Haefelin T, Klotz JM, et al. Drug-related problems in
patients with ischemic stroke in hospital. Int J Clin Pharm 2012;34:828–31.
4 Leendertse AJ, Van Den Bemt PM, Poolman JB, et al. Preventable hospital
admissions related to medication (HARM): cost analysis of the HARM study.
Value Health 2011;14:34–40.
5 Kongkaew C, Hann M, Mandal J, et al. Risk factors for hospital admissions
associated with adverse drug events. Pharmacotherapy 2013;33:827–37.
6 Kripalani S, LeFevre F, Phillips CO, et al. Deﬁcits in communication and information
transfer between hospital-based and primary care physicians: implications for
patient safety and continuity of care. JAMA 2007;297:831–41.
7 Nickerson A, MacKinnon NJ, Roberts N, et al. Drug-therapy problems,
inconsistencies and omissions identiﬁed during a medication reconciliation and
seamless care service. Healthc Q 2005;8 Spec No:65–72.
8 Anguish I, Wick HD, Fonjallaz MH, et al. [Hospital’s discharge prescription: a
challenge for continuity of care and the interprofessional collaboration]. Rev Med
Suisse 2013;9:1021–5.
9 Bondesson A, Eriksson T, Kragh A, et al. In-hospital medication reviews reduce
unidentiﬁed drug-related problems. Eur J Clin Pharmacol 2013;69:647–55.
10 Pai AB, Boyd A, Depczynski J, et al. Reduced drug use and hospitalization rates in
patients undergoing hemodialysis who received pharmaceutical care: a 2-year,
randomized, controlled study. Pharmacotherapy 2009;29:1433–40.
11 Swiss Society of Public Health Administration and Hospital pharmacists (GSASA).
GSASA 1948–2008—Jubilee edition. GSASA J 2008;111–112.
12 Swiss Society of Public Health Administration and Hospital pharmacists (GSASA).
Deﬁnition of Clinical Pharmacy in Switzerland. In: (GSASA) SSoPHAaHp, ed. V.1,
2011. Deﬁnition of Clinical Pharmacy in Switzerland V1/2011. http://www.gsasa.ch/
seiten/aktivitaeten/klinische
13 Frontini R, Miharija-Gala T, Sykora J. EAHP survey 2010 on hospital pharmacy in
Europe: parts 4 and 5. Clinical services and patient safety. Eur J Hosp Pharm
2013;20:69–73.
14 Bussières J. Hospital Pharmacy in Canada > Clinical Services. Secondary Hospital
Pharmacy in Canada > Clinical Services, 2000. http://www.lillyhospitalsurvey.ca/
hpc2/content/rep_2000_3.asp
15 Pedersen CA, Schneider PJ, Scheckelhoff DJ. ASHP national survey of pharmacy
practice in hospital settings: dispensing and administration—2002. Am J Health
Syst Pharm 2003;60:52–68.
16 Pedersen CA, Schneider PJ, Scheckelhoff DJ. ASHP national survey of pharmacy
practice in hospital settings: dispensing and administration—2005. Am J Health
Syst Pharm 2006;63:327–45.
17 Pedersen CA, Schneider PJ, Scheckelhoff DJ. ASHP national survey of pharmacy
practice in hospital settings: dispensing and administration—2008. Am J Health
Syst Pharm 2009;66:926–46.
18 Pedersen CA, Schneider PJ, Scheckelhoff DJ. ASHP national survey of pharmacy
practice in hospital settings: dispensing and administration—2011. Am J Health
Syst Pharm 2012;69:768–85.
19 Schneider T. Key ﬁgures of Swiss hospitals, 2011. In: (BAG) BfG, ed, 2013.
Statistics on health insurance, Federal Ofﬁce of Public Health 2013;7:45–349.
20 Pharmaceutical Care Network Euorpe (PCNE). Workshop report ‘PCNE Working
Symposium 2014, Sliema, Malta / Medication review, Drug-related problems,
Standards and Guidelines’. Secondary Workshop report ‘PCNE Working Symposium
2014, Sliema, Malta / Medication review, Drug-related problems, Standards and
Guidelines’ 2014. http://www.pcne.org/conference/9/pcne-working-symposium-2014
21 Blozik E, Rapold R, Reich O. Prescription of potentially inappropriate medication in
older persons in Switzerland: does the dispensing channel make a difference?
Risk Manag Healthc Policy 2015;8:73–80.
22 Swiss Society of Public Health Administration and Hospital pharmacists (GSASA).
2015. http://www.gsasa.ch/seiten/bildung/fph-klinische-pharmazie/
weiterbildung-klinische-pharmazie/
23 Swiss Federal Statistical Ofﬁce. Medical statistics of Swiss hospitals 2013—standard
tables [Medizinische Statistik der Krankenhäuser 2013—Standardtabellen], 2015.
24 Claeys C, Dufrasne M, De Vriese C, et al. [Information transmission to the
community pharmacist after a patient’s discharge from the hospital: setting
up of a written medication discharge form, prospective evaluation of its impact,
and survey of the information needs of the pharmacists]. J Pharm Belg
2015;97:42–54.
25 Starmer AJ, Spector ND, Srivastava R, et al. Changes in medical errors after
implementation of a handoff program. N Engl J Med 2014;371:1803–12.
26 McLeod M, Ahmed Z, Barber N, et al. A national survey of inpatient medication
systems in English NHS hospitals. BMC Health Serv Res 2014;14:93.





































In  2013  (Berlin,  DE)  discussions  about  specific  opportunities  and  limitations  in  primary  or 
secondary  care  settings  triggered  a  splitting  of  the  intermediate MR  into  two  subtypes:  in 





‘all  medicines’  including  prescribed  and  OTC  and,  if  accessible,  the  history.  In  addition, 
‘medicines use’ was chosen according to the PCNE definition of Pharmaceutical care, which 
refers  to  the WHO  definition  of  «responsible  use  of medicines».  This  covers  effectiveness, 
quality  of  life,  efficiency,  and  safety.77  Further,  it  was  stated  in  form  of  a  comment  that 
medication  review  should  be  part  of  the  patient`s medication management  and  that  PCNE 
should define the term medication management. 
During the 5th PCNE Working Symposium 2016 in Hillerød (DK), a unique consensus method 
with  electronic  voting,  was  used  to  eventually  establish  a  solid  definition  of  the  term 
















could be detected with MR  type 2b. Dr.  Leikola  run  in parallel  another workshop aimed at 
establishing a list of DRPs that may be detected within type 1 and 2a medication reviews. 
 Time  schedule  was  limited  to  60  minutes.  Through  hand  voting  at  the  very  beginning, 
participants (n=21) were equally distributed in beginners (n=12) and experienced researchers 




definitions  for  critical  terms  used,  i.e.  pharmaceutical  care,  drug‐related  problems,  and 
medication review (including the PCNE typology) were identical. Later, the participants were 
divided  into  three  smaller groups. They agreed on different  settings,  in which a pharmacist 
might be involved and could provide medication reviews PCNE type 2b and/or 3. The discussion 











P1.1  No effect of drug treatment / therapy failure (x)  x
P1.2  Effect of drug treatment not optimal (x)  x
P1.3  Wrong effect of drug treatment (x)  x
P1.4  Untreated indication x  x
P2: Adverse reactions   
P2.1  Adverse drug event (non‐allergic) (x)  x
P2.2  Adverse drug event (allergic) (x)  x
P2.3  Toxic adverse drug event (x)  x
P3: Treatment costs   
P3.1  Drug treatment more costly than necessary x  x
P3.2  Unnecessary drug treatment x  x
P4: Others   











C1.1  Inappropriate drug (incl. contra‐indicated drug) x  x
C1.2  No indication for drug x  x
C1.3  Inappropriate combination of drugs or drug and food x  x
C1.4  Inappropriate duplication x  x
C1.5  Unnoticed indication x  x
C1.6  Too many drugs for indication x  x
C1.7  More cost‐effective drug available x  x
C1.8  Synergetic or preventive drug required x  x
C1.9  New indication presented x  x
C2: Drug form   
C2.1  Inappropriate drug form (x)  x
C3: Dose selection   
C3.1  Drug dose too low x  x
C3.2  Drug dose too high x  x
C3.3  Dosage regimen not frequent enough (x)  x
C3.4  Dosage regimen too frequent (x)  x
C3.5  No therapeutic drug monitoring x  x





C4.1  Duration of treatment too short (x)  x
C4.2  Duration of treatment too long (x)  x




C5.2  Drug underused / under‐administered   x
C5.3  Drug overused / over‐administered   x
C5.4  Drug not taken / administered at all   x
C5.5  Wrong drug taken / administered   x
C5.6  Drug abused (unregulated overuse)   x
C5.7  Patient unable to use drug / form as directed   x
C6: Logistics   
C6.1  Prescribed drug not available x  x
C6.2  Prescribing error (information wrong or missing) x  x
C6.3  Dispensing error (wrong drug or dose) x  x
C7: Patient    x
C7.1  Patient forgets to take drug (x)  x
C7.2  Patient uses unnecessary drug   x
C7.3  Patient takes food that interacts   x












In  2015,  PCNE  invited  the  author  to  give  a  lecture  during  their  9th  working  symposium  at 
Mechelen (BE). During the preparation of the structured discussion on the effect of medication 




outcomes.  According  to  the  PCNE  definition,  medication  reviews  end  in  their  theoretical 
process  structure  with  a  recommendation  for  an  intervention.  Thus,  this  methodological 
restriction has to be considered whenever different services are compared with each other. 




One  has  to  be  aware  that  recommending  is  not  performing,  and  performing  is  not 
implementing. Kempen et al. reported in their study implementation rates up to 47% from their 
interventions  (recommending  to  stop  a  medication),79  highlighting  the  gap  between 
pharmacists’ proposals and prescribers’ acceptance of advice. Within a defined risk population, 
Perera  et  al.  performed  a  ‘medication  therapy management’  (MTM)  program  in  2011  and 
thereby  yielded  1,548  pharmacist‐initiated  medication  recommendations  faxed  to  1,163 
prescribers for 1,174 patients in a 5‐month period.80 The overall prescriber approval rate for 
these  recommendations  was  47.2%,  255  (16.5%)  recommendations  were  denied,  and  562 





effectiveness  of  performed  medication  reviews.  In  an  ideal  setting,  the  NNR  would  be  1, 
representing the average number of reviews needed to be provided to detect a specific clinical 
relevant  drug‐related  problem  that might  be  solved  through  an  subsequent  intervention.81 












B1  Development  of  a  method  for  calculating  adherence  to  polypharmacy  from 
dispensing data records  55 
































In  terms  of  a  comprehensive  overview  of  the  theoretical  considerations  regarding  the 
development of outcome measurements for the evalPMC project, both articles are presented 
in the following part of the thesis. Their implications, i.e. DPPR as a new adherence measure 
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Abstract Background Several measures for calculating
adherence to one medication from dispensing data records
have been proposed, but the nomenclature is inconsistent
and computations vary. The same measures, like the
medication possession ratio (MPR), have been used for
multiple medication regimens, and have tended to over- or
under-estimate adherence rates. Objective To demonstrate
the impact of varying elements in MPR to a single medi-
cation regimen; to define standards for the estimation of
adherence to polypharmacy; to propose a new method for
calculating adherence to polypharmacy; to face validate it.
Setting Face validity of the proposed method. Method
Variations in the MPR formula were simulated. Standards
for the estimation of adherence to polypharmacy were
defined. A new method to calculate adherence to poly-
pharmacy was established. Its face validity with three
illustrative cases obtained from a pharmacy refill database
was assessed. Main outcome measure Adherence rate to
polypharmacy from refill data records. Results MPR to a
single medication is operationalized in the numerator and
denominator and is influenced by the parameters like
observation period, medication gaps, overlap. For poly-
pharmacy, an average MPR is commonly used, which is
not accounting for the specificity of multiple medications,
and hence overestimating adherence rate. We propose the
daily polypharmacy possession ratio (DPPR) as an index
of adherence to polypharmacy. It estimates the proportion
of time a patient had medication available for use by
considering the presence or absence of multiple medica-
tions on each day in the observation period. We calculated
possession rates from refill histories over 31 months
(January 1, 2011–July 31, 2013) for three illustrative
patients. The average MPR estimates were 80 % for a
patient with 6 medications/20 refill dates, 90 % for a
patient with 4 medications/11 refill dates, and 89 % for a
patient with 3 medications/17 refill dates. The corre-
sponding DPPRs were 75, 88 and 99 %, indicating over-
estimations by 5 and 2 %, and underestimation by 10 %,
respectively. Conclusion The DPPR accounts for the
specificity of polypharmacy including number of medica-
tions, medication switching, duplication, overlapping.
Research is needed to further confirm the validity of this
new index.
Keywords Adherence  Compliance  Daily
polypharmacy possession ratio  Medication
possession ratio  Pharmacy claims  Polypharmacy 
Refill data
Impact of findings on practice
• The Daily Patient Possession Ratio (DPPR) offers cli-
nicians and researchers a method for estimating
adherence to polypharmacy regimens.
• When calculating adherence to polypharmacy, the DPPR
avoids the overestimation inherent to using single-med-
ication records.
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Introduction
Because a patient’s medication-taking behaviour is a pre-
requisite for evaluating the effectiveness of medications [1]
accurate and consistent measurement of adherence is critical.
The advance of computerized pharmacy records in developed
countries that use medical informatics in their health system
enables the assessment of adherence to an index medication
based on refill patterns [2]. Several measures for calculating
adherence rate from secondary database have been proposed,
such as: medication possession ratio (MPR) and related mea-
sures of availability; discontinuation/continuation; switching;
medication gaps; refill compliance, and retentiveness/turbu-
lence [3]. All have in common that they measure the timeliness
of prescription or refills, not actual drug-taking, and use the
medication exposure time to estimate adherence. Conse-
quently, the measures quantify the patient’s possession of
medication and, thus, calculate the highest possible level of
medication consumption over a particular time frame.
Although there is no gold standard, MPR is the most commonly
used measure. It is calculated by dividing the days’ supply of a
medication dispensed by the number of days in the time
interval of interest. Another often used measure is the propor-
tion of days covered (PDC), which represents the proportion of
days a patient has a medication available in a given period of
time and uses indices truncated at 1.0 [4]. These measures are
widely used because dispensing databases contain the neces-
sary elements for calculation: (a) the quantity dispensed, which
usually is the package size or a multiple of it dispensed at one
time; or alternately for dispensing from bulk stock the number
of medications supplied at one time; (b) the prescribed daily
dosage, or the amount of medication to be consumed per day,
which is calculated as (pills per dose) 9 (dose per day); and
(c) the number of days’ supply, that is, the quantity dispensed
divided by the prescribed daily dosage.
Being derived from longitudinal dispensing databases, the
MPR and PDC can quantify long-term adherence and asso-
ciated outcomes. However, five definitions influence the cal-
culation of these measures and explain the variations in results
often seen. First, the observation period, i.e., the length of the
time over which adherence is assessed, may start and end at a
specific fill and refill date; on arbitrary start/stop dates that are
set as the index or inventory date and are independent from
fills and refills; or a combination of a fixed and an arbitrary
date. Second, an initial/terminal gap between dates of first/last
fill and arbitrary start/end dates may be present and can be
quantified as a proportion of time without supply. Third, an
interim gap may exist between refills when prior supply is
depleted before refill supply is available. Fourth, the number of
days’ supply dispensed at any fill/refill event may vary and
requires adjustments in the calculations. Alternately, and fifth,
overlap may occur as refill precedes depletion of the quantity
from a prior dispensing, and leads to stock piling of
accumulated supply. These five sources of bias may lead to an
under- or over-estimation of adherence to a single-medication.
The effects of these five sources of bias are likely to be
amplified when adherence to a polypharmacy regimen is
estimated using methods for single-medication adherence
such as the MPR or, as commonly done, averaging the MPR of
each medication in the polypharmacy regimen. Polyphar-
macy is common due to comorbidities [5], an aging popula-
tion [6], clinical practice relying on multi-drug combinations
[7], or evidence-based guidelines recommending synergistic
drug combinations [8]. Polypharmacy is different from regi-
men complexity, which refers to the number of daily doses for
a medication, the presence of non-oral routes of administra-
tion, and the need for specific dosing instructions [9]. Because
polypharmacy is known to be associated with medication non-
adherence [10] because of the greater number of medications
that can be missed on a daily basis, the assessment of adher-
ence to the entire polypharmacy regimen is essential. Further,
because irregular and inconsistent intake of one or more drugs
in a polypharmacy regimen is common and may impact on
clinical outcomes, assessment of adherence to polypharmacy
is clinically relevant. The few studies that have attempted to
calculate adherence to several concurrent medications have
averaged the indices obtained for each of the single-medica-
tions [11–15]. This method has been shown to overestimate
[16] but may also underestimate adherence to polypharmacy
regimens.
Aim and objectives
In the absence of an integrated method for assessing adherence
to polypharmacy regimens and the estimation errors likely
from averaging methods, our aim was to develop a new
method for quantifying adherence to polypharmacy regimens.
Five objectives applied: (1) to document the estimation bias in
single-medication adherence as a function of the sources of
variation identified above; (2) to document the estimation bias
resulting from averaging single-medication methods to poly-
pharmacy regimens; (3) to specify the standards for calculat-
ing an integrated measure of polypharmacy adherence; (4) to
define the proposed method for calculating adherence to pol-
ypharmacy regimens; and (5) to establish initial face validity
of the method by applying to three illustrative cases obtained
from the dispensing records of a community pharmacy.
Methods
Estimation bias in single-medication adherence
We constructed a hypothetical refill scenario commonly
seen in reimbursement records for medicines for long-term
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conditions in order to illustrate the impact of variable
elements on the calculations of adherence to single-medi-
cation such as hypertension. We selected seven dispensa-
tions in analogy to Steiner et al. [14] and calculated several
indices. Two different observation periods of 250 days
each were used: (1) from the first fill to the last refill date;
and (2) over two arbitrary dates. Four calculations were
performed:
1. The proportion of supply between dispensations or
adherence in one refill interval (An/Bn), calculated as
the days’ supply obtained at the beginning of a specific
interval divided by the days elapsed before the
subsequent fill and expressed as a percentage.
2. The days without supply between dispensations or
gaps in one refill interval (Gn = Bn - An), calculated
as the days elapsed before the subsequent fill i.e., the
number of days between dispensations, minus the
days’ supply obtained at the beginning of the interval.
3. The proportion of time with adequate supply or





as the total days’ supply obtained over the observation
period and across all time intervals divided by the
number of days of the observation period and
expressed as a percentage.
4. The proportion of time without adequate supply or





as the total days of gaps (?) or surplus (-) divided by
the total days to next dispensation or to end of
observation period; that is, the cumulative sum of the
number of days between dispensations minus the total
days’ supply divided by the number of days in the
observation period.
Estimation bias in polypharmacy adherence calculated
with averaging methods
We again constructed a hypothetical scenario, this one
involving 3 medications with a combined 15 refills [17]
and an observation period beginning with the initial fill at
the start date and ending with the medication review.
Medication 1 came in a package size of 14 with seven
refills at days 1, 15, 29, 43, 57, 71, 101 and end date at
110 days. Medication 2 came in a package size of 30 with
four refills at days 1, 41, 61, 120 and end date at 120 days.
Medication 3 came in package size of 60 with four refills at
days 1, 31, 51, 101 and end date at 110 days.
Specification of standards
On the basis of the above bias estimation exercises, prior
review work, and literature evidence, calculation standards
were set to assure uniformity in calculations.
Development of method
A proposed method based on these standards was devel-
oped and evaluated for arithmetic accuracy.
Initial assessment of face validity
We applied the method to three illustrative cases varying in
the number of medications and refills obtained from the
dispensing data records of a community pharmacy in Basel,
Switzerland.
Results
Estimation bias in single-medication adherence
Figure 1 depicts the adherence calculations for a patient
with a chronic condition with a hypothetical refill scenario
of a medication to be taken once daily with 7 dispensations
in analogy to Steiner et al. [14]. Table 1 summarizes the
calculated adherence rates between each refill event and the
next.
Table 2 presents the days without supply between dis-
pensations (or gaps).
Table 3 summarizes the MPR results. The overall pos-
session rates are 108 %/84 % if calculations consider all
values without the last refill, and 93 %/87 % if single
values are capped at 1.0, underscoring that adherence is
underestimated with truncated values.
Table 4 presents the proportion of time without ade-
quate supply (or gaps) over all refill intervals. The pro-
portion of gaps is -0.08/0.04 if calculations consider all
values and 0.14/0.22 if negative values are set to zero, thus
masking the surplus (negative gaps’ value). If accumulated
oversupply is assumed to be used when the supply is
exhausted and carryover from one interval to the next is
allowed, the proportion of time without medication
declines from 35 to 25 days, which corresponds to an
overall 4 % improvement in supply.
Estimation bias in polypharmacy adherence calculated
with averaging methods
Figure 2 graphs the average MPR calculation with a
hypothetical scenario of 3 medications with a combined 15
refills. Note that the observation period begins with the first
refill at start date ‘‘day 1’’ and runs until the medication
review (an arbitrary date). The MPR for medication 1 is
(7 9 14)/110 = 89 %; for medication 2 it is (4 9 30)/
120 = 100 %; and for medication 3 it is (4 9 60)/
110 = 218 %. Hence the average MPR is
[(7 9 14) ? (4 9 30) ? (4 9 60)]/
194 Int J Clin Pharm (2014) 36:192–201
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(110 ? 120 ? 110) = 135 %, denoting an overconsump-
tion of medication.
Specification of standards
The average MPR calculation does not control for the
influence of several medications having been prescribed,
across varying schedules, and the expectation that patients
adhere to all medications regardless of regimen. Further,
patients rarely refill a medication on exactly the day fol-
lowing the last day of use of the previous dispensing. In
addition, because of different package sizes, patients may
have refills due on different dates. As a consequence, they
adapt their refill obligation to daily duties and schedules
and may refill a prescription earlier (overlap of two dis-
pensations, surplus) or later (gap without supply between
two dispensations). Thus, apparently excessive or insuffi-
cient refill patterns may be misinterpreted as oversupply or
lack of medication, when they may represent daily life
days‘ supply

































Fig. 1 Scenario of adherence to a single-
medication, starting at the first fill (dark,
bold line) or an arbitrary date (grey, dotted
lines) over an observation period of
250 days (arbitrary end date). RnX = refill
number and quantity dispensed;
An = number of days’ supply;
Bn = interval between dispensations; gaps
indicate number of days with no medication.
Note the arrows from R2 to R3 indicate
carryover of excess medication from one
interval to the next interval
Table 1 Estimates of single-medication adherence between each refill event and the next, for each observation period (starting at a refill date or
an arbitrary date)
Refill event R1 R2 R3 R4 R5 R6























R(number) refers to interval starting at a given refill event and ending at the next refill event; e.g., R1 is refill event 1 and the interval ends with
R2
Table 2 Days without supply between dispensations (or gaps), for each observation period (starting at a refill date or an arbitrary date)
Refill event R1 R2 R3 R4 R5 R6



































A positive value indicates a lack of supply, a negative value indicates a surplus of supply
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conditions such as foresight before holidays or using up all
medication before the next refill.
We propose new definitions of the parameters needed to
calculate medication possession rates with refill data
(Table 5). In the numerator, extra doses beyond the end of
the observation period should be excluded (no oversupply);
therapeutic switching and therapeutic duplication should be
considered as one medication (no duplication), and changes
in dosage should be recognised and accounted for. In the
denominator, the observation period should start at the first
dispensation date, end either at the last refill date or at the
medication review date, and cover at least two refills (no
gaps). Finally, the carryover of excess medication from one
interval to the next interval should be allowed, yet without
retroactive compensation.
Table 3 Medication possession ratio (MPR) calculated over all refill intervalls, with or without the last refill, and with single values capped at
1.0, for each observation period (starting at a refill date or an arbitrary date)
Specifications With last refill Without last refill With single values capped at 1.0




(0.86 ? 1 ? 0.70 ? 1 ? 1 ? 1)/6
(93 %)




(0.67 ? 1 ? 0.70 ? 1 ? 1)/5
(87 %)
Table 4 Proportion of time without adequate supply (or gaps) over
all refill intervals, with all values or negative values set at zero (no
surplus), for each observation period (starting at a refill date or an
arbitrary date)




(10 - 10 ? 25 -
20 - 5 - 20)/250
(-0.08)





(30 - 10 ? 25 -
20 - 15)/250
(0.04)






























14 14 14 14 14 14 14
average MPR
= 135%
Fig. 2 Scenario of adherence to a combined drug regimen for a
patient (with a chronic condition) with a medication to be taken once
daily in analogy to [17]. The refills of 3 medications are depicted with
15 dispensations over an observation period defined between the first
fill (R1 at day 1, start date) and a medication review (arbitrary end
date). R refill number; box with number quantity dispensed
Table 5 New definitions proposed of the parameters required to
calculate possession rates with refill data
New definitions of the parameters Pros




End the observation period at the last refill
date or at the medication review date
No artificial terminal
gaps
Exclude any extra doses of the last




Allow the carryover of excess medication




Exclude patients with two refills or less No artificial gaps
Consider therapeutic switchinga as one
medication and not as a duplication
No artificial
duplication
Consider switching from two medications to
one combination pill as therapeutic
switching, with the first refill in time
determining the index medication
substituted by the combination pill
No artificial
duplication




Consider therapeutic duplicationb as one
medication, with the index medication being
the one with the first refill in time
No artificial
duplication




a Medication switch occurs when a subject initially fills a prescription
for one product, then at a later point fills a prescription for a different
product in the same therapeutic class and never refills the first product
within the observation period
b Therapeutic duplication is defined as multiple medication use
within the same therapeutic class, and can result from therapeutic
augmentation; prescription error must be excluded
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New method for calculating adherence
to polypharmacy
With these definitions, we posit that the numerator cannot
merely be the sum of the days’ supply, that each day should
be assessed independently, and that the proportion of daily
medications on-hand be calculated. We propose as new
index the daily polypharmacy possession ratio (DPPR).
The method is as follows: Look at each day in the obser-
vation period separately, and determine how many medi-
cations are available, set a score between 0 (no medication
available) and 1 (all medications available) weighted by the
number of medications to be taken each day, resulting in
daily scores indicating the proportion of medications
available for each day. Sum the scores and divide by the
number of days in the observation period to obtain the
proportion of all medications available for daily use.
Figure 3 shows the calculation of the DPPR for 3
medications to be taken once daily with 15 dispensations
over the same observation period as used in Fig. 2. Each
daily score can take a value of 1 (all medications avail-
able), 2/3 (two medications available), 1/3 (one medication
available) or 0 (no medication available). The sum of the
daily scores (10 9 1/1) ? (20 9 3/3) ? (10 9 2/
3) ? (54 9 3/3) ? (6 9 2/3) ? (10 9 1/3) ? (9 9 2/
3) ? (1 9 3/3) is 104.9. Next 104.9/120 = 87.5 % yields
the DPPR and represents the weighted percentage of
medications available. The accumulated surplus of daily
doses is 80 (medication 1). The accumulated number of
days with at least one missing dose is 16 for medication 1
(4.7 %) ? 30 for medication 2 (8.8 %) = 46 (13.5 %).
The DPPR requires a ‘‘supply diary’’ for each patient-
day. Because overuse or excess prescription of medications
cannot be detected with the DPPR, the surplus of daily
doses and the total number of missed doses (gaps) during
the observation period should be evaluated to complete the
description of the observed population.
Initial assessment of face validity
Three patients with polypharmacy using a single commu-
nity pharmacy in Basel (Switzerland) were selected by the
pharmacist who subjectively and clinically identified an
adherer, an underadherer and an overadherer. The medi-
cation histories between January 1, 2011 and July 31, 2013
were retrieved from the pharmacy database. They include 1
male (M1) and 2 female (F1, F2) patients; aged 72, 78 and
74 years; with 4, 3 and 6 medications daily; and 11, 17, and
20 refill dates over the observation period of 31 months,
respectively (Box 1).
The results are presented in Box 1. The MPRs were
calculated with the average MPR method and yielded 90 %
for patient M1, 89 % for patient F1, and 80 % for patient
F2. With the DPPR method and the standards defined
above, the DDPR rates were 88, 99 and 75 %, respectively.
The mean numbers of days without supply (gaps) were
-10, -1 and -24 %, respectively.
Discussion
The two methods most often used to measure medication
adherence from dispensing data records are the MPR and
the PDC. However, because of lack of standards and def-
initions necessary for the parameters used in calculation,
the methods described in studies vary widely. As an
example, Hess et al. [18] calculated adherence rates rang-
ing from 63.5 to 104.8 % when applying 11 different cal-
culation methods to the same set of pharmacy data. As a
consequence, comparing results between studies is often
difficult if not impossible. Further, many assumptions are
made when adherence rates (i.e., medication consumption)
are calculated from secondary databases; e.g., that a person
has the medication available on the day of the prescription;
that patients consume the medication as prescribed; that
patients start taking the medication on the day of dispen-
sation until the supply is exhausted; that medication con-
sumption is consistent throughout the observation period;
or that all extra doses accumulated during the observation































Fig. 3 Calculation of daily polypharmacy possession rate DPPR for 3
medications to be taken once daily, with 15 dispensations over an
observation period defined between the first fill (R1 at day 1, start
date) and a medication review (end date), same as in Fig. 2. Daily
possession is depicted as follow: all medications available (score of 1,
black bar), two medications available (score of 2/3, dark grey bar),
one medication available (score of 1/3, light grey bar). The arrow
indicates carryover of excess medication from one interval to the next
interval
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Patient F1 No days in the interval Quantity dispensed at the refill date of the medication (prescribed daily dosage)






18.01.11 100* 98 –
18.03.11 59 100* 98 100
14.05.11 57 100 0 0*
27.06.11 44 100 98 100
12.08.11 46 100 0 0
01.10.11 50 100 98 100
21.11.11 51 100* 0 0*
23.01.12 63 100 98 100
01.03.12 38 100 0 0
16.04.12 46 100 98 100
19.06.12 64 100 0 0
02.08.12 44 200* 98 100*
20.11.12 110 100 98 100
31.12.12 41 100 0 0
19.02.13 50 100 98 100
08.04.13 48 100 0 0
25.05.13 47 100 98 100
16.07.13 52 200 0 100
31.07.13 15
Box 1 Medication histories of three illustrative patients (M1, F1, and F2) between the start date (January 1, 2011) and an arbitrary review date
(July 31, 2013), with indication of the prescribed daily dosage (e.g., 1–0–0 stands for one tablet every morning), number of days in the single
intervals and in the observation period (total); quantity dispensed at the refill date and total of days’ supply (calculated as quantity dispensed
divided by the prescribed daily dosage), and total number of days without supply (gaps). Asterisks (*) indicate insufficient supply for the next
interval
Patient M1 No days in the interval Quantity dispensed at the refill date of the medication (prescribed daily dosage)






Salmeterol 25 lg ? fluticason 250 lg
(1–0–0)
11.01.11 100 – 90 60*
05.04.11 84 100* – 196 60*
11.10.11 189 100 100 98 60*
12.01.12 93 100 100 98 60
07.03.12 55 100 100 98 60*
27.06.12 112 0* 0* 0 60
08.08.12 42 100* 100* 98* 120
07.12.12 121 100 100 98 60*
27.02.13 82 100 100 98 60
23.04.13 55 0 0 0 60
14.06.13 52 100 100 98 120
31.07.13 47
Total 932 900 700 972 780
Total gaps -96 -23 -18 -238
Calculation: ‘‘average MPR’’ = [(900 ? 700 ? 972 ? 780)/4]/932 = 90 %
DPPR = [(60 9 3/3 ? 24 9 2/3) ? (60 9 3/3 ? 56 9 2/3 ? 73 9 1/3) ? (60 9 4/4 ? 33 9 3/4) ? 55 9 4/4 ? (65 9 4/4 ? 47 9 3/
4) ? (40 9 4/4 ? 2 9 2/4) ? (100 9 4/4 ? 3 9 2/4 ? 18 9 1/4) ? (77 9 4/4 ? 5 9 3/4) ? 55 9 4/4 ? 52 9 4/4 ? 47 9 4/4]/
932 = 88 %
Gaps: mean -10 %
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not obtained on time or before the next refill [19]. This
might explain why some studies specify corrections for
values, often without a clear rationale, like setting negative
values to zero [17] or multiplying duration of drug use by
factor 1.1 to control for irregular use and early drug dis-
pensation [20].
continued
Patient F1 No days in the interval Quantity dispensed at the refill date of the medication (prescribed daily dosage)






Total 925 1,000 980 1,000
Total gaps -22 0 -13
Calculation: ‘‘average MPR’’ = [(500 ? 980 ? 1,000)/3]/925 = 89 %
DPPR = [(50 9 2/2 ? 9 9 1/2) ? (50 9 3/3 ? 7 9 2/3) ? (43 9 3/3 ? 1 9 2/3) ? 46 9 3/3 ? 50 9 3/3 ? 51 9 3/3 ? (53 9 3/
3 ? 6 9 2/3 ? 4 9 1/3) ? 38 9 3/3 ? 46 9 3/3 ? 64 9 3/3 ? 44 9 3/3 ? (108 9 3/3 ? 2 9 1/3) ? 41 9 3/3 ? 50 9 3/3 ? 48 9 3/
3 ? 47 9 3/3 ? 52 9 3/3 ? 15 9 3/3]/925 = 99 %
Gaps: mean -1 %
Patient
F2
No days in the
interval





















04.01.11 120 98 – – – –
10.02.11 37 120 196 – 98 100 240
03.05.11 82 0* 0 28* 0* 0 0*
21.06.11 49 120 0 0* 98 0 120
04.08.11 44 240 0 98 0* 0* 0*
18.10.11 75 0 0* 0 196 0* 0*
08.11.11 21 0 98 0* 0 0* 0*
03.12.11 25 0* 0 0* 0 100 120
03.01.12 31 120* 0* 98 0 0 0*
15.03.12 72 120 98 0* 98 0 0*
14.05.12 60 120 0 0* 0 0 0*
04.06.12 21 0 0* 98 0 0* 0*
25.06.12 21 0* 98 0 98 0* 0*
25.08.12 61 120 98 98 0 100 0*
20.10.12 56 240 0* 98 98 0 240
25.01.13 97 120 98 0 0* 0 0*
25.02.13 31 0 0 0* 0* 0* 120
05.04.13 39 120 98 98 0* 0* 0*
13.05.13 38 0* 0 0* 0* 100 0*
13.07.13 61 0* 98 98 98 0 120
31.07.13 18
Total 939 780 980 714 784 800 480
Total
gaps
-159 -66 -186 -204 -223 -497
Calculation: ‘‘average MPR’’ = [(780 ? 980 ? 714 ? 784 ? 800 ? 480)/6]/939 = 80 %
DPPR = [37 9 2/2 ? 82 9 5/5 ? (1 9 6/6 ? 15 9 5/6 ? 12 9 4/6 ? 10 9 3/6 ? 11 9 2/6) ? 44 9 5/6 ? (16 9 6/6 ? 9 9 5/
6 ? 29 9 4/6 ? 21 9 3/6) ? (7 9 4/6 ? 14 9 3/6) ? (2 9 4/6 ? 23 9 3/6) ? (15 9 5/6 ? 16 9 4/6) ? (29 9 6/6 ? 13 9 5/
6 ? 18 9 4/6 ? 12 9 3/6) ? (26 9 5/6 ? 34 9 4/6) ? 21 9 4/6 ? (16 9 5/6 ? 1 9 4/6 ? 4 9 3/6) ? (18 9 4/6 ? 43 9 3/6) ? 56 9 5/
6 ? (79 9 6/6 ? 18 9 5/6) ? (23 9 6/6 ? 2 9 5/6 ? 6 9 4/6) ? (16 9 5/6 ? 12 9 4/6 ? 11 9 3/6 ? (13 9 4/6 ? 25 9 3/
6) ? (39 9 4/6 ? 21 9 3/6 ? 1 9 2/6) ? 18 9 5/6)]/939 = 75 %
Gaps: mean -24 %
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To enable a more uniform presentation of data and thus
improve the consistency and quality of adherence analyses,
international experts developed a checklist of key issues on
how to perform retrospective analyses of refill medication
databases [21]. Unfortunately, the proposed measurements
of adherence lack key details and procedures, such as rules
to avoid double-counting covered days or handling over-
supply. It is evident that accurate calculation of adherence
rates from refill data requires standard definitions of the
considered time frame, the numerator and denominator,
and the management of missing values and/or time periods.
A more subtle calculation has been advocated [16] to allow
for the comparison of results across studies and the trans-
lation to real world practice. With the advance of com-
puterized pharmacy records, some researchers developed
computational frameworks to detect such events as medi-
cation lapses in refill databases [22]. However, these
technical developments are only useful for individual
patient information and need further evaluation.
The influence of variable terms on the assessment of
adherence to single drug is amplified with multiple drug
assessment, especially when the method used is indifferent
to the specific settings. A study comparing different cal-
culation methods showed that the use of MPR for more
than one medication overestimates adherence, predomi-
nantly due to the presence of duplication [4]. Since the
‘‘average MPR’’ does not account for the number of
medications, the frequency of medication switching, the
duplication, the overlapping, or the unexpected and same-
day refills, it can hardly reflect the actual adherence that it
was intended to measure. Thus, MPR methods are inade-
quate for quantifying adherence to polypharmacy
regimens.
In this article, we defined new standards for the calcu-
lation of possession rates with refill data and proposed a
new index, the DPPR. This index considers the presence or
absence of multiple medications on each day in the
observation period. It quantifies polypharmacy adherence
as the percentage of medications daily available. This
approach accounts for the specificity of polypharmacy such
as the number of medications and frequency of medication
switching. It also eliminates duplication and overlapping,
the parameters responsible for the general overestimation
of adherence. With the three illustrative cases we selected
in a community pharmacy over 31 months, we piloted the
new method and demonstrated its face validity in daily
practice. As predicted, the DPPR values were lower than
the average MPR estimates. Thus, we posit that the DPPR
is closer to the actual adherence rate than other
calculations.
Our approach has several strengths. First, we propose a
standardization of the parameters used for calculation.
Second, we propose a method that is insensitive to
oversupply and duplication, the two parameters in mathe-
matical calculations that lead to overestimation of adher-
ence rates. Third, the DPPR represents a continuous index
of adherence across all subjects rather than a threshold-
based index, separating adherent from non-adherent sub-
jects. Moreover, the conversion from continuous data into
categorical data as well as the use of cut-points is only
recommended when the clinical validity of the specified
level of adherence has been demonstrated [21]. To our
knowledge, this exists only for oral contraceptives and HIV
drugs [23].
Our new index also has limits. First, the DPPR cannot
detect oversupply. Thus, we propose to indicate addition-
ally the evaluation of the accumulated surplus (oversupply)
and the accumulated days with at least one missing medi-
cation (gaps). Second, the DPPR requires a ‘‘supply diary’’
for each patient-day. This may be difficult to generate by
computer, mainly because dispensing and recording ser-
vices may differ across countries. For example, European
pharmacies dispense manufactured packagings of varying
sizes while US pharmacies have access to bulks and dis-
pense the exact number of units prescribed. The maximum
quantity of dispensed drugs is usually 90 days in the
Netherlands, with a maximum of 15 days for the first dis-
pensing, while no such restriction exists in Switzerland or
Germany, where the first dispensed package can be 100
tablets in size. Finally, calculation with variable dosage
schedule (e.g., ‘‘take 1 or 2 pills…’’) or ‘‘as needed’’ as part
of the instructions is not possible and these medications are
to be disregarded from the evaluation.
Conclusion
Estimates of adherence to single-medications obtained
from MPR-based methods may vary because of differences
in calculation methods. This problem is amplified by
multiple factors outlined in this article. Because adherence
to multiple medications has been assessed with methods
developed for single-medication use, results have so far
proved divergent. We propose new definitions to stan-
dardize the parameters needed to calculate possession rates
with secondary databases. We further propose a new
method to calculate possession rate with multiple medi-
cations that accounts for the specificity of polypharmacy.
Studies are needed to validate the new index DPPR, pref-
erably with a national database. Subsequently, defining of a
formula and programming of codes for computer-generat-
ing the DPPR from dispensing data records should be
considered.
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Introduction
Medication records are increasingly collected worldwide and 
available from different sources such as prescribing, dispens-
ing, or reimbursement databases. The ready availability of 
these records has stimulated widespread use of these data to 
study patterns of medication use and assess medication 
adherence in daily clinical practices. Medication records 
often contain several elements required to calculate the num-
ber of days’ supply, such as the date of prescribing or dispens-
ing, the quantity dispensed, and the prescribed daily dosage 
(PDD). Differences in information that is available may exist 
between Europe and the United States. As an example, the 
instructions to patients (ie, the daily dosage information, such 
as, “Take 1 tablet 2 times daily”) are rarely contained in US 
prescription claims. Nevertheless, the US data set might have 
the days’ supply included when the pharmacy staff has access 
to the dosing instructions and calculates the days’ supply with 
its subsequent entry into the computer processing system. 
Nevertheless, calculations with medication records represent 
a simple approach to determine how much of the prescribed 
medications are being taken (ie, adherence) and for how long 
(ie, persistence). These measures have intuitive appeal, and 
their value in clinical research has been shown.1,2 They are 
objective, noninvasive, and economical for use in large popu-
lations because they can be easily derived from data routinely 
collected for administrative or other purposes. The reported 
calculations of adherence from medication records are indu-
bitably based on the above-mentioned elements, but specifi-
cation of standards for these calculations is missing.3-5 In the 
absence of any gold standard, no less than 11 different meth-
ods for calculating adherence were identified by Hess et al,6 
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Abstract
Background: Medication adherence is the process by which patients take their medication as prescribed and is an 
umbrella term that encompasses all aspects of medication use patterns. Ambiguous terminology has emerged to describe 
a deviation from prescribed regimen, forcing the European ABC Project to define 3 phases of medication use: initiation, 
implementation, and discontinuation. However, different measures of medication adherence using medication records 
are currently available that do not always distinguish between these phases. The literature is lacking standardization and 
operationalization of the assessment methods. Objective: To propose a harmonization of standards as well as definitions 
of distinct measures and their operationalization to quantify adherence to medication from medication records. Methods: 
Group discussions and consensus process among all coauthors. The propositions were generated using the authors’ 
experiences and views in the field of adherence, informed by theory. Results: The concepts of adherence measures within 
the new taxonomy were harmonized, and the standards necessary for the operationalization of adherence measures from 
medication records are proposed. Besides percentages and time-to values, the addition of a dichotomous value for the 
reinitiation of treatment is proposed. Methodological issues are listed that should be disclosed in studies on adherence. 
Conclusions: The possible impact of the measures in adherence research is discussed. By doing this, the results of future 
adherence research should gain in accuracy. Finally, studies will become more transparent, enabling comparison between 
studies.
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the most often used being the MPR (medication possession 
ratio) and the proportion of days covered (PDC).7 When 
applying the 11 different calculation methods to the same set 
of pharmacy data, Hess et al6 obtained adherence rates rang-
ing from 63.5% to 104.8%, demonstrating the dramatic influ-
ence of the methods on the computed adherence values. 
Wilke et al8 identified 47 publications with pharmacy claims 
using 12 different calculation methods. When applied to a 
simulation with reimbursement data of 113 108 patients, the 
adherence ranged between 15.7% and 97.0%. In fact, of the 
47 publications, only 4 named all the elements that were 
included in the calculations.8 Similarly, Caetano et al3 identi-
fied 5 different methods for calculating persistence, which 
resulted in a wide range of values and interpretations when 
applied to a hypothetical patient. In some cases, 1 isolated 
refill beyond the 360 days following treatment start was suf-
ficient to qualify a patient as persistent.9 Authors publishing 
adherence rates mostly omit a description of the operational-
ization of the assessment methodology5—that is, how the 
adherence measures were calculated. This lack of transpar-
ency regarding the operationalization of adherence measures 
complicates the comparison of adherence results across stud-
ies6,10,11 and the translation to real-world practice.9
In parallel, and almost inevitably, a proliferation of terms 
emerged in the literature to describe medication use.12 They 
all describe a deviant behavior and are often used inter-
changeably but define different aspects such as seeking med-
ical care, acquiring medication, or deviating from the 
prescribed therapeutic plan.12 As a consequence, a European 
consortium defined a new taxonomy for the umbrella term 
adherence to medications, which is “the process by which 
patients take their medications as prescribed.”12 It is divided 
into 3 quantifiable phases: initiation, implementation, and 
discontinuation. Persistence represents one aspect of adher-
ence and encompasses the time over which a patient remains 
on treatment. In this context, standards and definitions are 
needed to calculate the adherence measures according to the 
recently proposed taxonomy.12
Aims and Objective
The aims were (a) to harmonize the concepts of adherence 
measures from medication records within the new taxon-
omy; (b) to propose the standards necessary for the opera-
tionalization of these adherence measures; (c) to refine 
adherence calculation with medication data; and (d) to list 
the methodological issues that should be disclosed.
Methods
Six researchers with considerable expertise in medication 
adherence from Switzerland and the Netherlands—2 lead-
ing European countries in the integration of adherence 
measurements from medication records into pharmacy sys-
tems—formed a panel in summer 2014. All members were 
researchers from academia and involved in governmental 
projects, and 2 members were doctoral candidates who 
worked on calculation methods. All are members of 
ESPACOMP (European Society for Patient Adherence, 
Compliance and Persistence); 2 are founding members, 
and 1 a former president. The leadership was taken by a 
member of the Special Interest Group on Adherence from 
the European Society of Clinical Pharmacy. Because the 
lack of standardization of adherence measures is a tena-
cious problem in adherence research, the panel decided to 
propose recommendations for future adherence research. A 
consensual nature of the process based on recent method-
ological articles12,13 and discussion among experts was 
selected to generate first results in November 2014. Final 
consensus on the last version was obtained in July 2015. 
The concepts describing medication use behavior were 
harmonized; standards were set for the elements related to 
the (re)fill of a prescription; and the measures were refined, 
together with their basic calculations capable of quantify-
ing 3 phases of adherence.
Results
Harmonization of Concepts and Proposed 
Measures Describing Adherence
Because medical records contain variables that are mostly 
specific to their source—that is, quantity prescribed in pre-
scription records versus quantity dispensed in dispensing 
records—some variable might be lacking for some calcula-
tion. The assumptions for adherence measurements with 
pharmacy dispensing records are listed in Box 1.
Initiation of the treatment occurs when the patient takes 
the first dose12 and represents a dichotomous variable, 
based on first-fill data. With prescribing and dispensing 
records at disposal, sometimes, initiation is defined as the 
time from prescription until the first medication fill14—that 
is, a time-to-event variable. To reduce confusion, it should 
be named time-to-initiation. In any cases, the output is the 
number of primary nonadherers—that is, patients with a 
prescription that is not followed by a dispense.
Implementation is achieved when the patient’s actual 
dosing is compared with the prescribed dosing regimen, 
from initiation until the last dose is taken.12 For this phase, 
several measures are proposed.
Discontinuation and persistence are driven by the conti-
nuity of medication refilling. Discontinuation occurs when 
the next due dose is omitted and no more doses are taken 
thereafter. Discontinuation is, therefore, a dichotomous 
variable. Persistence describes the time from initiation until 
last dose12—that is, the end of therapy. Persistence is, there-
fore, a time-to-event variable. The dimension of time is an 
integral part of both terms.4 Exceeding a maximal permis-
sible length without supply (grace period) qualifies for dis-
continuation or nonpersistence. This maximal gap can range 
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from zero to an infinite number of days. Between those 2 
extremes, almost every gap length from 7 to 180 days has 
been proposed in the literature.15 Setting the cutoff is equiv-
alent to defining the sensitivity of the measure because the 
smaller the allowable gap, the higher the number of patients 
classified as having discontinued or being nonpersistent.16 
A 90-day allowable gap might be adequate to detect true 
nonpersistence because a study investigating the impact of 
several gap selections on persistence observed no major 
change with increasing gap days >90 days.17 Ultimately, 
however, the length of the permissible gap should depend 
on the medication(s)/condition(s) being studied.
Because patients may restart treatment at any point in 
time, the quantification of reinitiation of treatment is pro-
posed as the proportion of patients with a dispensing after 
the maximal predefined gap length.
Definition of Standards
The definitions of the elements with standards and calcula-
tions are summarized in Table 1.
The observation period is defined as the length of time 
over which the adherence measures are assessed. The period 
should start at t1 at the first (re)fill date, with the assumption 
that the patient starts medication intake that very day. The 
period should end either at the last refill date tn or at an arbi-
trary date ta (eg, a medication review date; t1 + 360 days). 
The rationale for such variable end dates is that refills are 
time-dependent events.
The number of days’ supply is defined as the quantity 
dispensed divided by the PDD. The latter equals the amount 
of medication to be consumed per day and is calculated 
with the dosing instruction as Unit(s) per dose × Dose(s) per 
day. Changes in dosage regimen according to medical pre-
scription should be accounted for and should be exhaus-
tively described. If the data set does not contain the quantity 
dispensed as a variable, it should not be used. With data sets 
that contain PDD as a variable, if the dosing instruction is 
missing, extrapolation from the following interval (for t1) or 
from the previous interval (for all other t) should be allowed. 
A data set should be excluded if dosing instruction is miss-
ing for 2 intervals in a row or if the instruction changed over 
time and is unknown. With data sets that typically do not 
contain dosage instructions as a variable, noticeable differ-
ences may result from assumptions made.18 Researchers 
should, thus, explicitly state what assumptions were made 
to estimate the numbers of days’ supply.
Oversupply (or stockpiling) results from overlapping 
days’ supply of subsequent refill intervals and equals accu-
mulated medications. Oversupply should be allowed, with 
the rationale that patients get supply before they have 
exhausted their drug supply and in a flexible manner accord-
ing to their daily activities and duties. It should be carried 
forward to the next interval (carryover) or at the end of a 
Box 1. Assumptions Underlying Adherence Measures With 
Pharmacy Medication Records.
•• Medication records are complete, comprehensive, and 
accurate
•• The first intake occurred on the day of the first fill
•• The medication is taken as indicated (eg, tablet ingested)
•• Lack of a refill equals a medication is not consumed after 
the oversupply is exhausted
•• Medications are not purchased or borrowed from another 
person or venue
•• No unknown treatment interruptions or dosing changes 
occurred during the observation period





Start and end 
points of the 
observation 
period
Period starts at t1 
and ends at tn or ta
t1 = date of first (re)
fill
tn = date of last refill
b




Number of days of 
the entire periodb










Amount of units 
to be consumed 
per day according 
to the dosing 
instructions
PDD = Number of 
units per dose × 
Number of doses 
per dayc
Number of days’ 
supply (An)




Refill interval (Bn) Number of days 
between 2 
dispensations
(Refill date tn) − (Refill 
date tn-1)






If (An > Bn), then 
oversupply =  
(An − Bn)
Gap Number of 
days without 
medication supply
If (An < Bn), then  
gap = (Bn − An)
Maximal gap 
length
Number of days of 
the longest period 
of time without 
supply (after 
taking carryover 
of oversupply into 
consideration)
 
aSee Figure 1 for graphical representation.
ba and n are integral numbers.
cCan be an integral or a fractional number.
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period with a gap, with the rationale that this pattern reflects 
real life—patients exhausting previous supply before start-
ing the new one. Retroactive compensation—that is, the use 
of an oversupply to compensate a gap that occurred earlier in 
the dosing history—should be forbidden. Results of a study 
with hypothetical dispensing patterns suggest that account-
ing for oversupply in adherence measurement (time-forward 
approach) performs better than other methods.10 Oversupply 
beyond the observation period should not be permitted—
that is, extra doses beyond the end of the observation period 
should be excluded. Oversupply beyond the end date was 
shown to overestimate adherence measures6 by inflating the 
value of the quantity dispensed.
A gap may exist between refills when prior supply is 
depleted before refill supply is available. It should be 
compensated to the extent possible by any existing over-
supply from a prior interval. Hospitalization or resi-
dence in a long-term care facility may lead to apparent 
gaps in pharmacy refills and are often interpreted as dis-
continuation, mostly because they remain unrecognized. 
If known, the hospitalization period should be subtracted 
from the denominator, assuming, first, complete adher-
ence to hospital drugs during hospital stay and, second, 
that patients do not obtain medications at discharge, and 
with the rationale that the amount of previous medica-
tion at the disposal of the patients after discharge is 
identical to that before hospitalization. A similar 
approach was used in a study developing an adherence 
index with inhaled corticosteroid.19 Unsurprisingly, 
adjusting for the time a patient was hospitalized by 
excluding the days of hospitalization marginally influ-
ences the adherence rate—that is, the adherence value is 
approximately 0.5% lower than without accounting for 
hospitalization days.7 If patients use their home medica-
tion in the hospital, no adaptation of the calculation is 
needed.
Switching is defined as one product being initially filled, 
then a different product in the same therapeutic class being 
filled at a later point within the observation period, and the 
initial product no longer filled. Generic switching is defined 
as switching between products with identical ATC code on 
level 5 (eg, C03EB01: Lasix 40 mg and Furosemide Actavis 
40 mg). In this case, switch is considered as the possession 
of 2 products one after the other, and carryover is granted 
under the above-mentioned conditions. Therapeutic switch-
ing is defined as 2 different medications—that is, different 
ATC code on level 5 (eg, A02BC01: Omeprazole 40 mg and 
A02BC02: Pantoprazole 40 mg; switching within chemical 
group) or on level 4 (eg, A02BC: proton pump inhibitor and 
A02BA: H2-antagonist; switching within pharmacological 
group). In this case, switch is considered as continuous use, 
and no overlap is granted—that is, a possible oversupply of 
one medication should be disregarded, with the rationale 
that a medical reason forced the physician to change medica-
tion (eg, lack of effectiveness, side effects, or intolerance).
Mandatory Information in Adherence Studies in 
Which Medication Records Are Used
To facilitate formal comparison between adherence stud-
ies published in the literature, some information should 
be clearly disclosed (Box 2). The issues are related to the 
operationalization of the adherence measures, which 
could dramatically influence the above-mentioned results.
Refinement of Calculation
Implementation is best given by the cumulative proportion of 
time at which medications are available—that is, in the posses-
sion of the patient. For monotherapy, the basic algorithm of the 
MPR is proposed. It sums the number of days’ supply (see cal-
culation below), divided by the number of days in the observa-
tion period, multiplied by 100. Some researchers and guidelines 
include the days’ supply for the last prescription dispensed (up 
to the end of the observation period) in adherence and persis-
tence calculations.20 However, oversupply beyond the obser-
vation should be excluded (see above), and the following 
calculation should be used:
If end date is tn (last refill date), then the numerator is 
[(Sum of days’ supply) − (Days’ supply obtained at tn)].
If end date is ta (arbitrary date), then the numerator is 
[(Sum of days’ supply without the last dispensing) + 
(Days’ supply obtained at the last dispensing up to the 
end date of the period ta).
The MPR ranges from 0% to 100%.
For polypharmacy, the basic algorithm of DPPR (daily 
polypharmacy possession ratio) is proposed. It has been 
Box 2. Issues to Clearly Disclose in Adherence Studies.
 1.  How was the data sample derived? (reimbursement, 
dispensing, prescribing data)
 2.  Was there a minimum number of fills and how was the 
minimum number of (re)fills defined?
 3.  Were all or only newly treated patients assessed? What 
was the definition of a newly treated patient?
 4.  Which adherence phase was assessed? (initiation, 
implementation, discontinuation)
 5.  How long was the observation period and how was it 
defined? (first vs last refill dates or first vs arbitrary end 
date)
 6.  How was the prescribed daily dose defined? (instructions 
for use, assumptions derived from treatment guidelines)
 7.  Was a single medication or polypharmacy analyzed?
 8.  How were hospitalization periods taken into account?
 9.  Which was the rationale for the use of threshold? (grace 
period, medication possession ratio)
10. How were missing values handled?
11. How were generic or therapeutic substitution handled?
12. How was dose switching handled?
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described elsewhere.13 The DPPR does not result from an 
equation but from the application of a stepwise algorithm. In 
brief, the number of all medications available is determined 
for each day separately over the observation period. A score 
between 0 (no medication available) and 1 (all medications 
available) is set. To obtain the proportion of all medications 
available for daily use, one has to sum the scores, divide by 
the number of days in the observation period, and multiply 
by 100. The DPPR ranges from 0% to 100%.
The basic algorithm for oversupply is (Number of days’ 
supply An) − (Days in the refill interval Bn) if An > Bn 
(Figure 1). The basic algorithm for gap is (Days in the 
refill interval Bn) − (Number of days’ supply An) if An < Bn 
(Figure 1). They are calculated simultaneously for each 
interval and summed up from one interval to the other. 
Because the use of an oversupply to compensate a gap 
that occurred earlier in the dosing history is forbidden 
(retroactive compensation), oversupply always has a 
value ≥0 (negative supply cannot exist).
Implementation is also depicted by the days without suf-
ficient medication supply (gaps). The basic algorithm for 
the time without supply sums the number of days without 
supply after each interval (after taking oversupply from pre-
vious intervals into consideration; see Figure 1) divided by 
the number of days of the observation period, multiplied by 
100. Last supply dispensed at the end of the observation 
period should be excluded. The value ranges from 0% to 
100%. Because this value does not capture the dynamics of 
the gaps, further measures are proposed. The maximum gap 
length is the number of days of the longest period of time 
without supply (after taking carryover of oversupply into 
consideration). The mean gap value ± standard deviation 
can be an indicator of dispersion.
Discontinuation and Persistence
The maximum period without supply (gap) should be 
clearly defined. The clinical relevance of stopping therapy 
should guide the maximal allowed gap. Thus, with drugs 
with short half-lives or when outcome is linked to short-
term drug effects such as cardiovascular or antidiabetic 
drugs, a shorter gap length can be justified, where patients 
are considered nonpersistent on the first day on which they 
would have exhausted their drug supply.21 Similarly, shorter 
gaps might detect clinically meaningful (“true”) nonpersis-
tence, for example, for HIV or anticoagulants. After setting 
the allowable gap length, persistence is best summarized 
using a Kaplan Meier curve or as a percentage of patients 
who have discontinued treatment during a defined time 
period.22 A cutoff at 3 to 6 months could be set to quantify 
the percentage of early discontinuers.
Reinitiation
Interruption of treatment and its subsequent reintroduction 
have been investigated, predominantly in HIV patients, 
where discontinuation(s) of treatment was shown to induce 
viral resistance23,24 and, ultimately, morbidity and mortal-
ity.21 In these studies, interruption was mostly self-reported25 
or was not defined.26 In larger studies analyzing cohorts 
from the national register, the probability of restarting a 
therapy with statin was estimated from gaps of different 
lengths—that is, after reinitiation of treatment.27,28 The pro-
portion of patients reinitiating therapy should be calculated 
by dividing the numbers of patients with a dispensing 
beyond the end of the allowable maximum gap by the num-
ber of patients defined as having discontinued therapy.
Figure 1. Graphical representation of the elements defined in Table 1. The observation period runs from the start day (t1 at the 
first dispensing date) to the end day (tn at the last dispensing date, or ta at an arbitrary date); A is the number of days with medication 
available, and B is the number of days between 2 dispensings. Oversupply obtained from A1 is carried forward to the next possible 
interval (arrow) at the end of A3, which is likely to occur in the real world. Oversupply obtained from A4 is disregarded if tn is the end 
date and added at the end of A6 if ta is the end date.
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Discussion
Standards and their operationalization are proposed to 
quantify adherence to medication from medication records 
of various sources within the new taxonomy of the European 
ABC Group.12 By doing this, this study builds on previous 
consensus-based work and links conceptual definitions to 
operational definitions.
Possession-related measures were selected (MPR for 
single medication and DPPR for multiple medication) to 
quantify the implementation phase of adherence because 
they are easy to calculate and interpret (the higher the 
value, the higher the medication possession). In addition, 
by integrating the last medication fill into the denomina-
tor, the MPR measures implementation over the time 
period that the patient was actually using the medication 
(from first fill to last fill). This deviates from the US stan-
dard for performance indicator–based reimbursement, 
which uses the PDC.29 PDC uses a fixed denominator, 
often 365 days (based on a calendar year or a year’s fol-
low-up). Even more confusing, some researchers used the 
last medication refill as their end date in PDC calcula-
tions, and some others used a fixed end date in their MPR 
calculations, leading to inconsistencies in the literature. 
Thus, it could be helpful to use the last fill date exclu-
sively for MPR measures and fixed end date for PDC 
measures. By doing this, the MPR value would indicate 
the quality of implementation in a single measure, 
whereas the PDC would be an indicator of both the qual-
ity and the length of implementation during a medication 
dosing history.
Some researchers have claimed that periods of under- or 
oversupply of medication may be obscured with possession 
rates.15 This might be true because the usual method of cal-
culation used so far does not account for duplication (simul-
taneous use of multiple agents from the same therapeutic 
class) and overlapping—the 2 parameters most frequently 
responsible for the general overestimation of adherence.30 
The proposed standards regulate duplication and overlap-
ping and, thus, eliminate major elements that distort calcu-
lation results. A special emphasis was set to avoid 
mathematical equations that would depict impossible situa-
tions in the real world, such as including the supply left over 
beyond the end of the study period. On the other hand, med-
ication oversupply through early refills (ie, stockpiling) is 
likely to occur in the real world and should be allowed. The 
most restrictive standard consists of forbidding the use of an 
oversupply to compensate a gap that occurred earlier in the 
dosing history (retroactive compensation). The proposed 
considerations reflect real-world situations because nega-
tive supply cannot exist. Patients either have supply (posi-
tive value) or they do not (zero value). Consequently, a 
stepwise algorithm along the intervals instead of an overall 
equation is needed. This algorithm is clearly more 
complicated, but it identifies more precisely periods of time 
where medication availability was unlikely.
The terms discontinuation and nonpersistence are used 
alternately to indicate the end of therapy. Confusion might 
occur when using nonpersistence as a dichotomous value 
because persistence is a time-to-event value. Choosing the 
term discontinuation might raise less doubt. Because medi-
cation records do not disclose what happens after the last 
dispense (ie, treatment stop or treatment holiday), uncer-
tainty forces decisions to be made. Defining a cutoff value 
for the number of days without supply (grace period) beyond 
which treatment is discontinued—that is, end of therapy—
determines nonpersistence. Part of the challenge is to set a 
limit that avoids misclassification of patients who restart 
treatment after a period of discontinuation and would other-
wise be lost to calculation if the grace period is too small. As 
a consequence, the assessment of reinitiation is proposed as 
a further measure in adherence research. By doing this, the 
cutoff value for discontinuation can still be applied, and pro-
longed gaps between refills, which may not signify cessation 
of therapy, will still be detected. It is likely that repetitive 
stop-and-go patterns have dramatic influence on therapy, 
and they have seldom been evaluated properly.31 With the 
setting of different cutoff values for discontinuation or non-
persistence, early discontinuers can be assessed, and new 
fields in adherence research are open for investigation. 
Generally, the allowable grace period is driven by the time 
between scheduled refills, and a pharmacological rationale 
is lacking for the definition of the grace period or the thresh-
old MPR. One study32 defined an allowable interruption gap 
of 42 days in accordance with a previous clinical trial that 
reported a potential loss of efficacy of the drug of interest 
after an interruption of 6 weeks.33 In most cases, the time 
between scheduled refills is an order of magnitude longer 
than the drug’s therapeutic effect. Nevertheless, the grace 
period should depend on the drug forgiveness, which allows 
larger gaps between scheduled doses without noticeable loss 
of pharmacological effect. In any case, the search for a uni-
versal value set to separate adherence from nonadherence is 
doomed to failure and can only result in contradictory 
results.34
To reduce confusion and inconsistency, several terms are 
excluded from the proposed concepts, such as the index 
date. Although this term has often been used in recent litera-
ture as the date of first claim,35 it also indicates the date of a 
drug-treated event in epidemiological matched cohort stud-
ies. Furthermore, the simple measure of refill rates is 
excluded—that is, a measure based on the number of refills 
during a specified period of time (flexible or anniversary 
model)—because the length of time between refills is given 
no consideration. In addition, the refill rate is implicit in a 
gap-based measure. The number of refills may nevertheless 
be a valuable calculation for medications that may be used 
as needed without detriment to the clinical condition. It may 
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further be appropriate for medications such as orally inhaled 
asthma drugs, where information on days’ supply may be 
imprecise.
The way in which raw data are obtained (eg, by pill 
count; prescribing, dispensing, or administrative data; 
electronic monitoring of single or multiple medication) 
determines the content of the database. However, manda-
tory information for calculations still includes drug name, 
drug dosage or dosing instructions, quantity of drug dis-
pensed at each (re)fill, and date of each prescription (re)
fill. In situations where the database contains the days’ 
supply (as entered by the pharmacist, for example), calcu-
lations can be performed when drug name and refill dates 
are also known. Provided the records are complete, the 
proposed measures can be calculated indiscriminately 
with prescribing and dispensing databases. In this regard, 
it is interesting to see that, increasingly, nationwide per-
sonal electronic medicine profiles are stored online for 
electronic prescribing and electronic monitoring of medi-
cine.36 However, a recent evaluation of the Danish system 
showed that it was yet unable to accurately detect nonad-
herence,36 predominantly because of incorrect prescrip-
tion information and missing dosage information. 
Experiences from the United States after the introduction 
of the Medicare Improvements for Patients and Providers 
Act37 in 2008 showed at least an increased use of e-pre-
scribing in response to the incentive program.38 Today and 
worldwide, the most accurate database remains the Dutch 
pharmacy dispensing system. It is worth noting that since 
January 1, 2014, Dutch physicians are obliged to use 
e-prescribing, and most of them send the prescription elec-
tronically to the pharmacy.
In future, the measures chosen by a researcher should be 
determined by the overall goals of the study—that is, clini-
cal efficacy trials (eg, MPR of the study drug), selection of 
ambulatory patients at risk in order to initiate an interven-
tion such as specific counseling (eg, nonpersistence with 
HIV medication), or conditions for reimbursement (eg, 
noninitiation). Much more, the study population should 
determine the cutoff values. As an example, the length of 
the observation period may vary depending on whether the 
study population is restricted to new or chronic users of the 
medications. Finally, because adherence is a complex 
behavior with several aspects, it cannot be caught in one 
number. In any case, a careful description of the definitions 
and operationalization used is crucial if comparisons 
between studies are to be made.
Strengths and Limitations
This study has several strengths. First, the proposed standards 
are close to a real-world setting and eliminate overestimation 
of adherence values. Second, the proposed measures build on 
the taxonomy established by the European ABC Project and 
pursue the work of promoting consistency for different exper-
imental investigations. Third, the proposed measures take full 
advantage of the information available in many databases, 
which is not the case for most of the current measures of 
adherence or persistence.
This study has some limitations. First, as is true of any 
indirect method of adherence assessment, the proposed mea-
sures are unable to confirm ingestion of the dispensed medi-
cation. As a consequence, they function as surrogate 
measures of medication adherence. However, they provide 
an estimate of the highest possible level of medication pos-
session and, thus, can identify those patients not able to con-
sume the medication in sufficient quantity. In that sense, the 
measures can be considered to have a high sensitivity. 
Second, different assumptions must be made, the main one 
being that all medication will be taken at the days’ supply 
indicated. However, a standardization of the assumptions 
will lead to comparable estimates of adherence across differ-
ent studies.
Conclusion
By following the displayed propositions, results of future 
adherence research should gain in accuracy and in confi-
dence, and results between studies should be comparable. 
Because the ultimate goal of adherence measurement is to 
improve patient care, the proposed measures could be used 
to set flags in electronic databases, based on which health 
professionals could select appropriate and effective inter-
ventions to move into practice. Researchers are invited to 
discuss this proposition of standards and to communicate 
their observations. Ultimately, generally approved standards 
are soon needed along with their operationalization, which 
could be endorsed by an umbrella society, so that health pro-
fessionals, researchers, health authorities, and policy makers 
can make informed choices for the benefit of patients and 
society.
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were  lucky  to  establish  a  collaboration  with  ProPharma  Systems  AG.  Together  with  their 
expertise, we developed an application based on Microsoft Visual Basic C++ 2010 and Microsoft 
Access 2010 and named it COMPARE for COMpute Polypharmacy Adherence RatE. With this 
application,  we  were  able  to  export  the  individual  refill  data  from  the  different  software 
solutions of the participating pharmacies. The tool then compiled the data in a standardised 





a  literature  research  to  select  validated  questionnaires.  In  collaboration  with  a  clinical 
psychologist,  a  comprehensive  in‐depth  patient  interview  was  created.  During  her  master 
thesis, Ms Véronique Lottaz  tested this drafted patient  interview with students during  their 
internship in a role‐play setting.84 Students (n=9) were instructed to answer as a pseudo patient 
following  a  fictive  patient  with  polymedication.  We  defined  the  ‘beliefs  about  medicines 
questionnaire’  (BMQ)85,86  and  two  questions  from  the German  8‐item  ‘Morisky Medication 
Adherence Scale’ (MMAS‐8D)87 as suitable. In addition, we focused on questions investigating 





to  face  with  the  investigator  and  occurred  problems  with  wording  were  subsequently 
discussed. After adaption, all nine students were  interviewed by  telephone and  interviewer 
entered data directly in a case‐report‐form, using Flexiform 2.6.9. The final patient interview 
contained 58 questions, subdivided in five sections, “medicines use”, “adherence and use of 


























RESEARCH ARTICLE Open Access
Impact of a community pharmacist-led
medication review on medicines use in
patients on polypharmacy - a prospective
randomised controlled trial
Markus Messerli1*, Eva Blozik2, Noortje Vriends3 and Kurt E. Hersberger1
Abstract
Background: In 2010 the ‘Polymedication Check’ (PMC), a pharmacist-led medication review, was newly introduced to
be delivered independently from the prescriber and reimbursed by the Swiss health insurances. This study aimed at
evaluating the impact of this new cognitive service focusing on medicines use and patients’ adherence in everyday life.
Methods: This randomised controlled trial was conducted in 54 Swiss community pharmacies. Eligible patients used
≥4 prescribed medicines over >3 months. The intervention group received a PMC at study start (T-0) and after
28 weeks (T-28) while the control group received only a PMC at T-28.
Primary outcome measure was change in patients’ objective adherence, calculated as Medication Possession
Ratio (MPR) and Daily Polypharmacy Possession Ratio (DPPR), using refill data from the pharmacies and
patient information of dosing.
Subjective adherence was assessed as secondary outcome by self-report questionnaires (at T-0 and T-28) and
telephone interviews (at T-2 and T-16), where participants estimated their overall adherence on a scale from 0–100 %.
Results and discussion: A total of 450 patients were randomly allocated to intervention (N = 218, 48.4 %) and
control group (N = 232, 51.6 %). Dropout rate was fairly low and comparable for both groups (NInt = 37 (17.0 %),
NCont = 41 (17.7 %), p = 0.845). Main addressed drug-related problem (DRP) during PMC at T-0 was insufficient
adherence to at least one medicine (N = 69, 26.7 %). At T-28, 1020 chronic therapies fulfilled inclusion criteria for
MPR calculation, representing 293 of 372 patients (78.8 %). Mean MPR and adherence to polypharmacy (DPPR) for
both groups were equally high (MPRInt = 88.3, SD = 19.03; MPRCont = 87.5, SD = 20.75 (p = 0.811) and DPPRInt = 88.0,
SD = 13.31; DPPRCont = 87.5, SD = 20.75 (p = 0.906), respectively).
Mean absolute change of subjective adherence between T-0 and T-2 was +1.03 % in the intervention and
−0.41 % in the control group (p = 0.058). The number of patients reporting a change of their adherence of more
than ±5 points on a scale 0–100 % between T-0 and T-2 was significantly higher in the intervention group
(NImprovement = 30; NWorsening = 14) than in the control group (NImprovement = 20; NWorsening = 24; p = 0.028).
Conclusion: Through the PMC pharmacist were able to identify a significant number of DRPs. Participants
showed high baseline objective adherence of 87.5 %, providing little potential for improvement. Hence, no
significant increase of objective adherence was observed. However, regarding changes in subjective
adherence of more than ±5 % the PMC showed a positive effect.
(Continued on next page)
* Correspondence: markus.messerli@unibas.ch
1Pharmaceutical Care Research Group, Department of Pharmaceutical
Sciences, University of Basel, Basel, Switzerland
Full list of author information is available at the end of the article
© 2016 Messerli et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Messerli et al. BMC Health Services Research  (2016) 16:145 
DOI 10.1186/s12913-016-1384-8
(Continued from previous page)
Trial registration: Clinical trial registry database, NCT01739816; first entry on November 27, 2012.
Keywords: Polypharmacy, Community pharmacy, Medication review, Drug-related problems, Adherence to
medication, Medicines use, Pharmaceutical care
Background
Increasing complexity of both, the therapy (polyphar-
macy) and the patient (multimorbidity) raises the risk
for drug-related problems with adverse events and
medication errors [1, 2]. Avoidable problems usually do
not result from individual misconduct, but from subopti-
mal processes. Drug-related morbidity as a result of these
risks is associated with high healthcare costs [3–5].
Situations with a high risk for drug-related problems
(DRP) include polypharmacy, significant changes in drug
therapy or changes in existing diseases, insufficient re-
sponse to drug therapy, suspected lack of therapy, symp-
toms of side effects, as well as discharge from hospital
with a change of drug therapy [6, 7]. One approach to
reduce the risks for developing DRP is to conduct medica-
tion reviews [8–10]. A worldwide shift in the professional
role of pharmacists is observed [11]. Pharmacists partici-
pate increasingly in clinical processes and perform tasks
in patient care. This transformation of the profession in-
cludes co-responsibility in the achievement of therapeutic
success, cost efficiency and avoidance of drug-induced
(re)hospitalisation. Accordingly, the Pharmaceutical Care
Network Europe (PCNE) felt the need to redefine
pharmaceutical care as “the pharmacist's contribution to
the care of individuals in order to optimise medicines
use and improve health outcomes” [12]. In the early
1990s, pharmaceutical care was introduced in community
pharmacy practice in Switzerland. Emphasis was given to
providing patient-centred care and cognitive services [13].
A postgraduate education program and mandatory
continuous education were launched together with
changes to pharmacists’ remuneration, which link pay-
ments to services delivered and not only to the volumes of
medicines dispensed. In 2010, the current remuneration
system was introduced, which defines a fee schedule for a
total of nine distinct services. Among these services the so
called ‘Polymedication Check’ (PMC) was newly intro-
duced as the first cognitive service to be delivered by
pharmacists independently of the prescriber for patients
on ≥ 4 prescribed drugs taken over ≥ 3 months. In addition,
the pharmacist may suggest - among other interventions -
to provide the medicines in a weekly dosing aid (WDA)
refilled by the pharmacy. Both services, the PMC and
the weekly filling of a dosing aid by the pharmacist
are reimbursed by the health insurance in the basic
insurance. Moreover, the current regulation allows
repeated dispensing of prescribed medicines for a
maximum of 12 months. Currently, such prescriptions
constitute nearly 75 % of all items dispensed [14].
Hence, Swiss community pharmacies assume very
responsible roles in the care of chronic patients.
Adherence and consequences of non-adherence
Approximately 25 % of patients with different diseases do
not take their medication as prescribed, although the
extent varies between 0–95 % [15]. On average, adherence
in long-term therapy is 50 % [16]. Lack of adherence is the
most common cause of the efficacy-effectiveness gap [17],
defined as the gap between therapy efficacy in daily life
compared to the effectiveness shown in clinical trials.
Previous studies have shown a positive impact of
structured interventions to improve adherence provided
by pharmacists [18, 19]. But there is still little evidence
related to the effectiveness of interventions performed
in community pharmacies. A recent Cochrane review
revealed that only a minority of studies with lowest risk of
bias (RCT design) improved both adherence and clinical
outcomes [20]. However, adherence as an outcome re-
mains challenging to measure because of methodological
issues and multifactorial influences [21]. Support of
adherence to treatment is only successful if the entire
medication is taken into account. Therefore, conducting
a medication review is the essential first step in any
adherence counseling.
Medication review
According to the current PCNE definition, a medication
review is ‘an evaluation of a patient‘s medicines with the
aim of optimising medicines use and improving health
outcomes. This entails detecting drug-related problems
and recommending interventions.’ [22]. The analysis in a
medication review always includes an inventory of current
medicines, a history of complaints, their course, a patient’s
concerns and individual needs for support. With respect
to the pharmaceutical care process [12, 23], the medica-
tion review is the starting point leading to the suggestion
of solutions, the planning and implementation of inter-
ventions and ultimately to the evaluation of the outcomes
[24]. Pharmacist-led medication review services are avail-
able in several countries such as the United Kingdom
(Medicines Use Review, MUR) [25], United States of
America (Medication Therapy Management, MTM)
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[26, 27], Australia (Home Medication Review, HMR)
[28], Canada (MedsCheck) [29, 30], and New Zealand
(Medicines Use Review, MUR) [31]. According to a
recent meta-analysis, a majority (57.9 %) of fee-for-
service pharmacist-led medication reviews improved
medication adherence and positively influenced pa-
tient outcomes [24].
The Polymedication Check
The Swiss Polymedication Check (PMC) is based on the
well-established Medicines Use Review (MUR) from
United Kingdom [32, 33]. Information is available from
the medication history, which is mandatorily kept in
community pharmacies and from a structured patient
interview. The Swiss PMC focuses on adherence prob-
lems, patients’ knowledge and handling problems and is
followed by specific interventions or recommendations
by the pharmacist. Implementation of such cognitive
services provided by a pharmacist is known to be very
challenging [34–36]. The same is true for Swiss com-
munity pharmacies. Implementation of the PMC is
low and after three years only about three checks per
pharmacy per year were registered, with a large ma-
jority of pharmacies not offering this service. While
in 2011 2’534 PMCs were carried out, in 2014 the
number of PMCs provided amounted at 6'940 PMCs
[37], which is an encouraging trend.
Rationale for the study
In Switzerland, new services remunerated by the basic
health insurance require a proof of their efficacy, appro-
priateness, and economic effectiveness according
national criteria [38]. The present study aimed at investi-
gating the impact of the PMC on patients on poly-
pharmacy. It was hypothesised that PMC would increase




A prospective, parallel group randomised controlled trial
(RCT) design was chosen to evaluate the impact of
the PMC. Contemporaneously, an in-depth evaluation of
the process and the perspectives of patients and pharma-
cists was planned to collect information for further
development of the service. The study setting considered
community pharmacies in a range of representative
regions of Switzerland (with and without self-dispensing
physicians, city versus country, German-speaking part
(D-CH) versus French-speaking part of Switzerland
(F-CH)). For each patient the observation period lasted
28 weeks from study start (T-0) until study end (T-28).
Eligibility for study pharmacists
The recruitment of 70 pharmacists was intended; thus,
community pharmacies in the cantons Aargau (AG),
Basel-Land (BL), Basel-Stadt (BS), Solothurn (SO),
Fribourg (FR), Neuchâtel (NE), Genève (GE), Vaud (VD)
und Valais (VS) were invited to participate in the study.
Basing on the principle of "first in, first served", the ideal
recruiting target was 50 pharmacists from the German
speaking and 20 from the French speaking part of
Switzerland in line with the national proportion of the
population. Study pharmacists were required to take part
in a study-specific training, and to give written consent
regarding the study design as well as a memorandum of
understanding through the pharmacy owner to collabor-
ate on the project until the end of study; in addition,
they were asked to commit to transfer patient’s refill
data to the study centre, and to collaborate with ei-
ther IFAK or OFAC (the two main clearing compan-
ies in Switzerland administering the charges between
pharmacies and health insurance and therefore also
holding the corresponding patient data). The three-
hour training session provided by the study centre in-
cluded an overview over the study, highlighted the
need for compliance to the study protocol, and clari-
fied rights and responsibilities of the study pharma-
cists. No further training on the execution of a PMC
was offered as the study aimed at assessing and
evaluating current practice.
Screening for eligible patients
In order to avoid selection bias through study pharma-
cist (e.g. Individual prejudices, preferences), a random
sample of 100 potential PMC candidates (age >18, ≥4
prescribed drugs for ≥3 months) was created for each
study pharmacy in collaboration with the two main
clearing companies IFAK and OFAC. The latter per-
formed an independent screening for each study phar-
macy and listed all patients fulfilling the selection
criteria for a PMC. Out of this sample of potential PMC
candidates, a random primary sample of 100 was se-
lected by IFAK and OFAC (Fig. 1).
Patient recruitment
The study pharmacist checked this primary sample for
exclusion criteria and consecutively invited subsamples
of ten patients by a letter to participate in the study.
Exclusion criteria for final recruitment were the following:
living in a retirement home, prior PMC, receiving weekly
dosing aids filled by the pharmacy or another person,
cognitive impairment, move or death, insufficient know-
ledge of written and spoken German or French. In addition,
study pharmacists re-checked if a patient met the primary
inclusion criteria. The study centre received informa-
tion on gender, date of birth and the reasons for
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exclusion of a patient. If the patient had expressed
his interest in the participation, the study pharmacist
informed him about the schedule, potential risks, and
compensation and handed over the declaration of
consent.
Randomisation process
The patients were assigned by 2 x 4 block randomisation
into intervention or control group. Initially, each study
pharmacist received two blocks containing eight dos-
siers (four intervention and four control) each packed
in sealed and unlabelled envelopes. Once the first
patient had consented, the study pharmacist opened
one envelope out of the first block to reveal what
arm of the study the patient had been randomised to.
Once all eight envelopes of block No. 1 had been
assigned, the next block was used. Upon request, fur-
ther blocks were available.
Structure of the intervention vs usual care
The intervention at T-0 included the execution of a
PMC according to the official guidelines. The adapted
study PMC protocol was used as assessment form. In a
structured face-to-face counselling with the patient, the
Fig. 1 Study flow chart with screening and recruitment process
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study pharmacists screened all medicines currently used.
The pharmacists checked for any gaps in knowledge or
other pharmaceutical care issues including handling and
adherence problems. The interview took place in a sepa-
rated area. Pharmacists were instructed to use open
questions to detect pharmaceutical care issues and to
decide if there was need for further investigation. For
each medication, the PMC protocol (Additional file 1)
required documentation whether the patient knew the
reason why he/she took the medicines (yes/no), if he/she
needed any counselling (yes/no) or had adherence prob-
lems (yes/no). Additionally, handling difficulties were
enquired, and the pharmacist documented all resulting
interventions such as consultation with the general prac-
titioner (GP), referral of the patient, potential suggestion
and implementation of a weekly dose reminder system,
or any other recommendations or interventions. Where
necessary, an individual patient education and a medica-
tion plan could be provided on the basis of the informa-
tion gained from the interview. None of this follow-up
interventions was standardised.
Usual care included no specific intervention and no
documentation at T-0. Patients of the control group only
received the two self-report questionnaires at study start
and study end, and the two telephone interviews.
Normal counseling for any new prescription or arising
question from the patient was always allowed and guar-
anteed, so patients from this arm were not restricted
from contacting the pharmacist for advice if they wished
to do so. If a PMC became indispensable during the
study period (e.g. by another pharmacist than the study
pharmacist), this patient of the control group was ex-
cluded. Overall, the study took seven months for each
patient and included two visits at the pharmacy with the
completion of questionnaires and participation in two
telephone interviews. Patients were able to contact the
study centre in case of further interest for the study pur-
poses or any problem with the study process (e.g. missed
telephone interview) using a separate telephone hotline
available 24 h seven days a week.
Classification of detected drug-related problems and
addressed interventions
To classify the addressed drug-related problems and
describe the pharmacists’ interventions, the GSASA
classification tool was used [39] This instrument com-
prises five main categories: i) problem, ii) type of prob-
lem, iii) cause, iv) intervention, and v) outcome. We
adapted the category ‘causes’ by dividing the section
‘Insufficient knowledge of the patient’ into three subdo-
mains focussing on patients’ individual needs for infor-
mation about a) safe and effective use of his medicines
b) the medicines’ potential adverse drug reactions c) his
lifestyle, nutrition or empowerment in general. Further
on, we added the category ‘More cost-effective therapy
available’ as the recommendation of generic drugs might
be likely triggered throughout a PMC.
Case report forms for study pharmacists
In order to support study pharmacists in their compli-
ance to the study protocol and to ensure coherent data
capture, case report forms (CRF) were developed. The
study pharmacist documented his interventions or rec-
ommendations resulting from PMC, classified the
underlying problems according to their urgency (low,
medium, high urgency) added any abnormalities or
changes in the care of the patient.
PMC protocol form
We used the official documentation form for PMC with
minor changes to ease data capture for the purpose of
the study (Additional file 1). This assessment form still
showed the format of one A4 side. At study end (T-28),
in addition to the PMC protocol the study pharmacist
documented observed drug-related problems, the fre-
quency of falls, and all changes in therapies since T-0
reported by the patient (dosage change, generic substitu-
tion, start/stop, no change). The documentation of these
changes was needed to identify eligible therapies for
objective adherence calculation.
Patient self-report questionnaires
Patient self-report questionnaires were developed to
collect demographic data (age, gender, living situation,
education and employment status, smoking status), but
also to describe his limitations in executing everyday
activities (four items extracted form of the Disabilities
of the Arm, Shoulder and Hand (DASH) questionnaire
[40]) and assess his subjective adherence at T-0 and
T-28. The patient therefore had to assess his adherence
to all his prescribed medicines for the last two weeks
using a visual analogue scale (VASAD) 0–100 mm repre-
senting 0 for ‘taken none’ and 100 for ‘taken all my med-
icines’. Patients were asked to fill in the questionnaires
in the pharmacy at T-0 and T-28, seal them in an enve-
lope and return the envelope to the study pharmacist.
Thus, the study pharmacists had no knowledge of the
responses given by their patients.
Telephone interviews
In collaboration with a clinical psychologist and an
economist, two comprehensive in-depth patient tele-
phone interviews were developed aiming at monitoring
possible impact of the intervention on patient’s know-
ledge and medicines use. After literature research, the
Rob Horne’s ‘Beliefs about Medicines Questionnaire’
[41] and two questions out of the ‘8-item Morisky Medi-
cation Adherence Scale’ (German version, 8-MMAS-D)
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[42] were defined as suitable to be used as validated
questionnaires fulfilling our criteria for telephone inter-
view 1. In addition, we developed new rating questions
to report their adherence to their therapy management.
Patient had to answer the same question as in the pa-
tient questionnaire T-0 to describe their adherence, but
in a spoken percentage value. We also chose consistently
a 10-item Likert scale. Options ranged from 1 (= ‘not at
all’) to 10 (= ‘very much’). The response category ‘no an-
swer’ was always available. Number of open questions
(N = 7) was limited to ease documentation.
The first telephone interview contained 58 questions,
divided into five sections: i) knowledge of their medi-
cines and daily use, ii) subjective adherence estimation/
use of reminder devices, iii) visits at general practi-
tioner/hospital, iv) beliefs about medicines question-
naire, v) support by pharmacists. The interview 2
contained 53 questions, divided into the same sections
as in the first interview. Compared with the first inter-
view, 18 questions were excluded and 13 new questions
were added. The telephone interviews were carried out
two (T-2) and 16 weeks (T-16) after study start by clin-
ical psychologists. The interviewers were blinded to the
intervention and without any knowledge of the content
of the PMC or the patient’s questionnaire T-0. A tele-
phone interviewer’s coaching and monitoring of compli-
ance with the study protocol was continuously provided
by an independent academic psychologist as external ex-
pert. A structured interview guide was created using the
software program Flexiform 2.6.9 to enable data entry
during the interview. Piloting of all study documents
and preparation of telephone interviews (recruiting in-
terviewers, briefing and test interviews) were carried out
in collaboration with the department of psychology of
the University of Basel. All survey instruments were
translated into French and retranslated into German to
check for differences.
Objective adherence measurement
Objective adherence rates based on refill data of the
pharmacies and patient reported dosing regimen. Two
methods for objective adherence calculation were used:
a) Medication Possession Ratio (MPR) [43], calculated
by dividing the days’ supply of a medication dispensed
by the number of days in the time interval of interest,
representing the adherence per each medicine and b)
Daily Polypharmacy Possession Ratio (DPPR) [44], the
proportion of time a patient had medication available for
use by considering the presence or absence of multiple
medications on each day in the observation period,
representing the adherence per patient with his chronic
polypharmacy. In this analysis only medicines were in-
cluded, of which the patient reported at T-28 a daily use
over the whole study period. Only oral drug forms with
definite dosage where considered. Further, a prescription
for the medicine had to be redeemed at least once before
T-0. Therapies were excluded if prescribed by self-
dispensing physicians (cantons BL/SO), changed in dos-
age during study period, chronic ‘on demand therapies’
(namely pain killers (ATC N02 and M01A), anxiolytics
(ATC N05BA), or magnesium supplements (ATC
A12CC). Also creams or drops where excluded from
analysis due to imprecise assumption concerning dosing
regimen. According to the theoretical calculation for
both, the MPR and the DPPR, refill data was exported
from the patient’s pharmacy. The export included the
history of patient’s refills from at least 200 days before
T-0 and the study period (T0 to T28, 196 days). For each
dispensed medicine, the export comprised the date of re-
fill, a product unique identifier number (pharmacode),
the drugs’ATC-Code, and the number of packages deliv-
ered. Subsequently, the pharmacode was matched with
the Swiss index database GALDAT®/pharmINDEX® [45]
to add the products’ package size (number of tablets)
and complemented with the patient reported dosing
regimen at T-28 (taken from the PMC protocol of both,
intervention and control group). The calculation algo-
rithm started with a look-back loop of 200 days before
T-0 taking any packages of medicines postponed to the
patient, equalising the fact that the patient was already
on therapy before study start. As in previous trials, ob-
jective non-adherence was defined as MPR <80 % [46].
Also for the patient’s individualised aggregated measure
DPPR, the cut-off for non-adherence was set <80 %.
Subjective adherence measurement
Subjective non-adherence was defined in patient re-
ported questionnaires (T-0 and T-28) as VASAD <100 m,
in telephone interview 1 and 2 as Likert scale <10 and in
telephone interview 2 additionally as 8-MMAS-D <6.00.
Unplanned visits at the general practitioner/hospital
In order to evaluate a negative impact on the health sys-
tem, patients’ unplanned visits at the general practitioner
or hospital were assessed within the patient’ self-report
at T-0 and T-28 and during telephone interview at
T-2 and T-16.
Sample size
To determine the required sample size, a power analysis
was conducted. In the present study, the null hypothesis
is rejected if the primary outcome adherence (as mea-
sured by MPR) improves by 5 % through the PMC on an
assumed baseline MPR of 60 %. These suggestions were
based on experiences from comparable projects [47].
We assumed a standard deviation of 20 % for both
groups and used the conventional alpha error of 5 %. To
have a statistical power of 80 % we would require 252
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patients at T-28 in each group. Assuming a dropout
rate of 35 % [48], this would lead to a total sample
size of 780 at T-0 (calculated with http://sampsize.-
sourceforge.net). Thus, we expected from each study
pharmacists an enrolment of 10–20 patients. There
was no minimal/maximal number for recruited pa-
tients per study pharmacist.
Statistical methods
Frequencies were evaluated using the chi-square test, or-
dinal scales were tested with the non-parametrical
Mann-Whitney-U-test. The time course of the various
endpoints was calculated using a general linear model
(GLM) for repeated measurement method. The study
groups were recorded as between-subject variable and
the course of the corresponding values as within-subject
variable in the model. In case of many missing values,
individual templates mixed models analysis was chosen
as an alternative method. All statistical tests were two-
sided with a significance level of 5 %.
Handling missing data
The intention-to-treat analysis included all enrolled sub-
jects, divided into intervention and control groups. Pa-
tients were rated as a drop out when they were excluded
at their request or when they were no longer available at
study end. Reasons for drop out were documented if
available. Patients who missed one or both telephone in-
terviews remained in the study.
Ethical approval
The study was approved by the responsible local ethic
commission ‘Ethikkommission beider Basel (EKBB)’
(23.05.2012, registry number EKBB 50/12) as the leading
committee for this multicentre study. Following the
positive decision from the EKBB, the project was also
approved by the local ethics committees of the following
cantons: AG/SO (26.11.2012), VS (05.03.2013), VD/NE
(12.03.2013), GE (22.03.2013), and FR (25.03.2013). The
study was registered with the https://clinicaltrials.gov/
trials database (NCT 01739816). The fee for providing
the PMC was covered by basic health care insurance.
Study pharmacists received a compensation of CHF 150
for participating in the training session and CHF 50 for
the delivery of each complete patient data set. Patients
were paid CHF 20 for their time spent for the telephone
interviews, and as a compensation for obligatory co-
payment to the PMC-fee.
Results
Implementation of the study
Patient recruitment was conducted in three stages (BS,
BL: July 2012 – February 2013, AG, SO: December 2012
– July 2013, the French speaking cantons (VS, VD, NE,
GE, and FR): April 2013 – October 2013) and ended in
April 2014 with the last patient completing the study
protocol.
Recruitment of study pharmacists and study pharmacies
Of 413 pharmacies invited for participation (NBS/BL =
110; NAG/SO = 135; NVS/VD/NE/GE/FR = 168), 70 pharma-
cists signed the informed consent and were trained to
follow the study protocol. In the end, 64 pharmacists
(91.4 %) from 54 different pharmacies took part in the
study (Table 1). Pharmacies were more or less evenly
distributed between central (N = 15, 27.8 %), peripheral
(N = 16, 29.6 %) and urban settings (N = 23, 42.6 %) as
well as between being independent (N = 17, 31.5 %), be-
longing to a group (N = 23, 42.6 %), and belonging to a
chain (N = 14, 25.9 %). A majority of 75 % of study phar-
macists were women (N = 48), mean age was 42.8 years
(SD 11.61), mean professional experiences working in a
community pharmacy was 14.9 years (SD 10.69), and 27
pharmacists (42.2 %) had post graduate qualification in
community pharmacy. The pharmacies showed variation
in both size and infrastructure. Virtually all pharmacies
were well equipped with a private area for the patients
in terms of ensuring privacy from other patients (N = 51,
94.4 %). The median consulting area was 7 square me-
ters (Range 1-25 m2).
Patient recruitment
For each pharmacy a random sample of potential candi-
dates was delivered directly to the study pharmacist by
Table 1 Demographics of study population at T-0, divided in language regions German-speaking (D-CH) and French-speaking
(F-CH) part of Switzerland. The total sum per study group is highlighted in bold
Intervention group (N = 218) Control group (N = 232)
D-CH (n = 146) F-CH (n = 72) Sum D-CH (n = 160) F-CH (n = 72) Sum pValue
Women (n/%) 76 52.1 42 58.3 118 54.1 78 48.8 47 65.3 125 53.9 0.958
Living alone (n/%) 53 36.3 25 34.7 78 36.5 42 26.3 31 43.1 73 31.9 0.310
Smoker (n/%) 20 13.7 19 26.4 39 18.5 27 16.9 7 9.7 34 15.0 0.335
Age in years (Mean/SD) 66.4 11.38 68.7 11.73 67.2 11.52 67.1 10.80 67.2 13.18 67.1 11.56 0.845
Dash-4 score (Mean/SD) 4.7 1.72 5.3 2.43 4.9 2.01 4.7 1.48 5.3 2.40 4.9 1.83 0.323
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IFAC and OFAC. The study pharmacists then consecu-
tively checked samples of ten candidates for inclusion
and exclusion criteria and invited the eligible patients.
Exclusion criteria are available for 3096 patients as re-
ported by 49 pharmacists (76.6 %) (Fig. 2). The other 15
pharmacists did not report about exclusions. After invi-
tation, a total of 450 patients signed the IC and were
randomly allocated to intervention (N = 218, 48.4 %) and
control group (N = 232, 51.6 %) (Fig. 3). Median number
of recruited patients per pharmacist was 7 (Range 1–17).
Demographic data of recruited patients
Demographic data of recruited patients (N = 450)
showed no significant differences between study groups
(Table 1). The proportion of women living alone (111
of 243) compared to men (40 of 207) was significantly
higher (p < 0.0001). Men showed a significantly lower
DASH-4 score than women (MenDASH-4 = 4.5 (SD 2.09),
WomenDASH-4 = 5.2 (SD 1.60); p < 0.0001). No differ-
ences between groups observed concerning education
and employment (data not shown).
Dropouts
Out of 70 study pharmacists, six (8.6 %) withdrew before
recruiting any patient for the study. While four stated
that they had under-estimated the time amount to com-
ply with the study protocol, two were no longer inter-
ested in the project. Dropout rate of patients was 17.3 %
(N = 78); the different reasons for dropout are listed in
table 2. Only 18 patients (4.0 %) withdrew from the
study. The largest single cause for dropout of patients
was that five of the 64 pharmacists who began recruiting
quit the study (7.8 %), resulting in 17 patients lost in
each group.
Intervention
Mean time per PMC was 29.8 min (SD 16.51; Range 5–
135 Min). Mean number of chronic medication per pa-
tient was 6.8 (SD 2.92; Range 1–19), while 1.9 medicines
(SD 2.07; Range 0–12) were prescribed on demand and
0.8 medicines (SD1.09; Range 0–5) were used as self-
medication. A majority (N = 115, 52.8 %) revealed to be
more time consuming than initial assumptions of the
professional association, pharmaSuisse (>25 min). At T-
0, study pharmacists reported 258 drug-related problems
(1.18 per patient) they had discussed during the PMC.
The two main causes of drug-related problems triggering
counseling through study pharmacists were a) insuffi-
cient adherence to at least one medication of a patient’s
polypharmacy (N = 69, 26.7 %) and b) lack of knowledge
about risks or need for further information for safe and
effective medicines use (N = 69, 26.7 %). The majority of
DRPs could be addressed by sole patient counseling
(58.9 %). Some pharmacists, however, also intervened by
directly changing a patient’s care plan in order to opti-
mise the administration of a therapy (15.5 %), adjust the
dosage or substitute a therapy (3.9 %) (Table 3). Study
pharmacists noted at T-0, that 69 patients in the inter-
vention group (31.5 %) already used a weekly dosing aid
(WDA) in their daily medicines management and they
recommended the implementation of a WDA for three
patients (1.4 %) (Table 4). During the first telephone
interview at T-2, 198 patients stated to own a WDA
(47.6 %); 173 of them regularly used the aid (41.6 %),
while seventeen patients mentioned a sometime use, e.g.
during holidays (4.1 %); eight patients did not use the
WDA at all (1.9 %). Until the end of the PMC study
(T-28), one patient in the intervention group (0.6 %)
and four patients of the control group (2.1 %) newly
received a WDA as a result of the PMC. When asked at
T-2, 74 (42.8 %) of 173 patients, who had originally been
Fig. 2 Pattern of reasons for exclusion after screening the random sample of potential candidates (N = 3096)
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recommended to use a dosing aid, reported that the phar-
macy initiated the use of a WDA. Another 54 (31.2 %)
bought the WDA themselves, while 20 (11.6 %) received
the aid from a hospital. Out of these 173 WDA used
at T-2, 158 were independently managed by the patient
himself (91.4 %), get refilled by their partner (N = 13,
7.5 %) or another third party (N = 2; 1.1 %). Thereby,
men (N = 77) were significantly more often supported
by their partners (N = 12) than vice versa (NWomen =
94, NSupport = 1; p < 0.001).
Objective adherence
Out of 2’453 chronic therapies registered in the PMC
protocol at T-28, 1’020 (41.6 %) met inclusion criteria
for the calculation of their Medication Possession Ratio
(MPR) using the defined algorithm (Additional file 2).
Sub-analysis of therapies inert to dose adjustments or
splitting (and therefore with highest expected validity for
calculation of MPR) showed consistent, but no signifi-
cant trend for improved adherence rates in the interven-
tion group (Table 5). For 212 out of 1'020 therapies
(20.8 %) the MPR was < 80 % (intervention N = 96
(19.5 %) and control group N = 116 (22.0 %), p = 0.318).
Out of all therapies, the Daily Polypharmacy Possession
Ratio (DPPR) was calculated for each individual patient as
shown in Table 6 (Additional file 3). Mean DPPR over the
whole eligible study population was 87.3 (N = 293, SD =
14.250). In both, intervention and control group, the DPPR
in D-CH (mean = 88.38, SD = 14.270) was significantly
higher compared to that of F-CH (mean = 84.86, SD =
13.972) (p = 0.01). Both regions showed no significant
improvement of DPPR through the intervention (Fig. 4).
Subjective adherence
In addition to objective adherence, we asked participants
how they estimated their overall adherence on a scale
from 0 to 100 %. The mean absolute change of subject-
ive adherence between T-0 and T-2 was +1.03 % in the
intervention and −0.41 % in the control group (p =
0.058) (Table 7). Sub-analysis revealed, that the number




- without information 5 7
- lack of motivation/interest 1 1
- poor health 0 4
Pharmacist was unable to
collect data
- not achieved 5 5
- patient has moved away 3 2
- patient is in a nursing home 2 0




Total n (%) 37 (47.4) 41 (52.6) 0.845
Fig. 3 Recruited pharmacists and patients (D-CH = BS/BL/AG/SO, F-CH = GE/FR/NE/VD/VS)
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of patients reporting a change of their adherence of
more than ±5 points on a scale 0-100 % between T-0
and T-2 was significantly higher in the intervention
group (NImprovement = 30; NWorsening = 14) compared to
the control group (NImprovement = 20; NWorsening = 24) (p
= 0.028). Table 8 summarises patient self-report of
adherence using validated questionnaires. Between the
two telephone interviews T-2 and T-16, mean difference
between patients’ beliefs and concerns about their
medicines did not change significantly (Intervention =
−0.01 (SD 6.609); Control = +0.64, (SD 6.289), p = 0.697).
At T-16, in total 74 patients had a MMAS-8D score <6
representing low adherence (intervention N = 37 (18.9 %),
control N = 37 (18.3 %)). Moderate adherence (Scores 6–8)
was shown in the intervention group for 83 patients
(20.8 %) and in the control group for 89 cases (22.3 %).
High adherence was present in 154 patients, 78 from the
intervention (39.4 %) and 76 from the control group
(37.6 %). No significant difference in adherence between
the two groups could be observed (p = 0.817).
Use of health care resources by patients and unplanned
visits at a general practitioner or hospital
According to the notations in the CRF in 18 cases
(8.3 %) out of the 258 DRPs addressed at T-0, the study
pharmacist contacted the responsible general practi-
tioner (N = 17) or an indicated specialist (N = 1) to dis-
cuss or inform about issues revealed through the PMC.
A phone call was reported in six cases (33.3 %), the
other issues were addressed by Fax (N = 5, 27.8 %), Email
(N = 1, 5.6 %), referral letter (N = 1, 5.6), otherwise (N =
3, 16.7 %), not specified (N = 2, 11.1 %). Four out of 18
physicians did not respond to the pharmacists’ initiative
(22.2 %). The remaining 14 (77.8 %) gave feedback on
Table 3 Drug-related problems addressed during PMC at T-0 in













Causes of pharmacists’ interventions
Insufficient adherence 69 26.7
Patient needs information about safe and
effective use of his medicines
50 19.4
Patient needs information about potential
medicines’ adverse drug reaction
19 7.4
Inappropriate timing or frequency of
administration
18 7.0
Under-dosed therapy 15 5.8
Drug-drug/drug-food interaction 14 5.4
Adverse effect 12 4.7
Inappropriate therapy duration 10 3.9
Inappropriate drug administration 9 3.5
Patient needs information about lifestyle,
nutrition or empowerment
8 3.1
Not received treatment 7 2.7
More cost-effective therapy available 5 1.9
No concordance with guidelines or
contraindication
4 1.6
No dose adjustment because of
pathological changes (renal/liver failure)
4 1.6
Not indicated drug or duplication 3 1.2
Incomplete patient documentation 3 1.2
Over-dosed therapy 3 1.2
Prescribed drug not available 2 0.8
Inappropriate monitoring 1 0.4
Not classifiable 2 0.8
Description of pharmacist's interventions
Counseling of patient, training 152 58.9
Optimisation of administration 40 15.5
Information to other caregivers 24 9.3
Dose adjustment 12 4.7
Substitution of a therapy 10 3.9
Table 3 Drug-related problems addressed during PMC at T-0 in
intervention group (N = 258) (Continued)
Therapy started/restarted 7 2.7
Therapy stopped 7 2.7
Therapy monitoring 3 1.2
Clarification in the patient history 2 0.8
Not classifiable 1 0.4
Table 4 Overview of weekly dosing aids in use during study
Intervention Control pValue
T-0 (assessed through pharmacist
during PMC)
72a N = 218 - -
T-2 (assessed through telephone
interview)
83 N = 202 90 N = 214 0.838
T-16 (assessed through telephone
interview)
90 N = 198 98 N = 203 0.699
aFrom which three were newly implemented through PMC
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the addressed issues. Nine fully accepted the pharma-
cists’ recommendations (64.3 %), one partially (7.1 %),
and two rejected the recommended intervention
(14.3 %). In two cases, the implementation of the recom-
mendations remained unclear (14.3 %). During the study
period, patients reported a total of 209 unplanned visits
at a general physician or hospital, showing no significant
difference between study groups (Table 9). The same
was observed for the incidence of falls during the study.
Discussion
Our study presents initial findings on a newly imple-
mented pharmacist-led medication review service, called
Polymedication Check (PMC) with respect to impact on
patients’ adherence. The multicentre parallel group ran-
domised controlled trial was conducted in community
pharmacies with very low to moderate experiences in
providing medication reviews. This paper presents re-
sults from multiple in-depth assessments focusing on pa-
tients’ adherence and drug-related problems; humanistic
outcomes and the patients’ as well as pharmacists’ per-
spectives will be dealt with in a second publication.
Study population
Recruitment of study pharmacists posed no problem; all
recruited pharmacists attended the required training ses-
sion. However, experience with providing a PMC proved
to be unequal with only 28 % of pharmacists featuring
prior experience in conducting >5 PMC and even 34 %
with no prior experience at all. Nevertheless, a majority
of the study pharmacists who finally started to enrol pa-
tients in the project was highly motivated to participate
in this evaluation study despite the complexity of the
study protocol and their lack of experience with partici-
pation in randomised controlled trials. In all regions a
suitable sample of pharmacies was involved into the
study. The demographics and characteristics of the par-
ticipating pharmacies were in line with the total of Swiss
pharmacies regarding organisational form of ownership
and gender compared to RoKA report 2012 [49] (per-
sonal ownership and group (study: 74.1 % vs. RoKA:
69.6 %) or chain (25.9 % vs. 30.4 %), women (75.0 % vs.
80.0 %)). The estimated number of ten patients recruited
by each study pharmacist was not reached by most phar-
macists (Median 7; Range 1–17) despite up to six
months of recruitment period per study region. During
the study, six study pharmacies cancelled participation
before they started recruiting patients and five more
dropped out during the study; as a consequence follow-
up of their patients was impossible. Patient dropouts
were fairly low (17.3 %), evenly distributed across both
study groups and caused by an expected pattern of com-
prehensible reasons, so there is little concern for a selec-
tion bias due to selective dropouts. The reported causes
were both rare and typical, such as patients’ moving
away or being unable to continue due to health reasons.
Impact of the Polymedication Check
The primary outcome objective adherence showed no
significant improvement in the PMC group (mean MPR
88.3 % vs 87.5 % in the control group (p = 0.811)).
The adherence in the control population was already
at an unexpectedly high rate of 87.5 %, leaving only little
room for improvement in the intervention group. This
made it nearly impossible to observe the 5 % increase in
objective adherence, on which the power calculation was
based. Notably, in the intervention group a higher per-
centage of patients showed more than 5 % increase of
subjective adherence compared to the controls. This
effect only appeared shortly after the intervention and
could not be observed again in the further course of
the study.
Our results show that during the PMC non-adherence
to medication was the most frequent issue addressed in
26.7 % of PMC cases, followed by a need for information
about safe and effective medicines use (19.4 %) or im-
provement of awareness for risks and adverse effects of
therapies (7.4 %). Previous research has shown that
adherence counseling was included in only 6.7 % of the
reported cases of unspecific pharmacist-patient contacts
Table 5 Objective adherence represented as MPR
Intervention Control
Mean % SD N Mean % SD N pValue
All therapies 88.3 19.03 493 87.5 20.75 527 0.811
Antiplatelets (B01AC) 91.3 16.24 61 85.4 23.75 64 0.119
Proton pump inhibitors (A02BC) 91.8 13.36 43 87.7 18.27 33 0.493
Table 6 Objective adherence to polypharmacy represented as





Mean SD Mean SD pValue
DPPR (%) 88.0 13.31 87.5 20.75 0.906
Number of medicines eligible for
DPPR calculation per patient
3.4 1.68 3.6 1.86 0.425
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in usual care [14]. This pattern of detected and discussed
drug-related provides an important indication on the
impact of the PMC and proves appropriateness of the
concept of the PMC regarding its aim at triggering ad-
herence and knowledge issues as topics for individual
counseling. The filling of a patient’s medicines into a
WDA could be implemented in only very few patients
(1.4 %). This unexpected result can be explained with a)
the pharmacist judged the patient sufficiently well-
organised without a WDA, b) the patient already used a
WDA in self-management (which was the case in 42 %
of patients in our study) or c) the patients were not will-
ing to delegate the preparation of their medicines to the
pharmacist. There is a necessity for guiding a compre-
hensive assessment of patient needs (self-management of
a WDS versus WDA provided by the pharmacy) and
differentiating between the active recommendation by
the pharmacists and the refusal by the patient. The im-
plementation rate of WDA in patients with chronic
polypharmacy revealed in our study, still offers room for
improvement; recent surveys in Canada could show that
75 % of patients in a comparable community sample
stated to regularly use a WDA [50]. With respect to the
interface between pharmacy and GP, 18 out of the 258
cases of detected and addressed DRPs in the PMC group
at T-0, cases triggered a consultation with the patient’s
GP (7.0 %), leading in 77.8 % to an interprofessional col-
laboration and discussion of patients’ DRP with high
acceptance rate of pharmacists’ recommendations
(71.4 %). Still, considering the recommendations without
feedback or acceptance by the GP (N = 8), the overall
implementation rate of 44.4 % is comparable to a study
of Kempen et al. [51], who reported implementation
rates of 42 %. Such low implementation of recommenda-
tions will decrease efficacy of any intervention substan-
tially. However, it can be deduced that the pharmacists
were able to solve more than 90 % of the patients’ issues
independently.
Unlike reported in previous studies [52], no harmful
effect of the PMC intervention as reflected by the non-
significant group differences in unplanned hospital ad-
missions or in visits to the GP (Table 9) could be ob-
served. This observation is meaningful when looking at
the frequency of contacts of pharmacists with the pre-
scriber resulting from a PMC (8.3 %) and considering
that only a few of the pharmacists’ recommendations
(14.3 %) were rejected. A significant number of DRPs
were discovered and solved through study pharmacists
providing a PMC (Table 3).
Reasons why we did not detect a significant effect
Overall, the study remained underpowered: The initial
estimation of the impact on adherence of the PMC was
set on 5 % with a baseline at around 60 %. This assump-
tion was based on the results of other studies from
different countries and settings [47]. The unexpected
high adherence observed in the control group allowed
only little improvement. Thus, a sole increase of the
study population, e.g. through an extension of the re-
cruitment period, would remain ineffective. A more
effective and internationally accepted approach to
enhance the efficacy of medication reviews would be the
targeting of patients at risk [9]. The high rate of imple-
mented WDA at T-2 (42 %) (Table 4) indicates an already
Fig. 4 Box plot of DPPR of patients stratified by the German (D-CH,
N = 199) and the French part of Switzerland (F-CH, N = 94)
Table 7 Subjective rating of adherence during the preceding two weeks
Intervention Control
Mean % SD N Mean % SD N pValue
Patient questionnaire T-0 96.2 8.62 211 96.8 7.05 232 0.204
Telephone interview T-2 97.2 9.31 202 96.4 10.24 213 0.118
Telephone interview T-16 98.5 5.56 198 97.8 7.64 202 0.400
Patient questionnaire T-28 95.5 10.28 178 96.3 9.51 186 0.338
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improved patient’s self-management mostly initiated
through pharmacists before study start. It was a deliberate
decision not to focus on patients with specific diseases or
drugs in this first evaluation since the service might be
offered to every patient meeting the inclusion criteria for a
PMC. Since the inclusion criteria were non-specific in
terms of risks for non-adherence, it must be assumed, that
already well-organised patients with established therapies
were included in this study. Further on, patients with the
highest need for intervention with manifest non-
adherence might not have been motivated to be part of a
clinical trial that explicitly aimed at uncovering indi-
vidual weaknesses in the correct administration of
medicines. Experiences with the MUR service from
UK resulted in the development of specific interven-
tions for various patient populations, offering to the
health care provider a structured and focused flow
chart supporting the process of screening for pharma-
ceutical care issues [53]. Thus, applying more specific
criteria in addressing the medication reviews to patients
with higher risk for drug-related problems would probably
increase the impact of the intervention.
Medication reviews such as the PMC are a screening
method aiming at detecting drug-related problems, and
the corresponding interventions are unspecific. Thus,
in a first step, this service only results in a number of
drug-related problems detected or number of referrals
etc. Looking at clinical outcomes, only well planned
and monitored interventions can have an impact. The
current PMC protocol specifies the provision of a
weekly dosing system filled by the pharmacy as its main
intervention. This intervention, though known to be
effective [54], was offered only to very few patients
(1.4 %). All other interventions such as delivery of a
medication plan or check of correct use of an asthma
device are not foreseen in the protocol and hence
could not been evaluated. On the other hand, explicit
listing of such predefined interventions on the
protocol would probably trigger more frequent
provision of such services. So far, the intervention
part is insufficiently specified in the current guideline,
and especially not well supported by the current
PMC protocol.
Strengths
First, the randomised controlled trial design is a distinct
strength of this study. Second, the trial was performed
under real-life conditions with a representative sample
of pharmacists from different regions, including the
French-speaking part of Switzerland with differences
related to health care (i.e. density of pharmacies,
Table 8 Summed scores of validated adherence questionnaires at T-2 and T-16
Intervention Control
Mean SD N Mean SD N pValue
T-2
BMQ Beliefs 20.58 4.463 171 20.99 4.301 181 0.328
BMQ Concerns 9.95 4.249 171 10.30 4.949 181 0.726
Difference Beliefs - Concerns 10.64 5.554 171 10.69 6.494 181 0.612
T-16
BMQ Beliefs 20.66 4.630 188 21.23 3.958 183 0.369
BMQ Concerns 9.89 5.020 188 9.72 4.583 183 0.872
Difference Beliefs - Concerns 10.77 6.360 188 11.51 5.705 183 0.337
MMAS-8D Scorea 6.85 1.226 198 6.82 1.237 202 0.817
aMMAS-8D Score: 8 = high adherence, 6–7.75 medium adherence, <6 low adherence
Table 9 Patient reported unplanned visits at general practitioner or hospital and falls during study period
Intervention Control
Unplanned visits … NYES NTotal NYES NTotal pValue
… from T-0 - > T-2 14 202 10 214 0.324
… from T-2 - > T-16 50 198 44 203 0.398
… from T-16 - > T-28 46 181 45 191 0.678
Incidence of at least one fall until T-28 31 17.7 % 30 15.9 % 0.638
… thereby injured 17 54.8 % 15 50.0 % 0.705
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preferred way of medication supply), cultural and socio-
economic factors. Thus, the results of the present study
are likely to be highly generalisable. Third, patients’
adherence was measured using several validated instru-
ments providing internal validity. Fourth, the in-depth
telephone interviews on patient’s acceptance and know-
ledge were performed by trained independent clinical
psychologists, blinded to the intervention. Fifth, pa-
tients’ written self-reports were blinded to the pharma-
cists; thus a Pygmalion effect could be excluded.
Limitations
First, due to restricted financial means, the study period to
investigate the objective adherence was limited to just
28 weeks. With regard to the common package size of 100
tablets for long-term medication, the short study duration
offered only two refills to be considered for evaluation of
adherence. Newer guidelines suggest follow-up periods of
1–2 years or more to capture long term non-adherence
[55]. Second, patients enrolled in clinical trials may be
more conscientious than the average patient. During the
consent process, patients were told that the purpose of
the study was to learn more about their daily medicines
use and that their adherence to medication was observed.
Thus, all our patients knew they were being monitored,
which on the one hand may have led to a higher baseline
in self-reported adherence at study start and also during
follow-up in both groups of our study patients compared
to other patients. The pharmacists on the other hand
knew that they were being studied, which may have led
them to increase their efforts in delivering pharmaceutical
care, notably for both groups. This is known as the
Hawthorne effect: a psychological response in which sub-
jects in a research study change their behaviour simply be-
cause they are subjects in a study, not because of the
research treatment [56]. Thus, the heightened awareness
of the patients and also of the pharmacists about the study
setting could have influenced the medicines intake for the
prospective time. Such influence can only be eliminated
through a randomisation at the level of the pharmacy – a
procedure posing other problems of bias as well. In order
to avoid selection bias by the pharmacists, patients were
selected at random solely fulfilling the PMC-criteria and
not because of an increased risk or any indicators for
manifest non-adherence. Third, because of time constraints
and limited resources the recruitment was stopped before
the intended number of patients was recruited.
Implications for practice
In line with other authors [9, 55], we recommend to
ensure efficiency and efficacy to reconsider and adapt the
service on various levels: First, the service should be more
tailored to patients at higher risk for drug-related prob-
lems, such as patients with respiratory diseases, diagnosed
cardiovascular disease, regularly being prescribed at least
four medicines etc. In addition, focusing on patients
recently discharged from hospital, or who had changes in
their medicines regimen would provide more opportun-
ities to screen for manifest DRPs possibly before the start
of a risky treatment. Ideally, these patients would receive a
medication review within a very short time (e.g. a few
days) after the start and are followed by a follow-up meet-
ing (face-to-face or by telephone call) to check for hand-
ling issues and implementations of the recommendations.
Second, after detecting the patient at risk for clinical rele-
vant drug-related problems, we recommend to proceed
with validated, structured and standardised interventions.
This process should allow a follow-up to ensure imple-
mentation of pharmacists recommendations (according to
the pharmaceutical care process, see also the New Medi-
cines Service from the NHS, UK) [57]. The PMC protocol
form should include the documentation of the recommen-
dations or follow-up interventions in a more specific
structure. Thus, the current process of the PMC as a
service and its protocol need to be re-engineered. Third,
pharmacists had no training and supervision when provid-
ing the service. An implementation program focusing on
the main barriers of the service could still encourage
pharmacists to provide PMC in the future. A responsible
professional body for coaching and answering frequently
asked questions is needed. Qualification and/or accredit-
ation of involved health care providers might be consid-
ered to ensure high quality and safe interventions on
patient level. Continuing education should be strength-
ened through systematic integration of PMC cases into
practice-oriented teaching. For distinct problems or care
issues structured guidance should be developed.
Conclusion
For the first time in the Swiss health care system, a
newly implemented cognitive service of community
pharmacists underwent an in-depth evaluation process
in daily life. The service showed no significant improve-
ment on objective adherence in the observed population.
Reasons for not being able to demonstrate significant
positive effects are likely to depend on a) an uninten-
tional selection of patients with very high adherence and
low risk for drug-related problems causing insufficient
power and b) on a low level of experience with providing
the PMC among the recruited pharmacists.
However, based on the study results, we conclude that
the so called Polymedication Check as a pharmacist-led
medication review i) was able to address a significant
number of drug-related problems concerning adherence
issues and need for knowledge improvement and ii)
showed no further financial burden to the Swiss health
care system as there was no harm induced and pharma-
cists’ interventions did not cause additional consultations
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with other healthcare professionals. Re-engineering of the
service should focus on the inclusion criteria to target the
patients with highest risk for non-adherence and on the
improvement of pharmacists’ skills in implementing
weekly dosing aids.
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Background: Since 2010, Swiss pharmacists have been offering their patients a Polymedication 
Check (PMC), a new cognitive pharmacy service in the form of a medication review for patients 
taking $4 prescribed medicines for a period .3 months. While a first publication of this 
project reported on the impact of the PMC on patients’ adherence, the present paper focuses 
on humanistic outcomes.
Methods: This randomized controlled trial was conducted in 54 Swiss community pharmacies. 
After recruitment, the intervention group underwent a PMC in the pharmacy (T-0) and 28 weeks 
after T-0 (T-28), while the control group did not receive the PMC until 28 weeks after the study 
started (T-28). A clinical psychologist, blinded to the intervention, interviewed the patients 2 
weeks (T-2) and 16 weeks (T-16) after T-0. Interviewer and patient both rated patient’s knowl-
edge of own medicines use. Furthermore, patients reported satisfaction with their pharmacy and 
appraisal of their medicines use. The availability of a written medication plan was assessed at T-16. 
Acceptance of the service was measured using a patient’s self-report questionnaire at T-28.
Results: General linear model analysis for knowledge about medicines revealed a significant 
effect on the factor “group” (F=5.86, p=0.016), indicating that the intervention group had 
higher ratings for knowledge about their medication at T-2 and T-16 compared to controls. 
The majority (83%) of patients judged the counseling by the pharmacist as being helpful for 
their daily medication management. Availability of a written medication plan was comparable 
in both groups (52.5% vs 52.7%, p.0.05).
Conclusion: For the first time, the benefits of a complex pharmacist-led intervention were 
evaluated in Swiss primary care with a randomized controlled trial. The PMC increased patients’ 
subjective knowledge of their medicines compared to no medication review. The effect remained 
sustainable over time. Recommendations resulting from the pharmacist-led service were highly 
appreciated by the patients.
Keywords: polypharmacy, community pharmacy, medication review, humanistic outcomes, 
patient knowledge, patient acceptance, pharmaceutical care
Introduction
The role of the community pharmacist in primary care has been undergoing change in 
Switzerland in parallel to international developments: it has become more clinically 
and patient oriented. Special services provided by community pharmacists addressing 
older patients taking long-term or multiple medications have been developed.1 A recent 
Cochrane overview of systematic reviews by Ryan et al reported positive effects on 
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adherence to medication, knowledge about medicines, drug-
related problems, and clinical outcomes when pharmacists 
were involved in medicines management interventions.2 
In particular, medication reviews were described as effec-
tive when they offer a consultation between pharmacist and 
patient to resolve drug-related problems, develop a care plan, 
and provide follow-up. Since 2010, Swiss pharmacists have 
been allowed to offer their patients a Polymedication Check 
(PMC), a new cognitive service in the form of a medication 
review involving patients using more than three prescribed 
medicines over a period of at least 3 months.3 This reim-
bursed service aims at detecting drug-related problems4 in 
a patient’s medicines use in daily life and recommending 
interventions to optimize medicines management in order 
to prevent negative health outcomes through drug therapy.1 
This pharmacist-led service can be delivered indepen-
dently from physician’s prescriptions. With respect to this 
interface between pharmacy and general practitioner (GP), 
7% of detected drug-related problems triggered a consulta-
tion with the patient’s GP, with a high acceptance rate of 
pharmacists’ recommendations (71%).3 This change in the 
role of pharmacists is remarkable, as pharmacists often lack 
self-confidence about their role in patient care and acceptance 
by their clients.5,6
In Switzerland, new services remunerated by the basic 
health insurance require a proof of their efficacy, appropri-
ateness, and economic effectiveness according to national 
criteria.7 As an investigator-initiated project, we aimed at 
evaluating efficacy and appropriateness of the PMC by pro-
viding a randomized controlled trial in Swiss community 
pharmacies. We hypothesized that the PMC would increase 
adherence and improve patients’ knowledge about their 
medications compared to the control group. While a first 
publication of this project reported on the impact of the 
PMC on patients’ adherence,3 the present manuscript high-
lights humanistic outcomes. It provides information about 
1) the impact of the PMC on patients’ knowledge about their 
medication, 2) effect of the PMC on the patients’ relationship 
with the pharmacy and the appraisal of their medicines use, 
3) acceptance of the PMC, and 4) the availability of organi-
zational tools to enhance self-management such as a written 
medication plan.
Methods
Data were available from the previously described 
randomized-controlled trial conducted in 54 Swiss commu-
nity pharmacies.3 Eligible patients used $4 prescribed medi-
cines for .3 months. After recruitment and randomization, 
the intervention group received a PMC in the pharmacy 
(T-0) and another PMC 28 weeks after T-0 (T-28), while 
the control group received a PMC only at T-28 (Figure 1). 
Study pharmacists were required to take part in a 3-hour 
training session provided by the study center. This training 
session included an overview of the study, highlighted the 
need for compliance to the study protocol, and clarified 
rights and responsibilities of the study pharmacists. As the 
study aimed at assessing and evaluating current practice, 
no other qualification criteria were applied other than being 
a pharmacist and no further training on the execution of a 
PMC was offered. This study was conducted according to the 
guidelines laid down in the Declaration of Helsinki. Written 
informed consent was obtained from all participants. All 
procedures involving human subjects were approved by the 
responsible local ethic commission “Ethikkommission beider 
Basel (EKBB)” (23.05.2012, registry number EKBB 50/12) 
as the leading committee for this multisite study. The project 
was registered at the trial database www.ClinicialTrials.gov 
(Identifier NCT 01739816, first entry in November 2012).
Outcome measures
Both patient groups filled out self-report questionnaires 
at study start (T-0) and study end after 28 weeks (T-28). 
Telephone interviews were carried out 2 weeks (T-2) and 
16 weeks (T-16) after T-0 by a trained telephone interviewer 
(Figure 1). Interviewers were intensively trained (4 hours 
of teaching and two exercise interviews) and regularly 
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supervised by the second author (clinical psychologist). The 
semi-structured interviews and the self-report questionnaire 
were newly developed in a collaborative, interprofessional 
approach,8–10 as validated questionnaires assessing patients’ 
knowledge about medicines did not exist in acceptable length 
when the study was conducted. Further detailed descrip-
tion of the development and piloting of these measurement 
instruments is published elsewhere.3 The interviews included 
additional questions that are not reported here. These items 
were beyond the scope of the study and we believe they did 
not influence the presented results.
rating of patients’ knowledge of their 
medicines
At T-2 and T-16, the patient completed an in-depth telephone 
interview about their medicine use. For each product that 
he/she mentioned, the interviewer asked
Do you know why you take this medicine? How often do 
you take this medicine? When exactly do you take this medi-
cine? Do you have to watch out for anything in particular 
when dealing with and applying/taking this medicine?
After the interview, the interviewer rated the knowledge of 
the use of their medicine on a scale from 1 (=poor knowl-
edge) to 10 (=very good knowledge). Patients also rated 
their subjective knowledge about the use of their medicine 
on this scale. Both patient and telephone interviewer used 
an identical scale. The patients were not informed about the 
interviewers’ rating.
Patient satisfaction and relationship with 
study pharmacists
Patients’ satisfaction concerning the relationship with the 
involved study pharmacies and related pharmacist was 
assessed at T-2 with six items using a rating scale from 1 to 
10 with specific descriptive hints, eg, “How satisfied are you 
with your pharmacy on a scale of 1–10? (1=very dissatisfied; 
10=very satisfied)”.
Patient appraisal of their medicines use
Patients’ appraisal concerning their medicines use was 
assessed at T-2 with six items using a rating scale from 
1 to 10 with specific descriptive hints, eg, “How difficult 
do you find it to administer your medication? (1=very easy; 
10=very difficult)”.
Availability of a written medication plan
At T-16, patients reported during the telephone interview if 
they were in possession of a written medication plan (yes/no).
Patient acceptance of the service
At T-28, patients reported acceptance of the service with a 
self-report questionnaire after both groups received a PMC 
(for the intervention group, the second PMC). Patients further 
reported whether they knew about the service before they 
were invited to the study (yes/no), if, from their perspective, 
the price for the service (CHF 48.60 per PMC) was 1) accu-
rate, 2) too high, or 3) too low, and if they were able to ben-
efit from the pharmacist’s advice provided within the PMC 
(yes/no). They also rated eight positive and two negative 
judgments concerning the PMC and the performance of the 
pharmacist using a 4-point Likert scale (1=disagree, 2=tend 
to disagree, 3=tend to agree, 4=agree). Ratings #2 were 
considered as negative, ratings $3 as positive statements.
statistical methods
For statistical analysis, IBM SPSS Statistics 22 (IBM Cor-
poration, Armonk, NY, USA) was used. Numerical scales 
are presented as mean and standard deviation. Ordinal scales 
were tested with the non-parametrical Mann–Whitney U-test. 
Analysis regarding patients’ knowledge about their medi-
cines were provided by using a general linear model (GLM) 
for repeated measures with “time” (T-2 and T-16) and “rater” 
(interviewer vs patient) as within-subject factor and “group” 
(intervention versus control) as a between-subject factor to 
analyze the main and interaction effects of the intervention on 
the knowledge of the patient. To describe internal consistency 
of relevant items, Cronbach’s alpha was used. Statistical 
tests were performed with a significance alpha level of 5%.
Results
Of 450 patients enrolled at T-0, 372 (82.7%, dropout rate: 
17.3%) completed the study (T-28). In total, 243 (54%) were 
women. The mean age of the patients was 67 years.3 
rating of patients’ knowledge of their 
medicines
Mean patients’ knowledge concerning their medicines at T-2 
and T-16 rated by the interviewer and by the patient himself/
herself are summarized in Table 1. GLM analysis revealed 
a significant main effect for the factor “group” (intervention 
vs control) as the mean of both ratings (self and interviewer) 
of the intervention group’s knowledge about medication 
was higher at both measure points (F=5.86, p=0.016) 
compared to controls. A significant main effect for “time” 
(F=45.99, p,0.001) showed that the knowledge ratings of 
both groups increased between T-2 and T-16. A signifi-
cant main effect for the factor “rater” (interviewer vs self) 
revealed that the patients rated their knowledge about their 





medicines higher compared to the ratings of the interviewer 
(F=435.59, p,0.001). A significant “time x rater” interaction 
(F=3.99, p=0.046) indicated that the ratings of the inter-
viewers increased more from T-2 to T-16 compared to the 
increase of the patients’ ratings. Other interactions were not 
significant (p.0.05).
Patient satisfaction and relationship with 
study pharmacists
Patient satisfaction with the study pharmacies assessed at 
T-2 is shown in Table 2. Cronbach’s alpha of this scale was 
0.693 in the intervention group and 0.749 in the control 
group. All six questions on satisfaction with PMC provision 
by the community pharmacy show very high satisfaction 
with no significant difference between control and inter-
vention (p.0.05).
Patients’ appraisal of their medicines use
Patients’ appraisal of their medicines use at T-2 is shown in 
Table 3. Cronbach’s alpha of this scale was 0.031 in the inter-
vention group and −0.078 in the control group. No significant 
difference between the groups was observed (p.0.05).
Availability of a written medication plan
At T-16, availability of a written medication plan was 
reported by 104 (52.5%) individuals in the intervention group 
and 107 (52.7%) individuals in the control group. There was 
not significant group difference (p.0.05).
Patient acceptance of the service
Response rate of the self-report questionnaire was 100% 
(n=372). One hundred sixteen patients (31.2%) knew about 
the PMC before being invited for the study. The price of 
the service was accepted as appropriate by 327 patients 
(87.9%) or too low by 13 patients (3.8%), while another 
13 patients (3.8%) stated the cost as too high and 19 (5.1%) 
did not answer. In total, 308 patients (83.1%) appraised the 
counseling by the pharmacist as, in general, being helpful for 
their daily medication management. In Table 4, the patients’ 
rating of the service is shown after both groups had received 
at least one PMC.
When aggregating the results from Table 4 (ratings #2 
were considered as negative, ratings $3 as positive state-
ments), 306 patients (82.3%) stated improved confidence in 
their medicines and 290 (78.0%) reported enhanced security 
in their medicines use after the PMC. Most patients (n=358, 
96.2%) agreed to recommend the PMC to other patients.
Discussion
We report secondary outcome measures of a randomized 
controlled trial. In the present evaluation of the cognitive 
pharmacist-led service, PMC patients showed a significantly 
greater subjective knowledge about their medication after the 
PMC compared to usual care. Although the effect appears 
small, the difference to the control group is remarkable since 
the organizational structure of the enrolled population was 
Table 1 Patient knowledge concerning medicine use at T-2 and 
T-16, rated by the interviewer and by the patient
Intervention Control 
n Mean SD n Mean SD
T-2 interviewer* 202 7.38 1.85 214 7.11 1.87
T-2 Patient** 201 9.27 1.22 213 9.21 1.34
T-16 interviewer* 198 7.99 1.83 203 7.62 2.10
T-16 Patient** 198 9.66 0.80 203 9.49 1.18
Notes: *Please rate the patient knowledge of the administration of his medication 
on a scale of 1–10. 1=poor knowledge; 10=very good knowledge. **if you had to 
rate your knowledge on a scale of 1–10, how sure are you of the administration of 
your medication?’ 1=poor knowledge; 10=very good knowledge.







1. How satisfied are you with your pharmacy on a scale of 1–10? (1=very dissatisfied; 10=very satisfied) 9.61 (0.79) 9.68 (0.68) 0.518
2. Do you generally accept recommendations made to you by your pharmacist? (1=you never accept 
recommendations; 10=you always accept recommendations)
9.34 (1.26) 9.36 (1.20) 0.891
3. How competent would you consider your pharmacist, in his/her field of work, on a scale from 
1 to 10? (1=very incompetent in his/her field; 10=very competent in their field)
9.72 (0.68) 9.74 (0.65) 0.768
4. On a scale of 1–10, how satisfied are you with the amount of time your pharmacist has for you? 
(1=very dissatisfied; 10=very satisfied)
9.71 (0.81) 9.75 (0.60) 0.695
5. On a scale of 1–10, how strongly do you feel your interests to be in good hands with your 
pharmacist? (1=not in good hands at all; 10=in very good hands)
9.68 (0.76) 9.75 (0.64) 0.366
6. On a scale of 1–10, how much better do you understand your medications and their application 
after you consulted your pharmacist? (1=not at all better; 10=much better)
9.19 (1.85) 9.15 (1.84) 0.753
9.57 (0.66) 9.58 (0.70) 0.605
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high at the start of the study leaving only little room for 
improvements.3 In both interviews, both groups reported an 
overall high and constant satisfaction with individual care 
offered by community pharmacists and a fairly high appraisal 
of their medicines use during the study. This important result 
underscores that pharmacists should not be concerned about 
unsettling the patient in his/her medicine use or causing 
harm when performing medication reviews as previously 
postulated by Holland et al.11
improved knowledge on medicines use
The PMC positively influenced the patient’s knowledge 
on his/her medicine use. Patients seemed to subjectively 
know more about their medication use after the intervention 
compared to controls. This finding may be explained with 
the observed pattern of addressed drug-related problems 
during the intervention at T-0. In 27% of cases, need for 
further information on safe and effective use of medicines 
or potential adverse drug reactions represented a cause for 
further recommendations by the study pharmacist.3 While 
Grymonpre et al did not show any impact on patients’ 
knowledge through a pharmaceutical care model,12 Ryan et al 
concluded in their Cochrane review that pharmaceutical care 
services were affected, with positive effects on adherence 
and knowledge.2 Similarly, Latif et al investigated improve-
ment of knowledge through Medicines Use Reviews (MUR), 
a service similar to the Swiss PMC. Thereby, they reported 
that MURs did little increase patients’ knowledge and rarely 
affected medicine use. Nevertheless, some patients felt reas-
sured about their medicines use.13
Interestingly, we found that patients overestimated their 
own knowledge about their medication in comparison to the 
external ratings of the interviewers about patients’ knowl-
edge. This might indicate an overestimation of capabilities by 
the patients comparable to subjective adherence ratings.14,15 
The “one question fits all” approach (eg, “Do you know 
how to use your medicines”?) represents a first step for a 
loose detection of individual issues with medication intake, 
but needs further in-depth assessment. This should include 
evaluating patients’ knowledge on “why”, “how often”, 
and “when exactly” they take their medicines in order to 
provide individualized patient education to address these 






1. How satisfied are you on a scale from 1 to 10 with your daily medication intake (eg, number of 
medicines, condition)? (1=very unsatisfied; 10=very satisfied)
9.12 (1.39) 8.95 (1.56) 0.208
2. How competent do you feel administering your medication? (1=very incompetent; 10=very competent) 9.33 (1.18) 9.29 (1.49) 0.529
3. How comfortable do you consider administering your medication? (1=very uncomfortable; 10=very 
comfortable)
8.23 (2.23) 8.35 (2.20) 0.613
4. How difficult do you find it to administer your medication? (1=very easy; 10=very difficult) 1.50 (1.26) 1.42 (1.12) 0.965
5. How unappetizing do you find taking medication? (1=delicious; 10=very unappetizing) 2.06 (1.95) 2.08 (1.80) 0.472
6. Do you think that your medicines are necessary? (1=you consider them absolutely unnecessary; 
10=you consider them very important)
9.46 (1.11) 9.39 (1.38) 0.661
6.58 (0.68) 6.56 (0.65) 0.935
Table 4 statements regarding the PMc rated by all 372 patients using a self-report questionnaire at study end after having received at 
least one PMC (4-point Likert scale; 1=disagree, 2=tend to disagree, 3=tend to agree, 4=agree; nA=no answer)
Statement Likert scale 1–4 (n/%) NA
1 2 3 4
 1. The consultation took place in a pleasant atmosphere 0/0.0% 0/0.0% 12/3.2% 359/96.5% 1/0.3%
 2. The aims of the PMc were clearly explained to me 0/0.0% 3/0.8% 20/5.4% 347/93.8% 2/0.5%
 3. The time spent was worth it for me 4/1.1% 8/2.2% 51/13.7% 296/79.6% 13/3.5%
 4. i would recommend the service 2/0.5% 3/0.8% 49/13.2% 309/83.1% 9/2.4%
 5. The instructions of the pharmacist helped me in handling my medication 9/2.4% 5/1.3% 42/11.3% 293/78.8% 23/6.2%
 6. Thanks to the pharmacist’ advice, I do have more confidence in my medication 17/4.6% 13/3.5% 72/19.4% 234/62.9% 36/9.7%
 7. The pharmacist had enough time to answer all my questions 0/0.0% 2/0.5% 10/2.7% 356/95.7% 4/1.1%
 8. Until today, i felt left alone with my medication 259/69.6% 44/11.8% 22/5.9% 31/8.3% 16/4.3%
 9. Thanks to the advice, i feel safer than before in the use of my medication 31/8.3% 21/5.6% 83/22.3% 207/55.6% 30/8.1%
10. Until today, i had far too little information about my medication 180/48.4% 65/17.5% 65/17.5% 45/12.1% 17/4.6%
Abbreviation: PMc, Polymedication check.





knowledge gaps. In this context, further research might 
investigate sensitivity and specificity in detecting critical 
gaps in patients’ knowledge about their medicines.
Within this context, we also found that the knowledge 
of controls (usual care) improved between T-2 and T-16. 
We assume that the interview at T-2 affected this increase 
in the control group. When answering detailed questions 
about every medication, both groups showed their in-depth 
knowledge concerning medicine use, which could have 
influenced the measurement at T-16. Implicitly, the impact 
of the intervention on the outcome “knowledge” has to be 
assumed reliable and valid at T-2 only.
high acceptance of pharmacists’ 
interventions
While pharmacists reported being uncertain about their 
role in patient-centered care and lack of self-confidence,6 
patients from this study highly appreciated the pharmacists’ 
recommendations resulting from the PMC. Furthermore, 
patients agreed on the price of the PMC. This very positive 
feedback is a valuable argument in favor of the new service. 
However, only 31.2% of the patients knew before the start 
of the study of the possibility of this pharmacist-led service, 
indicating a huge gap in communication of new services to 
the target population 2 years after implementation. While 
the pharmacists’ willingness to provide the service remains 
unclear, legal barriers hamper the public announcements of 
new services, since it is forbidden by Swiss law to advertise 
for remunerated health care services.
room for improvement of patients’ 
medication management
The fact that 47% of patients stated having no written medica-
tion plan to organize their complex medication schedule raises 
the question of responsibility to provide such an important 
tool. A written medication plan, which is accepted and under-
stood by any individual patient, would probably empower 
them in daily medicine management and is highly recom-
mended by current guidelines when optimizing a patient’s 
medicines.16 Since in Switzerland pharmacists are obliged by 
law to keep records of all dispensed medication, they are in an 
excellent position to initiate a written overview and validate 
its actuality in collaboration with the corresponding GP. 
Such initiatives are currently in development in Germany.17 
Unfortunately, the current PMC guidelines do not mention it 
as a part of the service. The detection of this issue also lack 
in the structured protocol form as a screening approach.
implications for practice
Based on patients’ overestimation of knowledge about the 
correct use of their medications observed within our study, we 
propose to investigate pharmacists’ techniques in identifica-
tion of knowledge gaps during patient counseling. Pharma-
cists should be aware of knowledge gaps as a drug-related 
issue and should be provided with specific communication 
techniques for patient education. The high acceptance of the 
service should encourage community pharmacists to increase 
their involvement in patients’ medicines management, eg, by 
compiling an individual medication plan in collaboration with 
the corresponding GP as a remunerated service.
In order to streamline implementation of this pharmacist-
led medication review, further evaluation and development 
of the service should follow a validated process, such as 
was proposed by Craig et al.18 In order to allocate human 
and financial resources in the most cost-effective manner, 
re-engineering of the service should be considered, eg, by 
revising the selection process for patients qualifying for 
a PMC with a pre-screening for obvious adherence issues 
using individual medication records,19–21 specific validated 
questions triggering hints for non-adherence to medication,22 
or knowledge gaps. Similarly, the eligibility criteria for the 
comparable MUR service in the UK were changed 6 years 
after its implementation, adding specific target groups in 
the intervention’s focus.23 This proposal is aligned with 
recent recommendations of the National Health Institute of 
Excellence, which highlights the importance of medicine 
optimization, approaching patients at highest risks for 
medicine-related problems or patients with special needs, eg, 
people with physical problems such as arthritis or inability 
to swallow.16
strengths
Firstly, the randomized controlled trial design is a distinct 
strength of this study. Second, the trial was performed 
under real-life conditions with a representative sample of 
pharmacies from the German and French speaking parts of 
Switzerland. Thus, the results of the present study are likely 
to be highly generalizable. Third, development of the tele-
phone interview measurement tools was conducted by a col-
laborative, interprofessional approach. Fourth, well-trained 
and supervised interviewers, blinded to the intervention, 
performed the in-depth telephone interviews on patients’ 
acceptance and knowledge. Fifth, patients’ written self-
reports were blinded to the pharmacists; thus a Pygmalion 
effect could be avoided.
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limitations
Firstly, patients enrolled in clinical trials may be more con-
scientious than a more general population. Second, during 
the consent process, patients were told that the purpose of the 
study was to learn more about their daily medicines use. Thus, 
all our patients knew they were monitored, which may have 
led to a higher baseline in self-reported knowledge about 
their medicines in both groups. The pharmacists, on the other 
hand, knew that they were being studied, which may have led 
them to increase their efforts in delivering pharmaceutical 
care for both groups, also known as the Hawthorne effect.24 
Third, in order to keep the questionnaires and interviews 
to an acceptable length, instead of using pre-existing vali-
dated instruments, new ones were developed with extensive 
piloting but they lacked in-depth validation. Fourth, rating 
of patients’ knowledge about their medicines remained a 
subjective judgment. Fifth, the score for patients’ appraisal 
of their medicines use showed a low Cronbach’s alpha as a 
marker for limited reliability of the measure. Sixth, due to 
limited human resources, the registration of the project in a 
WHO database was delayed for some months. However, this 
lag in registration had no influence on the study protocol, 
patient recruitment, or data analysis. The relevant ethics 
approval was obtained before the study was initiated.
Conclusion
For the first time in Switzerland, the benefits of a complex 
pharmacist-led intervention were evaluated. The randomized 
controlled trial revealed important results in order to better 
understand the acceptance of cognitive services provided by 
community pharmacists. The PMC as an intermediate medi-
cation review offers a promising starting point for in-depth 
counseling and for providing pharmaceutical care. Knowledge 
about medication rated by interviewer and patients themselves 
was higher in the PMC group when measured directly after the 
PMC and 4 months later compared to controls. The community 
pharmacist-led intervention was highly appreciated by the 
patients, as a majority rated the counseling as helpful for their 
daily medication management. Patients would recommend 
the service to other patients and were willing to pay for it. 
However, almost half of the polypharmacy patients seemed to 
lack a written medication plan, offering room for improvement 
concerning the patients’ self-management of medicines use.
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Implementation of new services has  to be considered as a crucial  step  in  the  translation of 
knowledge  from  research  to  practice.104  As  recommended  by  Feletto  et  al.,  sophisticated 
planning  and  performance  monitoring  systems  are  required  to  effectively  implement  new 
services  and  sustain  their delivery,  supported by  changes  to  infrastructure and  staff mix.105 
However,  in  the case of  the Polymedication Check  little efforts were made to  integrate  the 









A paper questionnaire‐based  survey was  sent  to 280 pharmacists  from  the German part of 
Switzerland  (BS  /  BL  /  AG  and  to  all  pharmacies  from  the  Toppharm  group).  From  280 
pharmacies  enrolled,  143  (51.5%)  returned  the  questionnaire.  Thirty‐five  (24.5%)  of  them 
stated to be sceptic regarding the PMC and were not motivated to implement the service in 
their pharmacy, while 108 (75.5%) rated the service positively. Out of them, 51 (47.2%) already 


















conducted  four weeks after  study end  individually  in each  study  region by voluntary online 






Preparation  13.8 10.86  2 / 60
Conducting  29.5 10.57  15 / 60

















wide  range of  time needed  to prepare a PMC among pharmacists  indicates heterogeneous 









(30‐35  min).  She  considered  expenses  of  pharmacy  staff,  operational  costs  (i.e.  private 
counseling  area)  and  material  costs  of  a  standard  pharmacy  based  on  ROKA  data.107  She 
concluded that the service causes the pharmacy costs of CHF 73.05, indicating a difference of 
CHF 24.45 (+ 50.3%) to the current reimbursement of CHF 48.60. Thereby we need to consider 












































for antihypertensive  (AHT) and  lipid modifying  therapy  (LMT) did not  reach  their biomarker 
targets as defined by guidelines. This prospective study aimed at confirming the results of the 
pilot  study  based  on  data  that  was  collected  within  a  refined  screening  campaign  with 
standardised measuring methods and specific training of pharmacists. 
Method:  In  a  screening  campaign  for  cardiometabolic  risk  factors,  blood  chemistry,  blood 
pressure (BP), waist circumference, drug therapy and physical activity were assessed in Swiss 
pharmacies arranged in the group TopPharm in April 2010. 
“Not on  target” was defined as having  a BP ≥140/90 mmHg  (systolic/diastolic  BP),  or  ≥150 
















Screening  for  cardiometabolic  risk  factors  provided  by  community  pharmacies  attract  also 
patients already treated for cardiovascular risks. A previous retrospective sub‐analysis of data 
from 4380  patients  demonstrated  that  one  third  of  patients with  prescribed medicines  for 
antihypertensive and lipid modifying therapy did not reach their biomarker targets as defined 

































Waist  circumference was  taken as  another  risk  factor.110 A waist  circumference ≥88 cm  for 
women  and  WC  ≥102  cm  for  men  was  defined  as  optimisable  and  involved  appropriate 
counseling. Furthermore, we screened  for patients with  risk  for metabolic  syndrome111 and 




From  a  total  of  1’347  screened  subjects,  329  (24.4%)  were  eligible  because  they  had  a 























achievement,  mainly  through  adherence  support  and  life‐style  optimization.  In  particular, 





who  fail  to  achieve  treatment  targets  despite  prescribed  therapy.  Thus,  in  addition  to 
interventions  for patients newly  identified  to be at  risk  for  cardiovascular disease  validated 
interventions are needed to support community pharmacies in addressing contributing factors 






8.2 Swallowing difficulties with medication  intake assessed with a novel  self‐report 
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1Pharmaceutical care research 
group, Department of Pharmaceutical 
sciences, University of Basel, Basel, 
switzerland; 2european centre for the 
rehabilitation of scleroderma, reha 
rheinfelden, rheinfelden, switzerland
Objectives: To assess subjective swallowing difficulties (SD) with medication intake and 
their practical consequences in patients suffering from systemic sclerosis (SSc) with a novel 
self-report questionnaire.
Design and setting: Based on a systematic literature review, we developed a self-report 
questionnaire and got it approved by an expert panel. Subsequently, we sent the questionnaire 
by post mail to SSc patients of the European Center for the Rehabilitation of Scleroderma 
Rheinfelden, Switzerland.
Participants: Patients were eligible if they were diagnosed with SSc, treated at the center, and 
were of age $18 years at the study start.
Main outcome measures: Prevalence and pattern of SD with oral medication intake, includ-
ing localization and intensity of complaints.
Results: The questionnaire consisted of 30 items divided into five sections Complaints, Inten-
sity, Localization, Coping strategies, and Adherence. Of the 64 SSc patients eligible in 2014, 
43 (67%) returned the questionnaire. Twenty patients reported SD with medication intake 
(prevalence 47%), either currently (11; 26%) or in the past that had been overcome (9; 21%). 
Self-reported SD were localized mostly in the larynx (43%) and esophagus (34%). They were 
of moderate (45%) or strong to unbearable intensity (25%). Modification of the dosage form 
was reported in 40% of cases with SD. Adherence was poor for 20 (47%) patients and was not 
associated with SD (p=0.148).
Conclusion: Our novel self-report questionnaire is able to assess the pattern of complaints 
linked to medication intake, that is, localization and intensity. It may serve as a guide for health 
care professionals in selecting the most suitable therapy option, enabling tailored counseling to 
reduce inappropriate medication modifications.
Keywords: swallowing difficulties, medication intake, systemic sclerosis, coping behavior, 
self-report questionnaire, deglutition disorders
Introduction
Swallowing difficulties cause problems with the intake of solid oral dosage forms, 
an issue that has been reported in 9% of polypharmacy patients attending community 
pharmacies and 27% of a general practice population.1,2 Such problems may affect 
the patient’s quality of life, lead to hazardous coping strategies (splitting or crushing 
pills), and reduce adherence to medication regimens.1
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Several questionnaires assessing dysphagia (ie, swal-
lowing problems), in general, are available in the literature,3 
but very few detect swallowing difficulties with medicine 
intake. Moreover, most questionnaires aim at evaluating 
swallowing in its detailed physiologic function4 or tend to 
be tantamount to diagnostic tools.5 Questionnaires that con-
sider medication swallowing were primarily developed for 
research purposes and are too comprehensive to be used in 
practice by health care professionals.6 Further, reports men-
tion poor linkage between patients’ complaints and diagnostic 
findings.7,8 We hypothesize that the “one single question fits 
all” approach (eg, “Do you suffer from swallowing difficul-
ties when taking your medication?”) represents a first step 
for a loose detection of individual issues with medication 
intake, but needs further in-depth assessment.
Systemic sclerosis (SSc) is a rare multisystem autoim-
mune disease with a prevalence of 1–10 cases per 100,000 
individuals in Europe.9 Vascular remodeling, inflammatory 
reaction, and abnormal fibroblast activation lead to impaired 
circulation and fibrosis in skin and multiple inner organs. SSc 
is a chronic, often progressive disease with high morbidity 
and mortality. Organ failure can also include the gastroin-
testinal (GI) tract.10 Progressive worsening of the disease 
often leads to swallowing problems with food and liquids11 
and, therefore, probably medicines. A common comorbidity 
of patients suffering from SSc is the autoimmune Sicca or 
Sjögren’s syndrome, which may also affect the swallowing 
process.12,13 Since SSc cannot be cured yet, treatment of organ 
manifestations remains the main therapeutic strategy usually 
involving oral medications.14 Patient education, psychologic 
support, and highly specialized physical therapy are essential 
to the management of SSc. The European Centre for the 
Rehabilitation of SSc in Rheinfelden, Switzerland, serves the 
trinational region’s 1 million residents and offers specialized 
care for patients suffering from SSc.
This study aimed at developing a patient self-report 
questionnaire that assesses subjective swallowing difficulties 
with medication intake, which can be used to guide a health 
care professional when choosing therapy options or optimiz-
ing a patient’s medicines. The purpose of this questionnaire 
was not a diagnostic, but a screening approach. Pilot testing 
was performed in patients suffering from SSc, a very specific 
population at risk for swallowing disorders.
strengths of this study
•	 Based on a systematic literature search, a patient self-
report questionnaire assessing swallowing difficulties 
with medication intake was developed.
•	 Face validity of the initial questionnaire involved profes-
sional experts as well as patients.
•	 The use of a visual analog scale (VAS) to indicate the 
intensity and a human profile to indicate the localization 
of complaints ensured that answers were provided inde-
pendently of language and health literacy.
•	 First validation steps of the questionnaire was performed 
in patients with SSc, a highly specific population prone 
to develop swallowing difficulties.
limitations of this study
•	 As SSc is a rare disease, the investigated population 
provided a limited number of patients.
•	 Construct validity (defined as placing the measure of a 
construct in a nomological network and establishing its 
relation to other variables) and criterion validity (defined 
as the association with other measures of the same 
variable) were not performed.
Methods
systematic literature search and article 
eligibility
The databases PubMed, CINAHL and Embase were searched 
on 29th March 2014 with the terms “deglutition disorders 
[MeSH]” OR “swallowing difficult*” AND “drug dosage 
form*” AND “interview*” OR “questionnaire*”, with 
publication date being before February 2014 and without 
language restriction. Findings were reported according 
to the PRISMA statement (Preferred Reporting Items for 
Systematic reviews and Meta-Analyses).15,16 The identified 
abstracts were screened for eligibility according to the follow-
ing inclusion criteria: 1) human population, 2) swallowing 
difficulties with medication intake assessed in a systematic 
and structured form as an outcome measure (eg, interview 
guide), and 3) full-text publication in English or German 
language. The full texts were then screened again for eli-
gibility by two independent researchers. Discordance was 
resolved by consensus.
Development and validation of the 
questionnaire
Items from the questionnaires retrieved from the literature 
search were summarized, translated in German language, 
rephrased, and compiled into a patient self-report questionnaire. 
We termed the questionnaire SWAMECO for SWAllowing 
difficulties with MEdication intake and COping strategies. 
Face validation was performed with a panel of 11 experts 
(4 patients, 4 pharmacists, 2 speech-language pathologists, 
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and 1 professor in pharmaceutical care). Positive statements 
on sections, content relevance, intelligibility, comprehensibil-
ity, impact on patient privacy, and length of a first draft were 
graded from 1 (totally disagree) to 4 (totally agree). The higher 
the value, the more positive was the judgment.
Content validation was performed with nine SSc patients 
(mean age 52 years; four Germans, five Swiss; six women) 
attending an information seminar in Rheinfelden on 29 March 
2014. Completeness, comprehensibility, appropriateness and 
ambiguity of question wording, interpretation of the ques-
tions, ability to provide accurate answer, and length were 
tested with structured questions using a 4-point Likert-scale 
(1= fully disagree, 2= tend to disagree, 3= tend to agree, 
4= fully agree). Reliability was tested with six patients 
by a retest procedure 2 weeks later through post mail and 
measured using Cohen’s Kappa.17 A value .0.80 indicates 
substantial test–retest reliability. Construct and criterion 
validation were not performed because SWAMECO does 
not deliver a score or a threshold that could be compared to 
existing questionnaires.
study design, sample, and recruitment
The cross-sectional population study took place at the 
European Centre for the Rehabilitation of Scleroderma, 
Rheinfelden, Switzerland. All patients fulfilling the new 
classification criteria for SSc,18 currently being treated at the 
center, and of age $18 years were eligible. Pathophysiologic 
swallowing problems were not an inclusion criterion because 
dysphagia is not routinely diagnosed in the SSc patients 
attending the center (eg, by radiographic assessment or taking 
a medication with a standardized bolus of water).
Eligible patients were invited by letter in March 2014 to 
participate in the study. They received a written overview 
of the study, including purpose, an informed consent 
form (including consent to publish data), a SWAMECO 
self-report questionnaire, and a demographics sheet (includ-
ing confounding factors that may influence swallowing 
difficulties, such as tobacco and alcohol consumption, 
unexplained weight loss [as sign of GI manifestation in 
SSc], and diagnosed pneumonia in the past 6 months). The 
participants were asked to complete and return the informed 
consent form, the questionnaire, and the demographics form 
within 4 weeks.
reporting standards and data analysis
The authors followed the STROBE reporting standards for 
observational studies. Patient characteristics and answers of 
face validation are presented as percentages or means with 
standard deviation. Chi-square test was used to compare 
group variables. p-values ,0.05 were considered significant. 
Statistical analysis was conducted using SPSS Version 22 
(IBM Corporation, Armonk, NY, USA).
Ethical approval and trial 
registration
The study was approved by the local ethics committee 
Northwest/Central Switzerland (EKNZ 2014-013) and 
registered in the international clinical trial registry platform 
www.ClinicalTrials.gov (Identifier: NCT02105818, first 
entry March 28, 2014).
Results
systematic literature search
A total of 47 articles were identified (Figure 1). After 
screening of titles and abstracts, 41 articles were excluded 
from further analysis. The remaining six articles reported 
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Figure 1 Flow chart of the systematic literature search.





results from observational studies with low level of evidence 
according to GRADE19 (Supplementary material, Tables S1 
and S2). Four articles contained specific questionnaires.1,2,6,20 
None of them was designed as a self-report form.
Development and validation of the 
questionnaire
The two categories “Complaints” and “Coping strategies” 
were retrieved from the literature search and expanded with 
two new sections “Localization” and “Intensity”. The initial 
version of the questionnaire contained 32 items fitting on four 
pages as a DIN A4 double-sided, color-printed brochure.
Face validity was given with a mean overall agreement of 
3.7 (Table 1). The experts agreed with all items (no deletion), 
proposed 27 changes in the wording or the layout, 2 changes 
in the scales (adding the category “no answer” for 2 items), 
and suggested the separation of one item in two single items, 
the addition of one free-text item, and the inclusion of “chok-
ing” as a single item.
All changes were implemented. The final questionnaire 
contained 30 items (Table 2) and was redesigned as a DIN 
A3 landscape format and folded, to be provided as a double-
sided, color-printed brochure.
Item 1 asked for current oral medication intake (yes/no). 
The presence of swallowing difficulties with intake of 
liquid (item 2), food (item 3), or medication (item 4) was 
evaluated on a 3-point Likert scale (1=	current, 2=	past, 
3=	never suffered from swallowing difficulties). Complaints 
(items 5–14) were rated on a 4-point Likert scale (1=	totally 
agree, 4=	totally disagree) and contained four items related 
to the Sicca syndrome (item 6: “I have a dry mouth during 
daytime”).21,22 Intensity of the complaints (item 15) was 
rated on a VAS using pictorial representations of facial 
expressions (0/laughing face =	no complaints, 10/weeping 
face =	unbearable complaints). A drawing of the upper human 
body from head to stomach (item 16) was divided into four 
segments according to the physiologic swallowing process,23 
that is, oral preparatory stage (mouth), oral propulsive stage 
(throat), pharyngeal stage (pharynx), and esophageal stage 
(esophagus). Patients placed a cross to mark the localization 
of their complaints at the corresponding site. Item 17 assessed 
medicines (product name, dosage, and intake interval). 
Position of the head while swallowing medication (item 18) 
was asked with three predefined answers (chin toward 
chest, head straight ahead, head straight back). As the chin-
tuck technique, that is, to put chin toward the chest, changes 
pharyngeal dimensions through postural maneuver, it is rec-
ommended by speech specialists to move the bolus anterior in 
patients with dysphagia.24 Thus, we considered this technique 
as appropriate for patients reporting swallowing difficulties. 
Coping strategies were reported by answering open ques-
tions with free-text options or predefined answers (items 19, 
20) and closed questions with dichotomous options (items 
21–27). Three single items (items 28–30) to assess patients’ 
adherence were selected from existing cognitive services25 
(“Do you sometimes forget to take your medicines” [yes/
no]) and literature26 (“People sometimes miss taking their 
medications for reasons other than forgetting. Thinking over 
the past 2 weeks, were there any days when you did not take 
your medicine?” [yes/no] and “Have you ever cut back or 
stopped taking your medication without telling your doctor, 
because you felt worse when you took it?” [yes/no]). Patients 
Table 1 expert judgment on the sWAMecO questionnaire 
(n=11) by scoring from 1 (totally disagree) to 4 (totally agree), 
wherein one answer is missing





The handling of the questionnaire is 
clear and logical for me
11 3.7 (0.45)
The questions are formulated in a 
generally understandable way
11 3.8 (0.39)
The questions are formulated precisely 11 3.5 (0.50)
The questions have not violated 
my privacy
10 3.7 (0.64)
The response scales offer all options 
for my answer
11 3.6 (0.48)
The typeface is legible 11 3.8 (0.39)
The time value of 15 min for completing 
the questionnaire is appropriate
11 3.6 (0.78)
Note: Descriptors of the statement are given in bold.
Abbreviation: SWAMECO, SWAllowing difficulties with MEdication intake and 
cOping strategies.
Table 2 sections, number of items, and type of response scales 




complaints 15 Dichotomous (yes/no)/4-point Likert 
(1=	totally agree, 4=	totally disagree)
intensity 1 Visual analogue (scale 0–10 cm, 
0/laughing face =	no complaints, 
10/weeping face =	unbearable complaints)
localization 1 Visual analogue (mark a cross on the 
upper human body)
coping strategies 10 Dichotomous (yes/no)/open questions 
with free text or predefined single items
Adherence 3 Dichotomous (yes/no)
Abbreviation: SWAMECO, SWAllowing difficulties with MEdication intake and 
cOping strategies.
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were assessed as nonadherent when answering items 28–30 
once with “yes”.
Content validation was given with a median score of 
4 (range 3–4) over all criteria. The questionnaire was judged 
as understandable, helpful, and clear. Patients were able to 
fill in the questionnaire within 15 min, which was estimated 
as acceptable by all nine participants. Test–retest reliability 
showed an acceptable kappa κ=0.81.
cross-sectional population study
Of the 64 eligible patients, 43 (67%) returned the ques-
tionnaire, 35 (81%) of them within 3 weeks. Mean age 
was 54.6 years (standard deviation 12.23); the majority of 
them were female (n=36, 84%) and Swiss (n=32), ten were 
Germans, and one was an Austrian.
Of the 43 returned questionnaires, a total of 46 empty 
fields (3.3% missing data) were irregularly disseminated 
over 15 questionnaires (65% fully completed questionnaires). 
Seventeen empty fields concerned a block of responses 
(“Taking oral medication triggers 1) a choking, 2) a cough, 
3) nausea, 4) tightness while swallowing.”). In ten cases, 
questions with free-text options were left unanswered, that 
is, 1) “Describe how you feel the discomfort of swallowing 
medication(s)” and 2) “Which of your medication(s) cause 
swallowing difficulties?”.
Swallowing difficulties were reported by 20 patients 
(47%), as a current problem by 11 patients (26%), and as 
past difficulties that had been overcome by 9 patients (21%). 
Two patients left the question on swallowing difficulties 
with medication intake unanswered (missing data), but 
answered the question on swallowing difficulties with food 
or liquids in the negative. Thus, they were assigned to the 
group without complaints with medication intake for further 
analysis. Presence of possible confounding factors (tobacco 
and alcohol consumption, unplanned weight loss) was not 
correlated to swallowing difficulties with medication intake 
(data not shown).
Appropriate swallowing technique, that is, the chin-tuck 
technique, was mentioned in four (9%) cases. Patients with 
current complaints tilted their head backward as often as 
patients with past or no difficulties (5/11, 45% vs 11/29, 
38%; three missing; p=0.467). All 43 patients support their 
medication intake with a sip of water, and 11 patients reported 
regularly choking on their medication (26%).
Nonadherence (answering items 28–30 once with “yes”) 
was present in 47% of all patients and did not correlate with 
swallowing difficulties (12/19, 63% vs 8/20, 40%; four miss-
ing values; p=0.148).
Pattern of difficulties with swallowing 
medication
Of 20 patients with current or past self-reported swallowing 
difficulties with medication intake, 19 (95%) marked their 
complaints on the human profile (Figure 2) with a total of 
35 locations and a median number of marks per patient of 
2 (range 1–4). Most marks were placed at the pharynx (n=15; 
43%) and esophagus (n=12; 34%). Five marks were placed 
outside the GI tract.
The 20 patients indicated the intensity of complaints with 
a median of 4.4 (range 0.8–9.4). After repartition in tertiles, 
the intensity was low for six (30%) patients, moderate for 
nine (45%) patients, and strong for five (25%) patients. All 
patients but one (19 patients; 95%) reported pills or capsules 
stuck in the throat and could mostly name them (Figure 3). 
In 9 of 23 (39%) medicines involved, available drug form 
alternatives could have been recommended by a health care 
professional (Supplementary material, Table S3) according 
to the summaries of product characteristics currently in use 
in Switzerland.27
The most frequent complaints related to Sicca syndrome 
were ocular and nasal dryness (80%), dry mouth during day-
time (80%), the need to drink water for better speech (70%), 
and burning sensations (35%). Four patients (20%) were 
afraid of taking their medication because of the complaints. 
Ten patients (50%) had been worried about their swallowing 
difficulties during the past 4 weeks (Figure 3).
Coping strategies were reported by 10 patients, who 
modified the dosage form (n=8; 40%) or stopped medica-





Figure 2 Localization of patient’s swallowing difficulties with medication intake 
(35 marks provided by 19 patients).
Note: The segments correspond to the stages of the physiologic swallowing 
process, that is, oral preparatory stage (mouth), oral propulsive stage (throat), 
pharyngeal stage (pharynx), and esophageal stage (esophagus).





(n=8; 100%), opening capsules (n=4; 50%), dissolving 
medication in liquids (n=2; 25%), or crushing pills (n=1; 
13%). Only one patient consulted a health care professional 
before applying the coping strategy.
Discussion
We retrieved from the literature questions assessing swal-
lowing difficulties with medication, amended them, and 
developed a patient self-report questionnaire that screens 
for swallowing difficulties with medication intake. Face and 
content validity confirmed the completeness, clarity, and 
appropriateness of the questionnaire. The use of the pictorial 
VAS to indicate intensity and of a human profile to indicate 
localization ensures that answers are provided independently 
of language or health literacy. Pilot testing was performed 
in patients suffering from SSc, a specific population at high 
risk for swallowing disorders. We added specific items 
covering xerostomia and ocular or nasal dryness because 
these symptoms are often developed by SSc patients.28 The 
observed high response to these complaints (80%) in our 
study confirmed the influence of these specific symptoms 
on the swallowing process and the appropriateness of the 
SWAMECO questionnaire to reveal them. Generalization to 
other patients will be investigated in a further study.
We selected a self-report structure because patients with 
swallowing difficulties with medication feel a subjective 
complaint, which may be difficult, time-consuming, and 
frustrating to depict in words. In contrast to others,1,2 the 
SWAMECO self-report questionnaire was able to detect 
a heterogeneous pattern of complaints. On one hand, the 
human profile allows the patient to indicate precisely the 
subjective place of the complaints. On the other hand, a 
number from 0 to 10 from a psychometric response scale 
is able to quantify the intensity of complaints. Our ques-
tionnaire cannot be used for diagnostic purpose. Previous 
studies observed that the place of the complaints indicated 
by the patients was poorly correlated with objective findings, 
and concluded that the ability of patients to self-localize 
dysphagia symptoms is weak,7 especially in those with 
esophageal problems.8 Other reports similarly indicate that 
the intensity of symptoms is not reliable for predicting 
the location of the responsible lesion.29 Inversely, many 
functional abnormalities that are unrelated to the patients’ 
symptoms can be found with radiographic evaluation or 
video fluoroscopy.8 In summary, symptom referral varies 
between patients and can hardly be used as a diagnostic tool. 
Nevertheless, regardless of their correlation to diagnostic 
findings, subjective complaints during medication intake 
should be taken into account by health care professionals 
when choosing a pharmacotherapy. Thus, by using patient’s 
self-competencies in reporting, the SWAMECO question-
naire provides a snapshot of a patient’s experience with 
medication intake and their swallowing difficulties. In anal-
ogy to pain scales, intensity remains an important marker of 
patient’s burden with medication intake and enables tailored 
interventions to overcome hazardous coping strategies. The 
obtained answers can represent a starting point for deeper 
medical clarification and initiation of individual counsel-
ing, and conceivable communication difficulties become 
circumvented. Moreover, it may avoid time pressure when 
filled in advance of a consultation.
Prevalence of swallowing difficulties in 
patients with ssc
An unprecedented comprehensive insight into the medicine 
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Figure 3 Answers of the 20 patients who reported sD concerning general complaints associated with deglutition disorders.
Note: The darker the bar, the higher is the burden.
Abbreviation: SD, swallowing difficulties.
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existing population-specific tools have primarily focused on 
the reporting of a broad spectrum of GI disorders,30,31 while 
issues in the deglutition of medicines hereby were described 
for the first time by using the SWAMECO questionnaire. 
In total, difficulties with swallowing medication concerned 
as much as 47% of the surveyed patients at some point in 
time. The self-reported prevalence rate of current swal-
lowing difficulties in this population was high (26%) and 
in the upper range of studies performed in a more general 
population,1,2 while the rate of past difficulties (21%) was 
indicative of sustained complaints. This may be explained 
by the progressive nature of SSc disease that results in con-
tinuous suffering. It remains unclear whether the pattern of 
swallowing difficulties with medication intake in a more 
general population would be similar. These results highlight 
the need for a greater awareness of health care professionals 
on swallowing difficulties in this population.
coping strategies to overcome 
swallowing difficulties with medication
The coping strategies used by patients in our study, that is, 
opening capsules or crushing pills without informing the 
health care providers, are of great concern. Recent studies 
revealed that patients are often not aware of the safety issues 
when they modify medication dosage forms.32 In our study, 
patients were asked to report their coping strategies in a 
free-text format. The health care provider might use this 
individual information for further clarification or counseling, 
for example, by performing an in-depth medicine use review 
focusing on the coping strategies in daily use, and empower 
the patient with recommendations for safe and appropriate 
medication use. However, pharmacists and physicians rarely 
question patients about swallowing difficulties, and very few 
professionals systematically ask patients about this specific 
drug-related problem.1 Since health care professionals claim 
lack of time and personal resources, new screening tools such 
as the SWAMECO may reduce the workload and involve 
patients at an early stage.
Even if all patients reported taking water to ease the 
swallowing process, the amount of liquid remained unclear 
and might be critical. Schiele et al observed that 41% of all 
patients in their study took their medicines with less than half 
a glass of water.2 Similarly, the swallowing technique of the 
medication-water bolus showed potential for improvement 
regarding the low proportion of patients (9%) with head 
tilted forward, the strategy regarded as the best practice.33 
The use of the SWAMECO questionnaire may uncover 
some individual practices that might jeopardize successful 
swallowing.
In our study, the majority of medications reported for 
causing swallowing difficulties were essential therapeutic 
medications for the treatment of SSc (calcium channel 
blocker/PDE5 [phosphodiesterase type 5] receptor inhibitor) 
or for the prevention and treatment of gastroesophageal reflux 
disease (proton pump inhibitor/H2 receptor antagonists). 
For many of the involved products, available drug form 
alternatives could have been recommended. Continuous and 
appropriate use of the medicines is mandatory to slow down 
the progression of the disease. Consequently, any factor 
that may influence their efficacy needs the attention of the 
involved health care providers.
Adherence to medication
Nonadherence was self-reported by almost half of our 
patients (47%). Compared to other diseases with similar 
characteristics such as noticeable symptoms, chronicity, and 
evolution with degradation, our result is much lower than the 
91% of outpatients with rheumatoid arthritis,34 or the 91% of 
elderly patients with asthma who indicated nonadherence.35 
We expected a higher proportion of nonadherent patients 
when reporting swallowing difficulties. As the participating 
patients were rather young, with full cognitive capabilities 
and high motivation to take their medicines as prescribed, we 
can hypothesize that the observed overall higher adherence to 
medication results from intense care and self-empowerment 
provided by the specialized center.
Further development of the 
questionnaire
When patients were asked to localize their complaints (Figure 2), 
four dots were placed in an indicating triangle instead of the GI 
tract. It remains unclear if the corresponding patients were con-
fused by the triangles representing a segment, or the difficulty 
really occurred at this place. Further development should also 
evaluate indicating signs. Also, next validation steps should 
focus on clinical examination and confirmation of swallowing 
difficulties with video fluoroscopy. Finally, further studies 
should investigate a larger cohort in a more general popula-
tion and evaluate the clinical implication of the questionnaire 
in daily practice, that is, patient counseling.
strengths and limitations
Our study has several strengths. First, face validity of the 
initial questionnaire involved both professional experts and 
patients, who commented predominantly the wording of 
individual items. They made a significant contribution to the 
comprehensiveness of the questions, and thus, to the accep-
tance of the questionnaire and the feasibility of the study. 





This may explain the high response rate of 67% without the 
use of any reminders. Second, the patient-oriented language 
may explain that the majority of missing values concerned 
personal items. We presume that patients did not wish to 
answer the questions, rather than failing to answer because 
of understanding difficulties. Third, we investigated het-
erogeneous symptoms in a highly homogenous population 
in regards to the underlying disease. Consequently, our 
questionnaire may be seen as able to catch all symptoms of 
swallowing disorders.
We acknowledge some limitations. First, our results are 
patient-reported outcomes, and thus, subjective information. 
We did not confirm the findings with clinical diagnosis of 
the swallowing process or of GI disorders. Consequently, a 
correlation between the reported swallowing difficulties and 
a clinical implication is not possible. The SWAMECO ques-
tionnaire remains inconclusive on the cause of the symptoms, 
but offers initial opportunity for further and targeted investi-
gations. Second, the European Centre for the Rehabilitation of 
Scleroderma Rheinfelden is a leading center in the German-
speaking region of Europe and takes care of a considerable 
number of SSc patients. However, since SSc is a rare disease, 
the investigated population provided a limited number of 
patients. Third, the investigated population was recruited in a 
highly specialized center where patients are under regular and 
specific surveillance. Therefore, some answers might have 
been influenced by this unique situation, such as the questions 
regarding communication with health care professionals. 
Fourth, nonadherence was assessed using a nonvalidated 
approach. To assess this issue from a more comprehensive 
perspective, the use of validated outcome measures inde-
pendently from the self-report should be considered. Also, 
a general quality of life instrument that is, SF-36 (36-Item 
Short Form survey) or EQ-5D (European Quality of Life-5 
Dimensions questionnaire) could be used to describe health-
related quality of life in patients with SSc.36
Conclusion
Through self-report questionnaires, patients can efficiently 
provide individual information that can be used for relevant 
counseling and tailored interventions. We developed a first 
self-report questionnaire assessing swallowing difficul-
ties with medication intake that entirely relies on patients’ 
impressions and not on detailed physiologic functions. Pilot 
testing of the SWAMECO questionnaire in patients with SSc, 
a highly specific population prone to develop swallowing 
difficulties, showed feasibility and acceptance of patients. 
Prevalence of swallowing difficulties with medication intake 
was remarkably high in the investigated population. Reported 
localization and intensity of complaints as well as potentially 
hazardous coping strategies indicated the need for in-depth 
counseling by health care professionals. Further validation 
of the SWAMECO self-report questionnaire should be con-
tinued in the general population, including evaluation of its 
complementary value in patient care.
Data sharing statement
The datasets used and/or analyzed during this study are 
available from the corresponding author on reasonable 
request.
Transparency statement
The corresponding author affirms that the manuscript is 
an honest, accurate, and transparent account of the study 
being reported, no important aspects of the study have been 
omitted, and any discrepancies from the study as planned 
have been explained.
Acknowledgments
We thank all participating patients from the European 
Centre for the Rehabilitation of Scleroderma, Rheinfelden, 
Switzerland. Furthermore, we are grateful to Christian 
Rutschmann (Business Images AG, Switzerland) for his 
support as a graphic designer.
Author contributions
All authors made substantial contributions to conception and 
design, acquisition of data, or analysis and interpretation of 
data; took part in drafting the article or revising it critically 
for important intellectual content; gave final approval of the 
version to be published; and agree to be accountable for all 
aspects of the work.
Disclosure
All authors have completed the ICMJE uniform disclosure 
form at www.icmje.org/coi_disclosure.pdf. The authors 
report no conflicts of interest in this work and declare no 
support from any organization for the submitted work, no 
financial relationships with any organizations that might have 
an interest in the submitted work in the previous 3 years, and 
no other relationships or activities that could appear to have 
influenced the submitted work.
References
1. Marquis J, Schneider MP, Payot V, et al. Swallowing difficulties with oral 
drugs among polypharmacy patients attending community pharmacies. 
Int J Clin Pharm. 2013;35(6):1130–1136.




Swallowing difficulties with medication intake
 2. Schiele JT, Quinzler R, Klimm HD, Pruszydlo MG, Haefeli WE. 
Difficulties swallowing solid oral dosage forms in a general practice 
population: prevalence, causes, and relationship to dosage forms. 
Eur J Clin Pharmacol. 2013;69(4):937–948.
 3. Speyer R, Cordier R, Kertscher B, Heijnen BJ. Psychometric proper-
ties of questionnaires on functional health status in oropharyngeal 
dysphagia: a systematic literature review. Bio Med Res Int. 2014;2014: 
458678.
 4. Dwivedi RC, St Rose S, Roe JW, et al. Validation of the Sydney 
Swallow Questionnaire (SSQ) in a cohort of head and neck cancer 
patients. Oral Oncol. 2010;46(4):e10–e14.
 5. Antonios N, Carnaby-Mann G, Crary M, et al. Analysis of a physician 
tool for evaluating dysphagia on an inpatient stroke unit: the modified 
Mann Assessment of Swallowing Ability. J Stroke Cerebrovasc Dis. 
2010;19(1):49–57.
 6. Kelly J, D’Cruz G, Wright D. Patients with dysphagia: experiences of 
taking medication. J Adv Nurs. 2010;66(1):82–91.
 7. Roeder BE, Murray JA, Dierkhising RA. Patient localization of 
esophageal dysphagia. Dig Dis Sci. 2004;49(4):697–701.
 8. Smith DF, Ott DJ, Gelfand DW, Chen MY. Lower esophageal mucosal 
ring: correlation of referred symptoms with radiographic findings 
using a marshmallow bolus. AJR Am J Roentgenol. 1998;171(5): 
1361–1365.
 9. Ranque B, Mouthon L. Geoepidemiology of systemic sclerosis. 
Autoimmun Rev. 2010;9(5):A311–A318.
 10. Coral-Alvarado P, Pardo AL, Castano-Rodriguez N, Rojas-Villarraga A, 
Anaya JM. Systemic sclerosis: a world wide global analysis. Clin 
Rheumatol. 2009;28(7):757–765.
 11. Vischio J, Saeed F, Karimeddini M, et al. Progression of esophageal 
dysmotility in systemic sclerosis. J Rheumatol. 2012;39(5):986–991.
 12. Ebert EC. Esophageal disease in scleroderma. J Clin Gastroenterol. 
2006;40(9):769–775.
 13. Pierce J, Tanner K, Merrill R, Miller K, Kendall K, Roy N. Swallowing 
disorders in Sjögren’s syndrome: prevalence, risk factors, and effects 
on quality of life. Dysphagia. 2016;31(1):49–59.
 14. Pope J, Harding S, Khimdas S, Bonner A, Baron M. Agreement with 
guidelines from a large database for management of systemic sclerosis: 
results from the Canadian Scleroderma Research Group. J Rheumatol. 
2012;39(3):524–531.
 15. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement 
for reporting systematic reviews and meta-analyses of studies that 
evaluate healthcare interventions: explanation and elaboration. BMJ. 
2009;339:b2700.
 16. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items 
for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 
2009;339:b2535.
 17. Altman DG. Practical Statistics for Medical Research. London: Chap-
man and Hall; 1991.
 18. van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification 
criteria for systemic sclerosis: an American college of rheumatology/
European league against rheumatism collaborative initiative. Ann 
Rheum Dis. 2013;72(11):1747–1755.
 19. Schunemann HJ, Oxman AD, Brozek J, et al. Grading quality of 
evidence and strength of recommendations for diagnostic tests and 
strategies. BMJ. 2008;336(7653):1106–1110.
 20. Wright D. Medication administration in nursing homes. Nurs Stand. 
2002;16(42):33–38.
 21. Fox RI, Saito I. Criteria for diagnosis of Sjogren’s syndrome. Rheum 
Dis Clin North Am. 1994;20(2):391–407.
 22. Daniels TE, Criswell LA, Shiboski C, et al. An early view of the inter-
national Sjogren’s syndrome registry. Arthritis Rheum. 2009;61(5): 
711–714.
 23. Matsuo K, Palmer JB. Anatomy and physiology of feeding and 
swallowing: normal and abnormal. Phys Med Rehabil Clin N Am. 
2008;19(4):691–707, vii.
 24. Saconato M, Chiari BM, Lederman HM, Goncalves MI. Effectiveness 
of Chin-tuck Maneuver to Facilitate Swallowing in Neurologic Dys-
phagia. Int Arch Otorhinolaryngol. 2016;20(1):13–17.
 25. Messerli M, Blozik E, Vriends N, Hersberger KE. Impact of a com-
munity pharmacist-led medication review on medicines use in patients 
on polypharmacy – a prospective randomised controlled trial. BMC 
Health Serv Res. 2016;16(1):145.
 26. Arnet I, Metaxas C, Walter PN, Morisky DE, Hersberger KE. The 
8-item Morisky Medication Adherence Scale translated in German and 
validated against objective and subjective polypharmacy adherence 
measures in cardiovascular patients. Journal of Evaluation in Clinical 
Practice. 2015;21(2):271–277.
 27. Swiss agency for therapeutic products (Swissmedic). Product information; 
2015. Available from: http://swissmedicinfo.ch/Accept.aspx?Lang=EN. 
Accessed December 12, 2015.
 28. Vitali C, Borghi E, Napoletano A, et al. Oropharyngolaryngeal dis-
orders in scleroderma: development and validation of the SLS scale. 
Dysphagia. 2010;25(2):127–138.
 29. Edwards DAW. Discriminatory value of symptoms in the differential 
diagnosis of dysphagia. Clin Gastroenterol. 1976;5(1):49–57.
 30. Spiegel BMR, Hays RD, Bolus R, et al. Development of the 
NIH patient-reported outcomes measurement information system 
(PROMIS) gastrointestinal symptom scales. Am J Gastroenterol. 2014; 
109(11):1804–1814.
 31. Baron M, Hudson M, Steele R, Lo E. Validation of the UCLA scle-
roderma clinica trial gastrointestinal tract Instrument version 2.0 for 
systemic sclerosis. J Rheumatol. 2011;38(9):1925–1930.
 32. Lau ETL, Steadman KJ, Mak M, Cichero JAY, Nissen LM. Prevalence 
of swallowing difficulties and medication modification in customers 
of community pharmacists. J Pharm Pract Res. 2015;45(1): 
18–23.
 33. Schiele JT, Schneider H, Quinzler R, Reich G, Haefeli WE. Two tech-
niques to make swallowing pills easier. Ann Fam Med. 2014;12(6): 
550–552.
 34. Gadallah MA, Boulos DN, Gebrel A, Dewedar S, Morisky DE. Assess-
ment of rheumatoid arthritis patients’ adherence to treatment. Am J Med 
Sci. 2015;349(2):151–156.
 35. Bozek A, Jarzab J. Adherence to asthma therapy in elderly patients. 
J Asthma. 2010;47(2):162–165.
 36. Gualtierotti R, Ingegnoli F, Scalone L, et al. Feasibility, acceptability 
and construct validity of EQ-5D in systemic sclerosis. Swiss Med Wkly. 
2017;146:w14394.






Table S1 Results from the systematic literature search. Excluded articles from the systematic literature search on swallowing difficulties 
with medication intake, published before February 2014 (n=37, without duplications). First author, year of publication, title and journal 
are given in alphabetical order
First author Year Title Journal
Aitichou1 2012 crushing pills, an easy practice of an old problem? evaluation of crushing practices in a 
geriatric long term care unit
Int J Clin Pharm
Andersen2 1995 [Problems when swallowing tablets. A questionnaire study from general practice] 
Article in norwegian
Tidsskr Nor Laegeforen
Baker3 2010 clinical results from a randomized, double-blind, dose-ranging study of pantoprazole in 
children aged 1 through 5 years with symptomatic histologic or erosive esophagitis
Clin Pediatr
Dabade4 2009 Proton pump inhibitor compliance does not impact gerD symptom resolution Gastroenterology
Fallon5 2011 An analysis of the impact of xerostomia on the quality of life of head and neck cancer 
patients receiving radiotherapy
Radiother Oncol
Focken6 2010 Prospective randomized controlled trial of an injectable esophageal prosthesis versus a 
sham procedure for endoscopic treatment of gastroesophageal reflux disease
Surg Endosc
gawron7 2013 Esophageal Hypervigilance: A Construct for Reflux and Dysphagia Symptoms Based on 
Patient reported Outcomes
Gastroenterology
go8 2013 Problems with swallowing pills commonly relates to properties like size Gastroenterology
gonçalves9 2008 speech-language and hearing complaints of children and adolescents with brain tumors Pediatr Blood Cancer
hanawa10 2012 [Questionnaire survey of air extruded jelly dosage form (i) – oral condition of elder 
patients and applicability of air extruded jelly formulation – ] Article in Japanese
Yakugaku Zasshi
hanssens11 2006 improving oral medicine administration in patients with swallowing problems and 
feeding tubes
Ann Pharmacother
iwase12 2012 The clinical use of Kampo medicines (traditional Japanese herbal treatments) for 
controlling cancer patients’ symptoms in Japan: a national cross-sectional survey
BMC Complement 
Altern Med
Kalf13 2013 Swallowing disorders in Parkinson’s disease: As frequent and severe as you think? Dysphagia
Kalf14 2011 Difficulty with pill swallowing in Parkinson’s disease Dysphagia
Kalf15 2011 Pathophysiology of diurnal drooling in Parkinson’s disease Mov Disord
Lazebnik16 2010 [Gastroesophageal reflux disease in the elderly patients: epidemiology, clinical features, 
therapy] Article in russian
Eksp Klin Gastroenterol
lucia17 2010 Analysis of pharyngeal phase of swallowing hard gelatine pills in asymptomatic adults Dysphagia
Martínez De 
haro18
2008 [Outpatient monitoring of oesophageal ph with a catheter-free ph-meter (Bravo 
System). A Study of tolerance, safety and efficacy] Article in Spanish
Cir Esp
Márton19 2011 evaluation of oral mucositis in children receiving intensive chemotherapy using proms 
questionnaire
Pediatr Blood Cancer
Mayadev20 2008 The amyotrophic lateral sclerosis center: a model of multidisciplinary management Phys Med Rehabil Clin N Am
Mcnally21 2012 randomised, double-blind, placebo-controlled study of a single dose of an 
amylmetacresol/2,4-dichlorobenzyl alcohol plus lidocaine lozenge or a hexylresorcinol 
lozenge for the treatment of acute sore throat due to upper respiratory tract infection
J Pharm Pharm Sci
Moretó22 2013 Treatment of achalasia by injection of sclerosant substances: a long-term report Dig Dis Sci
nishimura23 2012 Prospective evaluation of incidence and severity of oral mucositis induced by 
conventional chemotherapy in solid tumors and malignant lymphomas
Support Care Cancer
nito24 2013 surgical management of intractable aspiration Dysphagia
Obasan25 2012 Assessment of compliance to treatment among ambulatory asthmatic patients in a 
secondary health care facility in nigeria
Int J Pharm Sci Res
Ogata26 2008 [some problems for dosage form based on questionnaire surveying compliance in 
patients taking tamsulosin hydrochloride] Article in Japanese
Yakugaku Zasshi
Payot27 2011 Prevalence of patients’ difficulties in swallowing solid oral dosage forms Int J Clin Pharm
Peterson28 2010 Comparison of esomeprazole to aerosolized, swallowed fluticasone for eosinophilic 
esophagitis
Dig Dis Sci
Sakellariou29 2013 Medication swallowing difficulties reported by adults with idiopathic Parkinson’s 
disease and oropharyngeal dysphagia
Dysphagia
Sasaki30 2013 comments on selected recent dysphagia literature Dysphagia
seo31 2011 Longitudinal changes of the swallowing process in subacute stroke patients with 
aspiration
Dysphagia
simons32 2013 Munich dysphagia test-Parkinson’s disease (MDT-PD): A new clinical questionnaire for 
early assessment of dysphagia in Parkinson’s disease
Dysphagia
(Continued)
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Table S1 (Continued)
First author Year Title Journal
Thinrungroj33 2012 Alginate accelerates healing of post-endoscopic variceal ligation ulcers: A randomized-
controlled trial
Gastrointest Endosc
Truter34 2012 An approach to dyspepsia for the pharmacist SA Pharmaceutical Journal
Valenza35 2009 role of oro-pharyngo-oesophageal scintigrapgy in the evaluation of swallowing 
disorders in patients with myotonic dystrophy type 1 (DM1)
Medizinische Genetik
Verin36 2011 submental sensitive transcutaneous electrical stimulation (ssTes) at home in 
neurogenic oropharyngeal dysphagia: a pilot study
Ann Phys Rehabil Med
Zibetti37 2014 Levodopa/carbidopa intestinal gel infusion in advanced Parkinson’s disease: a 7-year 
experience
Eur J Neurol
Table S2 Articles selected from the systematic literature research on swallowing difficulties with medication intake, published before 
February 2014. First author, year of publication, title and journal are given in alphabetical order
First author Year Title Journal
Kelly38 2010 Patients with dysphagia: experiences of taking medication
(Open dialogue with patients exploring 3 questions: What problems do you have taking your 
medicines? How do you deal with any problems you have when taking medicines? What 
advice have you been given about coping with your swallowing problems?)
J Adv Nurs
Márquez-contreras39 2008 Pharmacological compliance and acceptability of lansoprazole orally disintegrating tablets in 
primary care
Curr Med Res Opin
Marquis40 2013 Swallowing difficulties with oral drugs among polypharmacy patients attending 
community pharmacies
(Questionnaire with 16 questions in 7 dimensions: current number of daily oral prescribed 
medicines, demographics, swallowing difficulties, coping strategies for overcoming difficulties, 
impact on medication adherence and on daily functioning, perception of state of health, 
whether patients had notified their difficulties to their physician and pharmacist)
Int J Clin Pharm
Mehuys41 2012 Medication management among home-dwelling older patients with chronic diseases: possible 
roles for community pharmacists
J Nutr Health Aging
Schiele42 2013 Difficulties swallowing solid oral dosage forms in a general practice population: 
prevalence, causes, and relationship to dosage forms
(Questionnaire with 32 questions in 5 major topics: demographics, medication intake habits, 
presence of diseases, attitude towards medication intake, coping strategies for overcoming 
difficulties)
Eur J Clin 
Pharmacol
Wright43 2002 Medication administration in nursing homes
(Questionnaire for nurses with the sections: guidance on completion, respondent details, 
nursing home population demographics, extent of swallowing difficulties, methods used to 
overcome swallowing difficulties, experience of overcoming swallowing difficulties, opinions 
on the ease of changing medication)
Nurs Stand
Notes: Articles in bold systematically investigated swallowing disorders and were selected to develop the sWAMecO questionnaire. A short summary is indicated in 
brackets.





Table S3 results from the cross-sectional population study. Active pharmaceutical ingredient, formulation of the medicine, frequency 
of medication reported to cause swallowing difficulties (n=21) and the possibility of an available alternative drug form according to the 
swiss summaries of product characteristics





Acetylsalicylic acid (low dose) Tablet 1× Antiplatelet Yes (Yes)
Amlodipine Tablet 2× Calcium channel blocker no Yes
Dutasteride/tamsulosin capsule 1× Urologic no noa
esomeprazole Tablet 1× Proton pump inhibitor no nob
levothyroxine Tablet 2× Thyroid hormone no Yes
nifedipine Tablet 1× Calcium channel blocker no noc
Omeprazole capsule 1× Proton pump inhibitor no nod
Pantoprazole Tablet 1× Proton pump inhibitor Yes nob
Prednisolone Tablet 1× glucocorticoid no Yes
Pregabalin capsule 1× Antiepileptic no noa
ranitidine Tablet 1× h2 receptor antagonist Yes (Yes)
sulfamethoxazole/trimethoprim Tablet 1× Antibiotic Yes (Yes)
Tadalafil Tablet 1× PDe 5 receptor inhibitor no Yes
Valsartan/amlodipine/hydrochlorothiazide Tablet 1× Calcium channel blocker/diuretic no Yes
Self-medication (n=3)
Acetylsalicylic acid (high dose) Tablet 2× Analgesic Yes (Yes)
ibuprofen Tablet 2× Analgesic Yes (Yes)
Paracetamol (acetaminophen) Tablet 1× Analgesic Yes (Yes)
Nutritional supplements (n=4)
Fish oil capsule 1× – no noa
Vitamin c Tablet 2× – Yes (Yes)
Unspecified herbal drug Tablet 2× – Unknown Unknown
Unspecified enzyme product capsule 1× – Unknown Unknown
Notes: aOpening of capsule possible. bNo crushing, only floating for suspension possible. cno crushing recommended due to photosensitivity. dOpening of capsule possible, 
but no crushing of pellets, only floating for suspension possible. If alternative drug forms were available, the option to crush a tablet was kept in brackets.
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This  thesis  aimed  at  giving  a  general  overview  over  clinical  pharmacy  services  already 
performed  in  the  Swiss  hospital  setting  and  discussing  the  strengths  and  limitations  of 
pharmacist‐led medication  reviews  in  primary  care  by  evaluating  the  Swiss  Polymedication 






after  establishing  a  national  definition  of  clinical  pharmacy.  It  may  be  interesting  to  the 
international audience that in certain regions of Switzerland physicians are allowed to dispense 
drugs  themselves  directly.  Therefore, we were  interested  in  differences  in  the  provision  of 
clinical pharmacy practice between these regions compared to those where pharmacies are 
exclusively dispensing medicine,  investigating a major disrupting  factor  for  interprofessional 
collaboration. While mapping clinical pharmacy practices in Swiss hospital, we also reported an 
obvious communication gap between ambulatory and stationary care – even within the same 
profession  i.e.  the  hospital  and  the  community  pharmacists.  To  closer  link  hospital  and 
community pharmacists, collaborative initiatives for postgraduate education i.e. acceptance of 
the  recently  established  Certificate  of  Advanced  Studies  (CAS)  in  clinical  pharmacy  as  a 
postgraduate program for both disciplines might become an interesting approach. 
Transitions  of  care  imply  changes  in  the  level,  location,  or  providers  of  care.  Community 
pharmacies  are  very  often  the  first  of  all  the  healthcare  providers  involved  after  hospital 
discharge.  Medication  reconciliation  is  widely  recommended  to  avoid  unintentional 
discrepancies  between  patients’ medications  across  transitions  in  care.144  Reconciliation  of 
therapies is much more than a puzzle game. When reconciliation is seen as the starting point 
for  a  structured  pharmaceutical  care  service  and  is  bundled  with  interventions  aimed  at 
improving care transitions post‐discharge, health care utilisation may be reduced.144 Further, 
Mulhem et al. observed 24‐48 hours after discharge non‐adherence in 20% of the patients.145 
Thus,  a  close  follow‐up  is  important  and  a  simple  telephone  follow‐up  could  be  easily 





rebound  effects  when medication  is  immediately  stopped.  The  basics  of  clinical  pharmacy 
knowledge and skills are essential also for community pharmacists to address all these issues. 
Moreover, specific knowledge is needed in order to perform clinical services for an individual 
patient.  In  fact,  community  pharmacists  providing  cognitive  services  (e.g.  motivational 
interviewing) are in need of much more training in clinical pharmacy issues related to patient 
care in this specific population to become adequately skilled. 
The  issue  of  lack  of  communication  between  settings  has  also  been  part  within  a  recent 
evaluation provided by the Swiss foundation for patient safety. In their survey, they report a 
lack  of  information  transfer  between  community  pharmacies  and  hospitals  from  the 
community pharmacists’ perspective. Although community pharmacists were willing to share 
data (given that the  legal  requirements are met  i.e. data protection, patient’s privacy),  they 
regularly had been contacted from a hospital  in only 4% of cases to support a patient’s best 
possible medication history.146 
Our  survey  also  showed  that  at  patient's  discharge  into  ambulatory  care  medication 







collaboration over  settings  for patients with  coronary artery disease.147 Adherence  to beta‐
blockers,  expressed  as  proportion  of  days  covered  (PDC),  was  significantly  higher  in 
intervention  versus  control  group  (71%  vs  49%,  respectively,  P=0.03).  The  PMC  as  an 
established  pharmacist‐led  cognitive  service  offers  an  ideal  starting  point  for  in‐depth 
reconciliation  in  the  community  setting.  Thereby,  seamless  care  between  settings  could  be 
improved,  given  a  sufficient  implementation  rate  of  performed  PMCs  as  well  as  adequate 





improving  patient  safety  through  structured medication  reconciliation  at  transitions  in  the 
hospital. 
As discussed within the work report A2, any type of medication review may detect a relevant 
number of DRPs  independently  the  setting. However,  the  impact of medication  reviews on 




In  Switzerland  repeat  prescribing  for  a  maximum  of  12  months  is  allowed  and  such 
prescriptions  currently  constitute  nearly  75%  of  all  items  dispensed.149  Hence,  community 
pharmacists  assume  very  responsible  roles  in  the  care  of  chronic  patients.  The  recently 





Check,  delivery of  a  dose dispensing  service poses multiple  issues  that  are  typically  part  of 
clinical pharmacy services. Often the therapy plan requires an adaption to fit the predefined 
options of a pill box, and not all medicines can be dispensed due to stability problems.150 
First  evaluations  of  the  PMC  service  showed  that  simplifications  in  therapy  plans  and 
improvement of knowledge provided by pharmacists are highly appreciated.151 Patients need 
well‐founded  answers.  An  example  is  the  frequent  question  on  best  timing  of  medication 
intake. As polypharmacy has developed over a long period of time in each patient, the review 
of  the  intake  schedule  becomes  essential  and  altering  the  timing  of  intake  may  improve 
therapeutic  outcomes.  While  some  medicines  need  to  be  taken  separately  (e.g. 
Bisphosphonate,  L‐Thyroxin),  most  chronic  medication  can  be  taken  at  the  same  time, 
preferably  in  the morning and avoiding doses  to be  taken at  lunch. Thus, when performing 
medication  use  reviews,  knowledge  of  disease  and  chrono‐pharmacology  is  important. 
Pharmacists  have  to  take  note  of  the  pharmacokinetic  properties  and  the  «forgiveness  of 
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drugs»  to  optimise  therapeutic  coverage  and  to  cope with  risks of  non‐adherence.  Skills  in 
disease management are important and chronotherapy is now also an emerging concept.152 




the  following  explanations  as  barriers  to  provide  PMC:  ‘no  time’,  ‘not  my  responsibility’, 








handling  of  the protocol  form. No  accreditation or  qualification was  regarded necessary  to 
provide a PMC and only few practical trainings were offered to support pharmacists  in their 
new role. 
This  evalPMC  project  was  proposed  as  an  investigator‐initiated  evaluation  project  by  the 
Pharmaceutical  Care  Research  Group  without  any  intention  to  comprehensively  proof  the 
concept  of  efficacy,  appropriateness  and  economics,  according  the national  'WZW'  criteria. 
Later, negotiations with the representatives of the health insurance companies within the so 










Our  primary  outcome  of  the  evaluation  study  was  a  change  in  patient’s  adherence  to 
medications. Based on reporting from previously performed projects, we hypothesised a much 
lower  adherence  rate  than  finally  observed.  Taitel  et  al.  investigated  face‐to‐face  patient 
counseling sessions with a pharmacist that addressed patient barriers to adherence.156 After 
12  months,  the  intervention  group  showed  a  MPR  of  61.8%  (CI,  54.5%‐69.2%)  and  the 
comparison group had a MPR of 56.9% (CI, 49.5%‐64.3%) with a significant difference of 4.9% 
between groups  (P < 0.01). Meanwhile,  a  systematic  literature  review and meta‐analysis of 
adherence‐enhancing  interventions  in  studies  assessing  medication  adherence  through 









a  centralised  telephone  service  contacted  the  patients  after  two  weeks  to  discuss  their 
medication‐related  needs.158  When  patients  were  followed‐up  after  four  weeks  by  a 
researcher, there was significantly less non‐adherence in the intervention group compared to 
the control group. Based on these findings, the so‐called ‘New Medicines Service’ (NMS) was 
introduced  in  2011.  Comparable  research  from  UK  recently  presented  data  on  adherence 
improvement  due  to  this  pharmacists‐led  intervention  for  newly  prescribed  medicines.  In 
parallel to the evalPMC project, the University of Nottingham conducted an in‐depth evaluation 
of  the  NMS  from  2013‐2015,  using  a  comparable  study  design  to  ours.159  The  authors 
performed  their  evaluation  study  in  46  community  pharmacies  in  England,  including  504 






























and  liver,  or  the  results  of  blood  tests  are  generally  not  routinely  available  to  the  Swiss 
community  pharmacist.  This  gap  can  be  overcome when  promising  eHealth  programs  and 





The  pharmacist‐led  intervention  was  highly  appreciated  by  patients  and  recommendations 
showed a high acceptance rate. Re‐engineering of the service should focus on a more efficient 
screening  for  patients  at  highest  risk  for  drug‐related  problems  and  provide  a  bundle  of 
standardised  interventions,  i.e.  interview  guides  with  algorithms  to  support  pharmacists. 
Kempen et al. analysed in a large‐scale implementation study of Dutch community pharmacies 
4,579  clinical  medication  reviews  conducted  in  patients  suffering  from  coronary  heart 
disease.79 On average, 2.9 (SD 2.1) DRPs per review were identified while we reported 1.2 DRPs 










In  order  to  respect  the  already  well‐organised  patients  without  any  further  risks  for  drug‐












criteria  around  issues  of  adherence  to  long‐term  medication  based  on  practice  electronic 
medical records101 while other initiatives focus on medicines overuse in order to save money, 
i.e. the Swiss injury insurance.163 Still, adherence as an outcome measure remains challenging 





high  baseline.  Little  is  known  concerning  pharmacists’  perceptions  and  barriers  towards 
recommendations  of  such  aids.  Communication  training  should  be  considered  to  support 
counseling with rational and practical arguments for implementing WDAs in patient’ daily life. 
Pharmacists need to foster practical training in performing patient‐oriented interventions and 
taking  responsibility  in  clinical  decision‐making.  This  should  include  interprofessional 
collaboration and independent supervision ensuring highest possible quality of the service and 
patient  safety.  The  complexity  of  the  PMC  regarding  its  multistage  intervention  was  not 




Another  observation  might  offer  new  opportunities  for  service  development.  During  the 
evalPMC project, patients were easily accessible by telephone. Therefore, a follow‐up meeting 
(or a new service) can also be conducted by telephone and does not necessarily have to take 

















In  order  to  discuss  the  need  for  a  pharmacist’s  choice  option  within  eligibility  criteria  for 





Assessing  lab  tests,  i.e.  blood  glucose  measurement  and  lipid  profile  are  well‐established 
standard services in a majority of pharmacies. Whenever lab results do not fit with a patient’s 
or  clinician’s  expectation,  further  clarification  is  of  crucial  importance  to  ensure  health 





report  questionnaire  uses  the  patient’s  capabilities  of  describing  individual  needs  and 
complaints and subsequently offers a basis for tailored counseling and individual interventions. 
Barenholtz et al. suggested already  in 2003 that a self‐administered questionnaire might be 




proportion  of  14%  of  patients  with  identified  drug‐related  problems  when  their  self‐
administrated 5‐item risk assessment was used. The referral rate was approximately 3 times 

























to  be  well  established  and  accepted.  Remarkably,  interprofessional  ward  rounds  were 
performed  periodically  in  hospitals,  which  offer  clinical  pharmacy  services.  However,  there 
were  hardly  any  services  enabling  external  access  to  valid  information  about  a  patient's 












initiate  pharmaceutical  care  as  a  contribution within  patient  care.  However,  the  impact  of 
medication  reviews  is  directly  linked  to  the  subsequently  provided  intervention  to  solve  a 




Project  B  confirmed  the  Polymedication  Check  (PMC)  as  a  promising  new  service  while  its 
impact  remained  low due  to  issues within  the selection criteria. The evaluation of  the PMC 
showed low impact on patient’s adherence and highlighted the need for re‐engineering. We 





and  establishing  a  strong  ‘pharmacists  –  patient’  relationship.  Nevertheless,  inducing  the 
paradigm  change  in  patient‐centred  care  through  pharmaceutical  care  seems  to  be  more 
challenging than expected by the pharmacists’ association and health insurance companies. In 
order  to achieve  this change, pharmacists claimed the need  for specific  training,  structured 
guidance,  and  supervision  during  the  implementation  process.  Therefore,  strengthening  of 
evaluation  research  on  a  local,  as  well  as  a  national  and  international  level  is  essential  to 
develop,  implement  and  continuously  improve  clinically  oriented  services  provided  by 
community pharmacists. 
Project C exemplified two potential domains for pharmacist‐led interventions based on already 
existing  resources,  i.e.  public  health  prevention  campaigns,  or  by  involving  the patient  in  a 
needs  assessment.  When  patients  do  not  achieve  individual  treatment  targets  (e.g. 
biomarkers), further clarification for potential drug‐related problems are needed. In order to 
provide  tailored counseling,  the use of patient self‐report assessments might become more 
important,  e.g.  in order  to detect drug‐related problems or  individual patient’s needs.  Self‐
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 Departement Pharmazeutische Wissenschaften Klingelbergstrasse 50 Markus Messerli, Studienkoordination 
Pharmaceutical Care Research Group CH-4056 Basel Tel. +41 (0)61 267 15 29 
 
2012_07_02_ic_patient  Seite 1 von 4 
PATIENTEN-INFORMATION zur Studie „Evaluation Polymedikations-Check – 
Medikamentenanwendung im Alltag“ 
 
 
Sehr geehrte Dame, 
Sehr geehrter Herr 
 
Sie erhalten seit mindestens drei Monaten vier oder mehr Medikamente vom Arzt verordnet. Ihre 
Apotheke beteiligt sich an einem nationalen Forschungsprojekt, in welchem die Betreuung von 
Patienten mit mehreren Medikamenten im Alltag untersucht wird. 
 
Wir laden Sie ein, an dieser Studie teilzunehmen. Sie wird im Rahmen der geltenden Gesetze 
und international anerkannten Grundsätzen durchgeführt und wurde von der Ethikkommission 
beider Basel geprüft und bewilligt (EKBB 50/12). 
 
Allgemeine Informationen zur Studie: Die Studie „Medikamentenanwendung im Alltag“ wird in 
öffentlichen Apotheken in Kantonen der Nordwestschweiz und der Romandie durchgeführt. Total 
werden 800 Patienten in 70 Studienapotheken teilnehmen können. Die Studie wird vom 
Schweizerischen Apothekerverband, pharmaSuisse, finanziert. Organisation und Koordination 
erfolgen durch die Universität Basel. 
 
Ziele der Studie: Ziel der Studie ist, die Anwendung von Medikamenten im Alltag zu 
untersuchen. Um die Patienten zukünftig noch besser beraten zu können, interessieren uns alle 
Ihre Schwierigkeiten, Probleme und Ihre Wünsche an eine begleitende Unterstützung während 
der Therapie. Zudem soll diese Studie den Nutzen eines vertieften Beratungsgesprächs mit 
Ihrem Apotheker/Ihrer Apothekerin (den sogenannten ‚Polymedikations-Check) untersuchen. 
 
Ablauf der Studie: Wenn Sie sich zur Teilnahme an der Studie einverstanden erklären, wird 
Ihnen mitgeteilt, ob Sie entweder der Gruppe A oder der Gruppe B zugeteilt wurden 
 
 Beide Gruppen A und B werden durch die Universität Basel zur Arzneimittel-Anwendung 
im Alltag befragt. 
 Patienten in Gruppe A werden zusätzlich zu Beginn der Studie ein ca. 30 minütiges 
Beratungsgespräch zum ‚Medikamenten-Alltag‘ mit dem/der Apotheker/in (einen 
sogenannten ‚Polymedikations-Check) durchführen. Bei Patienten in Gruppe B findet 
dieses Beratungsgespräch 7 Monate später statt. 
 
Die zufällige Einteilung in eine der beiden gleich grossen Gruppen ist die einzige Möglichkeit, um 
herauszufinden, ob ein strukturiertes Beratungsgespräch mit Ihrem Apotheker / Ihrer Apothekerin 
Vorteile bringt. 
 
Die Zuteilung wird von der Studienkoordination zufällig und unabhängig von der Anzahl oder Art 
Ihrer Medikamente getroffen. In jedem Fall erhalten Sie Ihre verordneten Medikamente weiterhin 
wie gewohnt durch Ihre Apotheke. Alle Patienten haben die gleiche Chance, in die eine oder 
andere Gruppe eingeteilt zu werden. 
 
 Departement Pharmazeutische Wissenschaften Klingelbergstrasse 50 Markus Messerli, Studienkoordination 
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2012_07_02_ic_patient  Seite 2 von 4 
Ablauf der Studie: mit der Unterzeichnung der Einverständniserklärung beginnt die Studie. Sie 
werden zu verschiedenen Zeitpunkten Fragen zu Ihrer Person, Ihrem Medikamentenalltag und 
Ihrer Betreuung durch die Apotheke beantworten. Dabei gibt es keine richtigen oder falschen 





 Befragung in der Apotheke: Sie beantworten Fragen zu Ihrer Person 
und der Anwendung Ihrer Medikamente im Alltag. 
 
 Gruppeneinteilung: Im Anschluss an diese schriftliche Befragung werden 
Sie einer Gruppe zugeteilt. Bei Studienteilnehmer/innen der Gruppe A 







1. Telefoninterview: die Universität Basel wird Sie telefonisch kontaktieren 






2. Telefoninterview: die Universität Basel wird Sie telefonisch kontaktieren 






Befragung in der Apotheke am Ende der Studie: Beide Gruppen A und B 




Weitere Datenerhebungen: Ihre Apotheke wird dem Studienzentrum die Daten Ihrer 
Medikamentenbezüge in anonymisierter Form übermitteln. Dies rückwirkend über den Zeitraum 
von sieben Monate vor der Einwilligung zur Studienteilnahme, sowie sieben Monate ab 
Einwilligung zur Studienteilnahme. 
 
Es werden zu keinem Zeitpunkt: Blutproben entnommen oder Laboruntersuchungen 
durchgeführt. 
 
Welchen Nutzen können Sie möglicherweise von diesem Projekt haben? Sie werden in 
jedem Fall mit den bestmöglichen Methoden behandelt und wie bisher von Ihrer Apotheke 
betreut. Zusätzlich könnten Sie von dem Beratungsgespräch mit dem/der Studienapotheker/in 
(Polymedikations-Check) und dem daraus bisher nicht sicher dokumentierten Vorteil gegenüber 
der klassischen Begleitung profitieren. Dank Ihrer Studienteilnahme können die Ergebnisse auch 
anderen Personen zugutekommen. 
 
Entschädigung: Ihren Aufwand für die Teilnahme an dieser Studie (Besuche in der 
Apotheke/Telefoninterviews) können wir mit CHF 20.- in Form von Reka-Checks entschädigen. 
 
Mögliche Risiken und Unannehmlichkeiten durch die Studie: Risiken im Zusammenhang mit 
dem Polymedikations-Check sind keine zu erwarten. Das Beantworten der Fragen in der 
Apotheke und am Telefon wird Zeit in Anspruch nehmen. Es steht Ihnen frei, auf für Sie 
unangenehme Fragen keine Antwort zu geben. 
 Departement Pharmazeutische Wissenschaften Klingelbergstrasse 50 Markus Messerli, Studienkoordination 
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Sollten aufgrund der Beratung Rückfragen oder Abklärungen mit einem Arzt nötig werden, so 
erfolgen diese in jedem Fall stets mit Ihrer Einwilligung. 
 
Kosten: Die Medikamente werden Ihrer Krankenkasse verrechnet. Die Kosten für den 
Polymedikations-Check werden ebenfalls regulär über Ihre Krankenkasse abgerechnet. 
 
Alternative Behandlungsmöglichkeiten: Unabhängig von Ihrer Zuteilung in eine der beiden 
Gruppen werden Sie weiterhin sämtliche Möglichkeiten haben, den Service ihrer Apotheke in 
Anspruch zu nehmen. 
 
Freiwilligkeit der Teilnahme und Rücktritt: Ihre Teilnahme an der Studie ist freiwillig. Sie 
können Ihr Einverständnis zu jedem Zeitpunkt zurückziehen, ohne dass Sie einen bestimmten 
Grund dafür angeben müssen oder Nachteile für Ihre weitere Behandlung zu erwarten haben. 
Das gleiche gilt, wenn Sie auf die Teilnahme an dieser Studie verzichten. 
 
Versicherungsschutz: Für Schäden, die Sie im Rahmen dieser Studie durch die Beratung 
erleiden sollten, sind die Studienapotheken durch eine Police des Studienzentrums versichert. 
 
Vertraulichkeit der Daten: In dieser Studie werden persönliche Daten von Ihnen erfasst. Diese 
Daten werden anonymisiert. Sie sind nur Fachleuten zur wissenschaftlichen Auswertung 
zugänglich. Ebenso kann die Ethikkommission beider Basel Einsicht in die Originaldaten 
nehmen. Sämtliche Daten werden dabei immer strikt vertraulich behandelt. Ihr Name wird in 
keiner Weise in Berichten oder Veröffentlichungen, die aus der Studie hervorgehen, publiziert. 
 
Kontaktpersonen: Falls Sie im Zusammenhang mit dieser Studie Fragen haben oder 
irgendwelche gesundheitliche Schwierigkeiten auftreten, so wenden Sie sich an Ihre/n 
betreuende/n Apotheker/in, Ihren behandelnden Arzt oder an folgende Kontaktpersonen. Diese 




Markus Messerli     
eidg. dipl. Apotheker, Doktorand 
Tel.: 061 / 267 15 29 
eMail: markus.messerli@unibas.ch 
Studienleitung 
Prof. Kurt E. Hersberger 
Offizinapotheker FPH 




24h-Studienhotline: 079 / 104 35 62 
 Departement Pharmazeutische Wissenschaften Klingelbergstrasse 50 Markus Messerli, Studienkoordination 
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SCHRIFTLICHE  EINVERSTÄNDNISERKLÄRUNG  DES  PATIENTEN 
zur Teilnahme an der Studie „Evaluation Polymedikations-Check – Medikamenten-
anwendung im Alltag“ (Studiennummer EKBB 50/12; Studienort: Basel-Land / Basel-Stadt) 
 
 Ich wurde vom unterzeichnenden Apotheker ausführlich mündlich und schriftlich über die 
oben beschriebene Studie informiert und habe die Patienteninformation gelesen und 
verstanden. Alle meine Fragen wurden mir zufriedenstellend beantwortet. 
 
 Ich hatte genügend Zeit, um meine Entscheidung zu treffen. 
 
 Mit meiner Unterschrift bestätige ich meine Einwilligung zur freiwilligen Teilnahme. Ich 
kann meine Zustimmung jederzeit ohne Angabe von Gründen und ohne für mich daraus 
entstehende Nachteile für meine weitere Behandlung zurückziehen. 
 
 Ich bin damit einverstanden, dass wissenschaftliches Personal des Departementes 
Pharmazie der Universität Basel oder der Studienapotheke im Zusammenhang mit dieser 
Studie Einsicht in meine medizinischen Daten nehmen darf. 
 
 Eine Kopie der schriftlichen Patienteninformation und der Einverständniserklärung habe 
ich erhalten. 
 




Geburtsdatum: Geschlecht:  
 
  weiblich 
 






Unterschrift des Patienten / der Patientin: 
Telefonnummer: ID Patient 
 
 
Wird von Studienapotheke ausgefüllt 
  
Bestätigung der/des Studienapotheker/in: Hiermit bestätige ich, dass ich diesem Patienten / 
dieser Patientin Wesen, Bedeutung und Tragweite der Studie erläutert habe. Ich versichere, alle 
im Zusammenhang mit dieser Studie stehenden Verpflichtungen zu erfüllen. Sollte ich zu 
irgendeinem Zeitpunkt während der Durchführung der Studie von Aspekten erfahren, welche die 
Bereitschaft des Patienten / der Patientin zur Teilnahme an der Studie beeinflussen könnten, 
werde ich ihn / sie umgehend darüber informieren. 
 










Unterschrift der aufklärenden Studienapothekerin / 





Polymedikations-Check Evaluationsstudie 2012/13 [Ref.Nr.EK.: 2012/079] 






















 Patient qualifiziert für Wochendosiersystem (WDS). 
Ja  Nein  
 Information an 
 
 Rücksprache mit 
 
 Weiterleitung des Patienten an 
Arzt Ja  Nein  Er nutzt    bereits    neu seit dem PMC   ein WDS, 
Auffüllen erfolgt  selbständig  durch die Apotheke. 
 Patient benötigt kein Wochendosiersystem Ja  Nein  




Ja  Nein  
 
Datum:   ____ / ____ / ____        Zeit Ende:____.____ Uhr Stempel Apotheke /Unterschrift Apotheker/in: 
 
Unterschrift Patient/in: _____________________________ 
 
Pat.-ID: Geburtsdatum: _____ / _____ / _________ Geschlecht        männlich         weiblich 
Der Patient/die Patientin nimmt zurzeit täglich 4 oder mehr Medikamente auf ärztliche Verordnung und über mind. 3 Monate ein   
1. Check Zeit Beginn: ____.____ Uhr   
Ärztlich verordnete Medikamente 
(dieser Check basiert auf Informationen vom 
Patienten und/oder aus der Dokumentation 
der Apotheke) 
Abklärung Bedarf für Beratung zur 





















1 Name/ Stärke / Galenische Form                neu ?   
 
__-__-__-__ 
Ja  Nein   Bei Bedarf 
 Befristet 
 Dauertherapie 
Ja    Nein  Ja  Nein   
2 Name/ Stärke / Galenische Form                neu ?   
 
__-__-__-__ 
Ja  Nein   Bei Bedarf 
 Befristet 
 Dauertherapie 
Ja    Nein  Ja  Nein   
3 Name/ Stärke / Galenische Form                neu ?   
 
__-__-__-__ 
Ja  Nein   Bei Bedarf 
 Befristet 
 Dauertherapie 
Ja    Nein  Ja  Nein   
4 Name/ Stärke / Galenische Form                neu ?   
 
__-__-__-__ 
Ja  Nein   Bei Bedarf 
 Befristet 
 Dauertherapie 
Ja    Nein  Ja  Nein   
5 Name/ Stärke / Galenische Form                neu ?   
 
__-__-__-__ 
Ja  Nein   Bei Bedarf 
 Befristet 
 Dauertherapie 
Ja    Nein  Ja  Nein   
6 Name/ Stärke / Galenische Form                neu ?   
 
__-__-__-__ 
Ja  Nein   Bei Bedarf 
 Befristet 
 Dauertherapie 
Ja    Nein  Ja  Nein   
7 Name/ Stärke / Galenische Form                neu ?   
 
__-__-__-__ 
Ja  Nein   Bei Bedarf 
 Befristet 
 Dauertherapie 
Ja    Nein  Ja  Nein   
8 Name/ Stärke / Galenische Form                neu ?   
 
__-__-__-__ 
Ja  Nein   Bei Bedarf 
 Befristet 
 Dauertherapie 
Ja    Nein  Ja  Nein   
9 Name/ Stärke / Galenische Form                neu ?   
 
__-__-__-__ 
Ja  Nein   Bei Bedarf 
 Befristet 
 Dauertherapie 
Ja    Nein  Ja  Nein   
10 Name/ Stärke / Galenische Form                neu ?   
 
__-__-__-__ 
Ja  Nein   Bei Bedarf 
 Befristet 
 Dauertherapie 
Ja    Nein  Ja  Nein   
Selbstmedikation:    Ja    Nein   
A Name/ Stärke / Galenische Form                neu ?   
 
__-__-__-__ 
Ja  Nein   Bei Bedarf 
 Befristet 
 Dauertherapie 
Ja    Nein  Ja  Nein   
B Name/ Stärke / Galenische Form                neu ?   
 
__-__-__-__ 
Ja  Nein   Bei Bedarf 
 Befristet 
 Dauertherapie 
Ja    Nein  Ja  Nein   
C Name/ Stärke / Galenische Form                neu ?   
 
__-__-__-__ 
Ja  Nein   Bei Bedarf 
 Befristet 
 Dauertherapie 
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 Patient qualifiziert für Wochendosiersystem (WDS). 
Ja  Nein  
 Information an 
 
 Rücksprache mit 
 
 Weiterleitung des Patienten an 
Arzt Ja  Nein  Er nutzt    bereits    neu seit dem PMCT-28 ein WDS, 
Auffüllen erfolgt  selbständig  durch die Apotheke. 
 Patient qualifiziert nicht für ein Wochendosiersystem Ja  Nein  




Ja  Nein  
 
Datum:   ____ / ____ / ____        Zeit Ende:____.____ Uhr Stempel Apotheke /Unterschrift Apotheker/in: 
 
Unterschrift Patient/in: _____________________________ 
 
 Geburtsdatum: _____ / _____ / _________ Geschlecht        männlich         weiblich 
Der Patient/die Patientin nimmt zurzeit täglich 4 oder mehr Medikamente auf ärztliche Verordnung und über mind. 3 Monate ein   
1. Check Zeit Beginn: ____.____ Uhr   
Ärztlich verordnete Medikamente 
(dieser Check basiert auf Informationen vom 
Patienten und/oder aus der Dokumentation 
der Apotheke) 
Abklärung Bedarf für Beratung zur 





















1 Name/ Stärke / Galenische Form                neu ?   
 
__-__-__-__ 
Ja  Nein  
 
__________ 
 Bei Bedarf 
 Befristet 
 Dauertherapie 
Ja    Nein  Ja  Nein   
2 Name/ Stärke / Galenische Form                neu ?   
 
__-__-__-__ 
Ja  Nein  
 
__________ 
 Bei Bedarf 
 Befristet 
 Dauertherapie 
Ja    Nein  Ja  Nein   
3 Name/ Stärke / Galenische Form                neu ?   
 
__-__-__-__ 
Ja  Nein  
 
__________ 
 Bei Bedarf 
 Befristet 
 Dauertherapie 
Ja    Nein  Ja  Nein   
4 Name/ Stärke / Galenische Form                neu ?   
 
__-__-__-__ 
Ja  Nein  
 
__________ 
 Bei Bedarf 
 Befristet 
 Dauertherapie 
Ja    Nein  Ja  Nein   
5 Name/ Stärke / Galenische Form                neu ?   
 
__-__-__-__ 
Ja  Nein  
 
__________ 
 Bei Bedarf 
 Befristet 
 Dauertherapie 
Ja    Nein  Ja  Nein   
6 Name/ Stärke / Galenische Form                neu ?   
 
__-__-__-__ 
Ja  Nein  
 
__________ 
 Bei Bedarf 
 Befristet 
 Dauertherapie 
Ja    Nein  Ja  Nein   
7 Name/ Stärke / Galenische Form                neu ?   
 
__-__-__-__ 
Ja  Nein  
 
__________ 
 Bei Bedarf 
 Befristet 
 Dauertherapie 
Ja    Nein  Ja  Nein   
8 Name/ Stärke / Galenische Form                neu ?   
 
__-__-__-__ 
Ja  Nein  
 
__________ 
 Bei Bedarf 
 Befristet 
 Dauertherapie 
Ja    Nein  Ja  Nein   
9 Name/ Stärke / Galenische Form                neu ?   
 
__-__-__-__ 
Ja  Nein  
 
__________ 
 Bei Bedarf 
 Befristet 
 Dauertherapie 
Ja    Nein  Ja  Nein   
10 Name/ Stärke / Galenische Form                neu ?   
 
__-__-__-__ 
Ja  Nein  
 
__________ 
 Bei Bedarf 
 Befristet 
 Dauertherapie 
Ja    Nein  Ja  Nein   
Selbstmedikation:    Ja     Nein   
A Name/ Stärke / Galenische Form                neu ?   
 
__-__-__-__ 
Ja  Nein  
 
__________ 
 Bei Bedarf 
 Befristet 
 Dauertherapie 
Ja    Nein  Ja  Nein   
B Name/ Stärke / Galenische Form                neu ?   
 
__-__-__-__ 
Ja  Nein  
 
__________ 
 Bei Bedarf 
 Befristet 
 Dauertherapie 
Ja    Nein  Ja  Nein   
C Name/ Stärke / Galenische Form                neu ?   
 
__-__-__-__ 
Ja  Nein  
 
__________ 
 Bei Bedarf 
 Befristet 
 Dauertherapie 
Ja    Nein  Ja  Nein   
PMC FollowUp Evaluationsstudie 2012/13 [EKBB 50/2012] 
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Hinweise auf arzneimittelbezogene Probleme: 
1. Sind Sie während der letzten sieben Monate gestürzt?  Nein  Ja 
2. 
Falls JA:  einmal  mehrfach: ca. ________ Mal. 
 Haben Sie sich dabei verletzt? 
 
 War in der Folge ein Arztbesuch notwendig? 
 






















Hatten Sie während den letzten sieben Monaten das Gefühl, einzelne Ihrer Medikamente 
wirken… … zu stark? 






 Ja, ID _________ 
 
 Ja, ID _________ 
Nur Patienten mit PMC bei T-0 [bitte mit PMC Protokoll T-0 abgleichen] 
4. 
Konnten unterdessen sämtliche der damals besprochenen Probleme behoben werden? 
 

















Dokumentation von Therapieänderungen 
innerhalb der letzten sieben Monate 






Etikette mit PatID /Datum 












erfolgt? Grund für die Änderung * 
1  Unverändert 
 Änderung 
 Neue Therapie 
 
 
___ / ___ / ______ 






 Arzt  Spital 
 
 Apotheke  Patient 
 
2  Unverändert 
 Änderung 
 Neue Therapie ___ / ___ / ______ 






 Arzt  Spital 
 
 Apotheke  Patient 
 
3  Unverändert 
 Änderung 
 Neue Therapie ___ / ___ / ______ 






 Arzt  Spital 
 
 Apotheke  Patient 
 
4  Unverändert 
 Änderung 
 Neue Therapie ___ / ___ / ______ 






 Arzt  Spital 
 
 Apotheke  Patient 
 
5  Unverändert 
 Änderung 
 Neue Therapie ___ / ___ / ______ 






 Arzt  Spital 
 
 Apotheke  Patient 
 
6  Unverändert 
 Änderung 
 Neue Therapie ___ / ___ / ______ 






 Arzt  Spital 
 
 Apotheke  Patient 
 
7  Unverändert 
 Änderung 
 Neue Therapie ___ / ___ / ______ 






 Arzt  Spital 
 
 Apotheke  Patient 
 
8  Unverändert 
 Änderung 
 Neue Therapie ___ / ___ / ______ 






 Arzt  Spital 
 
 Apotheke  Patient 
 
9  Unverändert 
 Änderung 
 Neue Therapie ___ / ___ / ______ 






 Arzt  Spital 
 
 Apotheke  Patient 
 
10  Unverändert 
 Änderung 
 Neue Therapie ___ / ___ / ______ 






 Arzt  Spital 
 
 Apotheke  Patient 
 
* Kategorien für Änderungsgrund: A) Unverträglichkeit, B) Kosten, C) Medi nicht mehr indiziert, D) neue Beschwerden, E) Wirkung zu 
stark, F) Wirkung zu schwach, G) Patient weiss es nicht, H) etwas anderes -->bitte beschreiben! 
A  Unverändert 
 Änderung 
 Neue Therapie ___ / ___ / ______ 






 Arzt  Spital 
 
 Apotheke  Patient 
 
B  Unverändert 
 Änderung 
 Neue Therapie ___ / ___ / ______ 






 Arzt  Spital 
 
 Apotheke  Patient 
 
C  Unverändert 
 Änderung 
 Neue Therapie ___ / ___ / ______ 






 Arzt  Spital 
 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Füllen  Sie  weiter  den  Fragebogen  zu  allfälligen  Schluckbeschwerden  mit  der  Einnahme  von 
Medikamenten und persönlichen Angaben aus. Bei den Angaben zu Schluckbeschwerden gibt es keine 




















die  zur  Verhinderung,  Feststellung  und  Behandlung  bestehender  oder  künftig  zu  erwartender 





werden  verschlüsselt,  d.h.  mit  einem  Code  versehen.  Dieser  Code  wird  im  Studienzentrum 
verschlossen und getrennt von anderen Daten aufbewahrt. Den wissenschaftlichen Fachleuten sind 
nur  verschlüsselte  Daten  zur  Auswertung  zugänglich.  Im  Rahmen  von  Inspektionen  können  die 
Mitglieder  der  zuständigen  Behörden  und  Ethikkommissionen  Einsicht  in  Ihre  nicht  codierte 







Kosten: Weder  Ihnen, noch  ihrer Krankenkasse entstehen  im Zusammenhang mit  Ihrer Teilnahme 

































































 Ich habe die  zur oben genannten Studie abgegebene  schriftliche Patienteninformation gelesen und verstanden. 



























Bestätigung  der  Studienkoordination:  Hiermit  bestätige  ich,  dass  ich  diesem  Patienten  /  dieser  Patientin  Wesen, 
Bedeutung und Tragweite der Studie schriftlich erläutert habe. Ich versichere, alle im Zusammenhang mit dieser Studie 
stehenden Verpflichtungen zu erfüllen. Sollte ich zu irgendeinem Zeitpunkt während der Durchführung der Studie von 



































2 Wann  wurde  bei  Ihnen  die  Diagnose Sklerodermie gestellt? 
 
___ ___ / ___ ___ ___ ___ [mm / j j j j , z.B. 10 / 2008] 







Studien  haben  gezeigt,  dass  Rauchen  oder  Konsumieren  von  Alkohol  Einfluss  auf  die 
Entwicklung  von  Schluckbeschwerden  haben  können.  Dieses  Risiko  möchten  wir  näher 
untersuchen. 
 
Sie  sind  nun  am  Ende  des  Fragebogens  angelangt.  Besten  Dank  für  Ihre  Teilnahme! 













Eine  Einheit  bedeutet  eine  3.3  dl  Büchse  bzw.  eine 
Stange Bier, 1 dl Wein, 4 cl  Schnaps oder ein Misch‐
getränk mit 4 cl Schnaps 
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Fragebogen ‚Schluckbeschwerden und Medikamenteneinnahme‘ [EKNZ 2014-013] 
 
Sehr geehrte Studienteilnehmerin, sehr geehrter Studienteilnehmer 
 
Der vorliegende Fragebogen wurde entwickelt, um Schluckbeschwerden bei der Einnahme von 
Medikamenten zu erfassen und zu erfahren, wie mit diesen umgegangen wird. Durch Resultate 
der Befragung soll es in Zukunft möglich sein, Schluckbeschwerden bei Patienten früher zu erkennen 
und damit die Lebensqualität und Sicherheit von Patienten zu erhöhen. 
 
Schluckbeschwerden werden individuell unterschiedlich empfunden. Es gibt deshalb keine richtigen 
oder falschen Antworten. Sämtliche Angaben werden anonymisiert ausgewertet und lassen keine 
Rückschlüsse auf Ihre Person zu. Der Fragebogen umfasst 35 Fragen auf vier Seiten und wird rund 
15 Minuten Ihrer Zeit in Anspruch nehmen. Die Fragen sind zumeist so gestellt, dass Sie das 
Zutreffende ankreuzen können. Falls nicht anders erwähnt, bewerten Sie bitte jede Frage nur mit 
einem Kreuz. Bitte beantworten Sie alle für Sie relevanten Fragen. 
 
Wenn Sie den Fragebogen fertig ausgefüllt haben, retournieren Sie diesen bitte in dem beiliegenden 
Antwortcouvert an das Studienteam der Universität Basel. 
 
 Besten Dank für Ihre Teilnahme! 
 
Angaben zu Ihrer Person 
ID: _____________ Jahrgang: __________________ 
 ☐ weiblich 
Geschlecht: ☐ männlich 
 
  Ja Nein 
1 Nehmen Sie zum heutigen Zeitpunkt mindestens ein Medikament ein, welches Sie schlucken müssen? ☐ ☐ 
 
 Haben Sie Schluckbeschwerden… Ja, zur Zeit Ja, in der Vergangenheit 
Nein, noch 
nie 
2 … beim Trinken? ☐ ☐ ☐ 
3 … beim Essen? ☐ ☐ ☐ 
4 … bei der Einnahme von Medikamenten? ☐ ☐ ☐ 
 
 falls Sie eine der Fragen 2-4 mit ‚Ja‘ beantworten, fahren Sie bitte mit Frage 5 auf Seite 2 fort. 
 
 falls Sie die Fragen alle mit ‚Nein‘ beantworten, fahren Sie bitte mit Frage 18 auf Seite 3 fort. 
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Bitte nehmen Sie zu den folgenden Aussagen Stellung: 
 











5.1 … ein Würgen ... ☐ ☐ ☐ ☐ ☐ 
5.2 … einen Hustenreiz ... ☐ ☐ ☐ ☐ ☐ 
5.3 … Übelkeit ... ☐ ☐ ☐ ☐ ☐ 
5.4 
… ein Engegefühl während dem 
Schlucken ... ☐ ☐ ☐ ☐ ☐ 
       
6 Ich habe tagsüber einen trockenen Mund. ☐ ☐ ☐ ☐ ☐ 
7 
Ich muss öfters einen Schluck Wasser zu 
Hilfe nehmen, um besser Sprechen zu 
können. 
☐ ☐ ☐ ☐ ☐ 
8 Ich habe ein unangenehmes Brennen in meinem Mund. ☐ ☐ ☐ ☐ ☐ 
9 Meine Augen und Nasenschleimhäute fühlen sich ausgetrocknet an. ☐ ☐ ☐ ☐ ☐ 
10 Ich habe das Gefühl, die Medikamente bleiben beim Schlucken im Hals stecken. ☐ ☐ ☐ ☐ ☐ 
11 Das Schlucken von Medikamenten verursacht Schmerzen. ☐ ☐ ☐ ☐ ☐ 
12 
Ich habe mir in den letzten vier Wochen 
Sorgen wegen meinen Schluckbe-
schwerden gemacht. 
☐ ☐ ☐ ☐ ☐ 
13 
Ich nehme manchmal ein Medikament 
absichtlich nicht ein, weil die Einnahme 
mir Beschwerden bereitet. 
☐ ☐ ☐ ☐ ☐ 
14 
Ich habe als Folge meiner Schluckbe-
schwerden Angst vor der nächsten 
Medikamenteneinnahme. 




Denken Sie an die Medikamenteneinnahme, die Ihnen am meisten Beschwerden bereitet oder 
bereitet hat. Markieren Sie mit einem Strich oder Kreuz in der untenstehenden Linie zwischen 
0 und 10, wie stark diese Beschwerden sind oder waren: 
 






 (0 = keine Beschwerden) (10 = unerträgliche Beschwerden) 
 










Markieren Sie mit einem Kreuz in der Abbildung, wo Sie Beschwerden beim Schlucken von 






























Wie würden Sie ihre Kopfposition beim 
Schlucken von Medikamenten beschreiben? ☐ ☐ ☐ 
 
  Ja Nein Keine Angabe 















Bitte beschreiben Sie, wie das Medikament dabei verändert wird (mehrere Antworten sind möglich): 
 
☐ Teilen von Tabletten ☐ Öffnen von Kapseln ☐ Kauen von Tabletten 
☐ Zerkleinern/Mörsern von Tabletten ☐ Auflösen von Tabletten in einer Flüssigkeit 
☐ Andere Strategie, nämlich: 
…………………………………………………………………………………………………….
 Bitte beschreiben Sie ihre eigene Strategie in Stichworten
 
  Ja Nein Keine Angabe 
21 Haben Sie je einen Arzt oder Apotheker um Rat gefragt, bevor Sie die Form des Medikaments verändert haben? ☐ ☐ ☐ 
17 
Welche(s) Ihrer Medikamente lösen oder lösten diese Schluckbeschwerden aus? 







Beschreiben Sie, wie sich diese anfühlen









(Mehrere Kreuze und Antworten sind möglich) 
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  Ja Nein 
22 Hat Ihre Ärztin / Ihr Arzt Sie je nach Schluckbeschwerden befragt? ☐ ☐ 
23 Hat Ihre Apothekerin / Ihr Apotheker Sie je nach Schluckbeschwerden befragt? ☐ ☐ 
24 
Hat Ihnen Ihr Arzt oder Apotheker bereits einmal eine andere 
Einnahmeform (Sirup, Lösung, kleinere Tabletten) an Stelle der 
bisherigen Tabletten / Kapseln angeboten? 
☐ ☐ 
25 Essen Sie zur Einnahme von Medikamenten etwas (z.B. Joghurt)? ☐ ☐ 
26 Trinken Sie zur Einnahme von Medikamenten etwas (z.B. Wasser)? ☐ ☐ 
27 Verschlucken Sie sich manchmal bei der Einnahme von Medikamenten? ☐ ☐ 
 
 
Es folgen nun einige Fragen zum Alltag mit Ihren Medikamenten: Ja Nein 
28 Vergessen Sie manchmal Ihre Medikamente zu nehmen? ☐ ☐ 
29 
Manchmal wird ein Medikament nicht genommen und zwar aus einem 
anderen Grund als Vergesslichkeit. Wenn Sie an die letzten 2 Wochen 




Haben Sie jemals die Einnahme Ihrer Medikamente verringert oder 
gestoppt ohne Ihren Arzt / Ihre Ärztin zu informieren, weil Sie sich 
schlechter fühlten nach der Einnahme? 
☐ ☐ 
31 Wenn Sie reisen oder Ihr Zuhause verlassen, vergessen Sie manchmal ihre Medikamente mitzunehmen? ☐ ☐ 
32 Haben Sie ihre Medikamente gestern genommen? ☐ ☐ 
33 Wenn Sie das Gefühl haben, dass Ihre Krankheit unter Kontrolle ist, hören Sie manchmal mit der Einnahme Ihrer Medikamente auf? ☐ ☐ 
34 
Jeden Tag Medikamente zu nehmen empfinden viele Personen als 
lästig. Fühlen Sie sich manchmal schikaniert, wenn Sie den Therapieplan 




Wie oft haben Sie Mühe, sich an die 


















Sie sind nun am Ende des Fragebogens angelangt. Besten Dank für Ihre Teilnahme! 
 
Retournieren Sie nun bitte den Fragebogen und die weiteren Studienunterlagen in dem beiliegenden 
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